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SUMMARY OF THESIS
The incidence of pancreatic cancer has increased 
throughout the world in the last 60 years such that it 
is now the fourth leading cause of cancer death in the 
United Kingdom. The tumour usually presents at an 
advanced stage and cure is rarely possible.
Extensive epidemiological investigations during 
this century suggest that cigarette smoking is the 
most consistent aetiological factor in the development 
of pancreatic cancer. Differences in dietary 
consumption of meat, fat, fruit and vegetables have 
also been implicated in altering susceptibility to 
this tumour; high consumption of fat and protein has 
been thought to increase risk while consumption of 
fruit and vegetables has been thought to be 
protective. It remains unclear how these dietary 
differences affect the risk of developing pancreatic 
cancer. One possible mechanism that has been 
suggested for the effects of protein and fat in this 
regard has been through their influence on endogenous 
secretion of gastrointestinal hormones such as 
secretin and cholecystokinin.
The late presentation of pancreatic cancer in 
man makes investigation of the early stage of the 
carcinogenic process impossible. Two animal models of 
pancreatic carcinogenesis have been developed in the 
last 20 years which have allowed investigators to 
increase our knowledge of some of the processes which
19
go on in this disease. Azaserine has been shown to 
induce pancreatic acinar cell tumours in rats whereas 
the nitrosamine family of chemicals, in particular N- 
nitrosobis(2-oxopropyl)amine (BOP), induces pancreatic 
tumours with a ductal or ductular morphology in the 
Syrian golden hamster.
The BOP hamster has generally been accepted as 
the best model for investigating aspects of pancreatic 
carcinogenesis. In addition to the fact that the 
tumour induced in the hamster is morphologically 
similar to the commonest form of human pancreatic 
cancer (namely ductal adenocarcinoma), the clinical 
features in the hamster with advanced disease resemble 
those seen in man, including a propensity for the 
tumour to metastasize to the liver and other organs.
The BOP hamster model has been used widely to 
investigate some of the factors which might predispose 
to the development of pancreatic cancer in man. Given 
that secretin and cholecystokinin have been implicated 
in the role of diet in the aetiology of human 
pancreatic cancer, the effects of these and other 
gastrointestinal hormones have been investigated in 
the BOP-hamster model. Cholecystokinin and a number 
of its analogues and secretin have been reported to 
increase the incidence and extent of BOP induced 
pancreatic cancer in hamsters. Somatostatin, a 
gastrointestinal hormone with numerous, predominantly 
inhibitory, actions, (and largely because of these
20
inhibitory properties,) has been proposed as a 
possible treatment for pancreatic cancer in man. The 
aims of this thesis were to investigate the effects of 
secretin, an octapeptide analogue of cholecystokinin 
(CCK-8) and a long-acting somatostatin analogue (SMS 
201-995) on BOP induced pancreatic carcinogenesis in 
the Syrian hamster.
The hamster model was successfully established. 
Intraperitoneal (IP) and subcutaneous (SC) BOP were 
compared for effect on the pancreas. Lesions seen 
throughout the 20 weeks study period were as 
previously reported in the literature for both groups. 
The degree and extent of pre-malignant and malignant 
change seemed to be greater after 20 weeks in the SC 
group compared to the IP group.
In the second experiment, CCK-8 and secretin 
stimulated pancreatic juice output when infused 
intravenously. Pancreatic juice protein and 
bicarbonate output were also increased. SMS 201-995 
suppressed pancreatic juice output. When infused 
■simultaneously with either secretin or CCK-8, SMS 201- 
:995 was still able to suppress pancreatic juice 
(output.
Repeated SC injections of secretin, CCK-8 and 
ISMS 201-995 did not have any effect on pancreatic wet 
weight or DNA content after one or six weeks of 
■treatment.
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When administered with the carcinogen BOP, CCK-8 
did not seem to influence pancreatic carcinogenesis. 
Secretin and, surprisingly, SMS 201-995, did seem to 
promote the development of pre-malignant and malignant 
pancreatic lesions seen histologically. Given that 
small doses of SMS 201-995 seem to promote pancreatic 
carcinogenesis in the hamster model, and given the 
wide interperson variation seen in man in relation to 
the pharmacology of many compounds, further 
investigation into the properties of somatostatin 
analogues should be undertaken before suggesting that 
these substances should be used to treat human 
pancreatic cancer.
In the light of the finding that the hormones 
could influence pancreatic carcinogenesis in doses 
which did not seem to influence pancreatic wet weight 
or DNA content, a further experiment was carried out. 
Flow cytometry has been used for many years to 
investigate tumour cell ploidy and cell cycle 
activity. This technique was used to investigate the 
effects of BOP on pancreatic cell cycle activity in 
the hamster. Bromodeoxyuridine (BRDU) immunostaining 
was used to identify which cells were undergoing 
proliferation. BOP significantly increased cell cycle 
activity during the 20 week experiment. Percentage S- 
phase fraction and G2/M fraction both increased. BRDU 
immunostaining demonstrated that the cells which were 
undergoing proliferation were predominantly ductal and
22
ductular cells.
In conclusion, the nitrosamine carcinogen BOP 
causes cellular damage and subsequent proliferation in 
the pancreas. These proliferating cells from which 
tumours probably develop might be susceptible to the 
e f f e c t s  of o t h e r  s u b s t a n c e s ,  i n c l u d i n g  
gastrointestinal hormones, which have been shown to 
act as t umo u r  promotors in animal models. 
Nitrosamines, which are carcinogenic in the hamster, 
are present in cigarette smoke and cigarette smoking 
has been identified as the most likely aetiological 
factor for pancreatic cancer in man. Dietary factors, 
which have been implicated in increasing risk for 
human pancreatic cancer, could act through their 
effects on various gastrointestinal hormones thus 
providing a mechanism whereby diet could act as a 
tumour promotor in man. SMS 201-995 seemed to act as 
a tumour promotor in the hamster model. Its use to 
treat pancreatic cancer in man cannot yet be 
justified.
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CHAPTER 1
PANCREATIC CANCER
HISTORICAL REVIEW
1.1 Introduction
1.2 Demographics
1.3 Aetiology/Epidemiology
1.4 Human Pathology
1.5 Animal Models of Pancreatic Cancer
1.6 Syrian Golden Hamster - Nitrosamine Model
1.7 Cholecystokinin (CCK), Secretin and the Pancreas
1.8 Somatostatin and Analogues
1.9 Summary
1.1 Introduction
The incidence of pancreatic cancer has increased 
steadily in the last 60 years throughout the world. 
Diagnosis is not often made until the disease is at an 
advanced stage and no reliable screening tests exist 
to detect early disease. Curative surgical therapy is 
only applicable to a small minority of patients and, 
even where possible, carries a high operative 
mortality and morbidity. Effective palliation is the 
aim of treatment in most patients but even this is 
sometimes not attainable. Responses to chemotherapy 
and radiotherapy have been singularly disappointing.
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1.2 Demographics
The incidence of pancreatic cancer has increased 
in the last 60 years such that it is now the fourth 
leading cause of cancer death in the United States of 
America after lung, colorectal and breast cancer 
(National Center for Health Statistics, 1968). 
Between 1920 and 1970 the age-adjusted mortality rate 
for pancreatic cancer in the USA increased from 2.9 
per 100,000 to 9 per 100,000 (Gordis and Gold, 1984). 
In England and Wales, the incidence of pancreatic 
cancer doubled between 1930 and 1970 (Office of 
Population Censuses and Surveys, 1975). In 1950, the 
mortality rate for pancreatic cancer in Japan was 1 
per 100,000 population? in 1974 this had risen to 
nearly 6 per 100,000 population (Aoki and Ogawa, 
1978) . In recent years, it has been suggested that 
the annual incidence in the USA is now levelling off 
at approximately 10 new cases per 100,000 population 
(Gordis and Gold, 1984).
The incidence of pancreatic cancer varies with 
age, sex and race. In most countries the incidence is 
higher in males than in females by a ratio of about 
two to one (Aoki and Ogawa, 1978) . The disease is 
rare in those under 25 years of age and uncommon under 
the age of 45 years (Morgan and Wormsley, 1977). Over 
80% of cases occur in the 60-80 years age group 
(Gordis and Gold, 1984). Pancreatic cancer is more 
common in Western or industrialised countries,
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although the highest incidence in men occurs in New 
Zealand Maoris, native Hawaiians and black Americans 
and in women, Hawaiians, Latins in El Paso and Maoris. 
The lowest rates are reported in Nigeria and India. 
In the USA, in both sexes, blacks have a higher rate 
of pancreatic cancer than whites (Fraumeni, 1975).
It is unclear whether geographic and racial 
demographic differences represent differences in 
genetic susceptibility to developing pancreatic 
cancer, or differences in exposure to environmental 
influences. Studies of migrating populations, which 
have been useful in investigating the aetiology of 
other tumours, have largely failed to shed light on 
the aetiology of pancreatic cancer. In 1957, Smith 
reported on the incidence of pancreatic cancer among 
Japanese immigrants to the United States of America. 
Migrants from Japan to America had a higher incidence 
of pancreatic cancer than native Americans or Japanese 
living in Japan. The pancreatic cancer risk to 
American-born offspring of such Japanese migrants to 
the USA was at a level between those of the native 
populations of the two countries in subsequent studies 
(Buell and Dunn, 1968? Haenszel and Kurihara, 1968). 
It has been suggested that this discrepancy in 
i n c i d e n c e  r a t e s  m i g h t  be e x p l a i n e d  b y  
undercertification of pancreatic cancer deaths in 
Japan or by certification of some such cases as 
gastric cancer, a more common tumour in that country
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(Jablon et al, 1966; Haenszel and Kurihara, 1968). 
Similar confusing migrant studies have been carried 
out on the negro populations of America; in one 
study, northwards migrating negroes born in the south 
of the USA, assumed a higher incidence rate than 
negroes born in the northern state of Ohio (Mancusco 
and Sterling, 1974).
Some religious groups experience a higher than 
average susceptibility to the development of 
pancreatic cancer. In studies based in New York City, 
pancreatic cancer occurred more frequently among Jews 
than Catholics or Protestants (MacMahon, 1960; 
Newill, 1961). Similar findings were reported by 
Seidman (1970); differences were particularly 
striking between Jewish and non-Jewish women. Enstrom 
(1978) reported that Utah Mormons had a lower risk of 
developing pancreatic cancer than non-smoking white 
American males although a previous Utah-based survey 
demonstrated low rates of pancreatic cancer in both 
Mormons and non-Mormons (Lyon et al, 1976).
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1.3 Aetiology/Epidemiology
a) Smoking
Many epidemiological studies have indicated that 
the most consistent risk factor for the development of 
pancreatic cancer is cigarette smoking. In a study of 
US veterans, Kahn (1966) reported a relative risk in 
cigarette smokers compared to non-smokers of 1.84:1. 
In the same year, Best (1966) demonstrated a dose- 
response relationship between the number of cigarettes 
smoked and the mortality rate from pancreatic cancer. 
This finding has been confirmed by others (Hammond, 
1966? Hirayama, 1977; Mack et al, 1986). In 1976, 
cigarette smoking male doctors were shown to have a 
relative risk of dying from pancreatic cancer of 1.6:1 
when compared to non-smoking controls (Doll and Peto,
1976). A Swedish group reported a mortality ratio of 
3.1:1 for cigarette smoking males and 2.5:1 for 
females (Cederlof et al, 1975). It is therefore 
generally accepted that cigarette smoking doubles the 
risk of developing pancreatic cancer present in a non­
smoking population (Fraumeni, 1975). The increased 
risk of developing pancreatic cancer does not seem to 
apply to pipe or cigar smokers (Kahn, 1966? MacMahon 
et al, 1981) although not all authors have agreed with 
this assertion (Best, 1966? Wynder et al, 1973). 
Krain provided circumstantial evidence in support of 
the role of cigarette smoking by indicating that the
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increase in cigarette smoking from 1940 to 1970 in the 
USA paralleled the increase in pancreatic cancer 
(Krain, 1970). This conclusion was supported in a 
study of smoking trends and pancreatic cancer 
mortality rates in the USA between 1920 and 1978 
(Weiss and Bernarde, 1983). It demonstrated that the 
mortality rate for pancreatic cancer closely shadowed 
rises and falls in the incidence of cigarette smoking. 
This relationship was more striking in males than in 
females. Unfortunately, both of these papers can be 
criticised on methodological grounds in that the 
figures used to calculate mortality trends were not 
entirely comparable.
Despite a substantial body of published data 
supporting the relationship between smoking and 
pancreatic cancer, there have been a number of studies 
which have failed to demonstrate this relationship. 
In a study of cancer incidence and mortality published 
in 1975, Armstrong and Doll failed to demonstrate any 
relationship between smoking and pancreatic cancer. 
Surprisingly, they also failed to demonstrate a strong 
relationship between lung cancer and cigarette smoking 
and admitted that there were several problems with the 
analytical methods used in their study. They also 
emphasised that failure to demonstrate a correlation 
between two variables in a population did not 
necessarily exclude a relationship in individuals. 
Binstock and colleagues (1983) reported a weak but
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statistically non-significant relationship between 
pancreatic cancer and smoking in a study concerned 
primarily with the putative link with coffee 
consumption. In a retrospective case-control study, 
Durbec et al (1983) reported an association between 
pancreatic cancer and alcohol consumption and smoking 
taken together, although alcohol seemed to be more 
important than tobacco.
While it seems likely that cigarette smoking 
does increase the risk of developing pancreatic 
cancer, the mechanism whereby this occurs remains 
obscure. Wynder (1975) hypothesised that tobacco 
smoke might influence the development of pancreatic 
cancer in three ways; a) carcinogens in tobacco 
excreted in bile might reflux into the pancreatic 
duct, b) tobacco carcinogens might reach the pancreas 
via the blood stream and c) cigarette smoking might 
increase blood lipids which have been shown to 
influence the development of pancreatic cancer. While 
certain nitrosamine chemicals have been shown to be 
carcinogenic in experimental animals, none of the 
nitrosamines in cigarette smoke have yet been shown to 
cause pancreatic cancer in this setting. The 
suggestion that reflux of carcinogen-containing bile 
into the pancreatic duct might be responsible for the 
development of pancreatic cancer is plausible and 
pancreatic cancer in man occurs most frequently in the 
head of the gland (Cubilla and Fitzgerald, 1979). In
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addition, it has been demonstrated in man that certain 
variations in the anatomy of the bile and pancreatic 
ducts at the sphincter of Oddi can allow bile to 
reflux from the bile duct into the pancreatic duct 
(Armstrong and Taylor, 1985). DiMagno and colleagues 
(1982) demonstrated an increase in pancreatic ductal 
epithelial abnormalities in patients who lacked a 
prominent pancreatic and bile duct common channel, 
although Armstrong and Taylor suggested that bile 
reflux into the pancreatic duct was more likely in 
patients with a long functioning common channel. It 
remains unclear whether this mechanism is relevant in 
the development of pancreatic cancer in man.
b) Diet
Demographic differences in the incidence of 
pancreatic cancer throughout the world has prompted an 
extensive search for dietary factors which might be 
implicated in the disease. In particular, the 
consumption of a "Western diet" seems to increase the 
relative risk; Doll and Peto (1981) suggested that in 
the USA, 35% of all cancer deaths could be attributed 
to dietary factors.
In 1967, Lea reported a significant correlation 
between the incidence of pancreatic cancer in various 
countries and per capita consumption of fats, oils, 
sugar, animal protein, eggs and milk. There was a 
significant positive correlation between pancreatic
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cancer and high meat, low vegetable intake in men, and 
low vegetable intake in women in a Japanese study 
published in the following year (Ishii et al, 1968) . 
Unfortunately, dietary histories in this latter study 
were obtained from relatives by questionnaire in many 
instances. Certainly, there is a significant 
correlation between pancreatic cancer death rates in 
different countries and the average per capita daily 
consumption of fat (Segi et al, 1969; F.A.O., 1969).
In a large follow-up study from Japan, Hirayama 
(1981) reported that daily, or more frequent 
consumption of meat was associated with an increased 
risk (1.5:1) of developing pancreatic cancer. This 
association, although weak, was statistically 
significant. It has been suggested that the great 
increase in the incidence of pancreatic cancer in 
Japan might be related to Westernisation of the 
Japanese diet with documented increases in protein and 
fat consumption (Wynder et al, 1973; Hirayama, 1975).
In a case-controlled study, Gold and colleagues 
(1985) reported an association between pancreatic 
cancer and the consumption of white bread and 
decreased risk with the consumption of raw fruits, 
vegetables and "diet soda".
It is interesting to note that in animals, 
dietary fat and protein have been shown to increase 
the incidence of nitrosamine-induced pancreatic cancer 
(Birt et al, 1981; Birt et al, 1983b; Longnecker et
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al, 1985b) while retinoids inhibit carcinogenesis 
(Longnecker et al, 1982; Longnecker et al, 1986).
Exactly why dietary factors should influence the 
development of pancreatic cancer remains unclear. 
Dietary fat and protein are potent stimulants of the 
release of many gastrointestinal hormones. Many 
workers have shown that in animals, exogenous 
administration of some of these hormones can cause 
pancreatic hypertrophy (Mainz, Black and Webster, 
1973; Barrowman and Mayston, 1974; Folsch and 
Wormsley, 1976) and potentiate the development of 
pancreatic cancer (Howatson and Carter, 1985). Diets 
rich in raw soya flour, a potent trypsin inhibitor, 
can promote the effect of the pancreatic carcinogen 
azaserine in rats (Morgan et al, 1977). It has been 
suggested that diets rich in fats and protein 
stimulate the release of various gastrointestinal 
hormones which act to increase pancreatic cell 
turnover, and thus increase the susceptibility of the 
gland to the effects of carcinogens (Morgan and 
Wormsley, 1977).
Nitrosamines, which induce pancreatic cancer in 
hamsters, have been shown to be formed during cooking 
and in the stomach from nitrites and nitrates used in 
the preservation of meats (Weisberger and Williams, 
1975; Miller and Miller, 1986). The average daily 
intake of volatile nitrosamines has been shown to vary 
from between 0.6 to 2ug per person per day, although
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actual values vary depending on local eating habits 
and food preparation (Bartsch et al, 1982; Preussman 
and Eisenbrand, 1984).
The role of vitamins in the development of 
cancer of various organs has received considerable 
attention in recent years. Vitamins C and E have been 
shown to inhibit or reverse n i t r o s a t i o n  in 
experimental conditions (Mirvish, 1986) and this might 
explain the inverse correlation between pancreatic 
cancer risk and fruit and vegetable consumption noted 
earlier (Gold et al, 1985). Low serum levels of 
vitamin A (retinol) have been reported as being 
associated with an increased risk of cancer (Wald et 
al, 1980) although a subsequent report from the same 
group suggested that low serum retinol levels might be 
a consequence of cancer metabolism rather than a risk 
factor for cancer development (Wald, Boreham and 
Bailey, 1986).
In the last 20 years, the amount of nitrates and 
nitrites in food have diminished and vitamin C has 
been added to all nitrate and nitrite preserved foods 
in the USA, to prevent the nitrosation reaction taking 
place (Preussman and Eisenbrand, 1984; Mirvish,
1986) .
The American Cancer Society have issued seven 
guidelines on nutrition to reduce cancer risk; avoid 
obesity, reduce fat intake, eat more high fibre foods, 
eat more foods rich in vitamins A and C, eat more
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cruciferous vegetables, e.g. cabbage, consume alcohol 
in moderation and consume salt-cured, smoked and 
nitrite cured foods in moderation (Weinhouse, 1986) . 
It seems likely that adoption of these guidelines 
could reduce the risk of pancreatic cancer.
c) Coffee Consumption
The role of coffee in the aetiology of 
pancreatic cancer has been the subject of much 
controversy in recent years. In a comparison of age 
adjusted death rates from various cancers and annual 
consumption of cigarettes, tea and coffee in a number 
of countries, Stocks (1970) reported a positive 
correlation between coffee consumption and pancreatic 
cancer in males but not in females. In a large case- 
controlled study, a highly significant association was 
also found between coffee consumption and the risk of 
pancreatic cancer even when the data were adjusted to 
take cigarette smoking, age and sex into account 
(MacMahon et al, 1981) . There seemed to be a dose 
response relationship? risk increased in proportion 
to the number of cups of coffee consumed. MacMahon 
subsequently urged caution in the interpretation of 
his initial data, in that the control group was not 
ideal (MacMahon, 1982). In a subsequent case- 
controlled study, MacMahon's group reported a slightly 
increased risk of pancreatic cancer only in those 
whose coffee consumption exceeded five cups per day
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(Hsieh et al, 1986). They concluded that any 
association between pancreatic cancer and coffee 
consumption was not as strong as their initial data 
had suggested.
Mack and colleagues failed to show a consistent 
link between coffee consumption and pancreatic cancer 
in a subsequent case-controlled study in Los Angeles 
(Mack et al, 1986) . In addition, they found no link 
between pancreatic cancer and previous consumption of 
tea, carbonated drinks, beer or spirits. Similar 
results were reported by Gold and associates from 
Baltimore, although there seemed to be a dose response 
relationship with coffee drinking in women, albeit not 
of statistical significance (Gold et al, 1985).
In 1981, Lin and Kessler reported a relationship 
between decaffeinated coffee and pancreatic cancer. 
More recent studies have failed to confirm this 
relationship (Jick and Dinan, 1981; Hsieh et al, 
1986; Wynder et al, 1986). Wynder and his group 
showed no relationship between decaffeinated coffee 
consumption and pancreatic cancer in males; in 
females an association existed for consumption of 1-2 
cups per day but was lost at higher levels of 
consumption (Wynder et al, 1986).
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d) Chronic Pancreatitis
A familial form of chronic pancreatitis was 
first reported in 1952 (Comfort and Steinberg, 1952). 
This disease seems to be inherited as an autosomal 
dominant trait with incomplete penetrance and other 
affected families have since been reported (Gross, 
Gambill and Ulrich, 1962; Whitten, Feingold and 
Eisenklam, 1968; Appel, 1974). Approximately one 
third of affected patients develop pancreatic cancer 
although family members without pancreatitis also 
develop cancer (Castleman, Scully and McNeeley, 1972). 
The relationship between chronic non-familial 
pancreatitis and pancreatic cancer is unclear. In 
19 50, Mikal and Campbell reported the presence of 
chronic pancreatitis in 49 of 100 cases of pancreatic 
cancer at autopsy. Similarly, Gambill (1971) reported 
histological chronic pancreatitis in 10% of 255 
consecutive patients with pancreatic and ampullary 
cancer, although in an earlier study he failed to 
demonstrate pancreatic cancer in 56 patients with 
chronic pancreatitis after 16 to 20 years of follow-up 
(Gambill, Baggenstoss and Priestley, 1960). In 197 0, 
Robinson and colleagues were only able to find 15 
authenticated cases of chronic pancreatitis and 
pancreatic cancer occurring together. There have been 
other reports of pancreatic cancer developing in 
patients with longstanding chronic pancreatitis 
(Bartholomew, Gross and Comfort, 1958; Mohr et al,
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1975) but most authorities on pancreatic disease are 
of the opinion that the relationship is probably 
fortuitous (Wynder et al, 1973; Morgan and Wormsley,
1977). It is possible that both diseases share common 
aetiologies; they certainly share the same symptom 
pattern and diagnostic differentiation is problematic 
in many cases. In addition, it is well recognised 
that obstructing pancreatic cancers may cause 
pancreatitis as a consequence of pancreatic duct 
obstruction (Gordis and Gold, 1984).
e) Diabetes
The relationship between pancreatic cancer and 
diabetes mellitus has been difficult to determine with 
any certainty because of problems in establishing 
cause and effect. Medical students are taught that 
pancreatic cancer can worsen carbohydrate homeostasis 
in established diabetics and can cause diabetes to 
develop de novo. Whether diabetes gives rise to an 
increased risk of developing pancreatic cancer is less 
clear.
The earliest reported association of pancreatic 
cancer and diabetes was made before the metabolic role 
of the pancreas was completely understood (Mirallie, 
1893). Since then there have been many reports of the 
association of the two diseases. In 1941, from 
collected statistics, Berk reported glycosuria in 9.4% 
and hyperglycaemia in 19.4% of patients with
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pancreatic carcinoma. Bell (1957) reported 38 cases 
of diabetes mellitus in 587 cases of pancreatic cancer 
at autopsy. The incidence of diabetes in the 
pancreatic cancer group was twice that of the general 
autopsy population for males and 50% greater for 
females. He pointed out, however, that the average 
duration of the diabetes in the 38 pancreatic cancer 
cases was only 3.4 years and was less than 1 year in 
ten of the cases. When the 13 cases where the 
symptoms of pancreatic cancer antedated or coincided 
with the development of diabetes were excluded from 
the analysis, the incidence of diabetes in the 
pancreatic cancer group fell to that of the general 
autopsy population, both in males and females.
In a further autopsy study, Green and colleagues 
(1958) reported that 4.3% of 209 pancreatic cancer 
patients had diabetes prior to the onset of the 
symptoms of pancreatic cancer; 15.3% were found to 
have diabetes after the onset of such symptoms and a 
further 29% were found to have glycosuria. No 
conclusion was reached as to whether diabetes 
predisposed to pancreatic cancer. Clark and Mitchell 
(1961) reported on 65 patients with pancreatic cancer, 
ten of whom were diabetic; in all but one of these 
cases the interval between diagnosis of pancreatic 
cancer and diabetes was less than one year. Karmody 
and Kyle (1969) also found that the interval between 
diagnosis of diabetes and pancreatic cancer was less
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than one year in 80% of their 51 cases. In six cases, 
diabetes was diagnosed more than two years prior to 
the development of pancreatic cancer symptoms; these 
authors concluded that the incidence of pancreatic 
cancer in such diabetics was greater than could be 
accounted for by chance.
The most exhaustive study of the relationship 
between diabetes and pancreatic cancer was published 
by Kessler in 1970. Cancer mortality among 21,447 
diabetic patients during a 2 6 year period ending in 
1956 was reported. Male diabetics were found to have 
a lower than expected mortality from all forms of 
cancer while in females, there was no difference from 
the expected rate. A statistically significant excess 
of deaths, in both males and females, was observed for 
pancreatic cancer; the standardised mortality rate 
(SMR) for males was 1.47 and for females it was 2.13. 
When the deaths of patients in whom it could not be 
established that the diabetes had preceded the cancer, 
were excluded from the analysis, the SMR* s fell to 
1.27 for males and 1.82 for females. This study has 
been criticised on the grounds that the SMR1 s were 
calculated using data from the general Massachusetts 
population, which may not have been appropriate to the 
Boston group of patients under study. Kessler made 
the interesting proposition that exogenous animal 
insulins should be examined closely for carcinogenic 
effects in humans given their antigenic and
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teratogenic potential in animals. In a subsequent 
review, Kessler urged caution in the interpretation of 
the many reports and studies of diabetes and 
pancreatic cancer given the wide variation in study 
design and the bias that is often present in autopsy 
studies (Kessler, 1971).
Green and Jensen (1985) followed the entire 
insulin-dependent diabetic community in Fyn County, 
Denmark for eight and a half years and reported a 
significant excess of pancreatic cancer cases (6 vs
2.4 expected) during this time. When they excluded 
those patients where diabetes was an early sign of the 
development of the tumour, this excess was reduced (4 
vs 2.4). They concluded that there was no association 
between pancreatic cancer and prior diabetes. In a 
case-control study based on three Swedish hospitals, 
patients with pancreatic cancer were more likely to 
have diabetes than either hospital based (relative 
risk 19.7) or population based controls (relative risk 
3.3) (Norell et al, 1986). When cases where the 
diabetes was diagnosed less than five years prior to 
development of pancreatic cancer were excluded, the 
increased relative risk remained (6.9 compared to 
hospital controls, 2.4 compared to population 
controls) although the number of cases in each group 
was small.
Part of the problem in studying the link between 
pancreatic cancer and diabetes is a failure in most
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reports to distinguish between insulin-dependent 
(IDDM) and non-insulin-dependent diabetes (NIDDM). It 
might be postulated therefore that any increased risk 
of pancreatic cancer in the two subgroups should be 
different. Animal work has only confused the 
situation. Bell and Strayer (1983) demonstrated that 
Syrian hamsters, made diabetic by destruction of 
insulin-secreting islet cells by streptozotocin, do 
not develop pancreatic cancer when injected with 
carcinogen. They subsequently examined the incidence 
of chemically induced pancreatic cancer in genetically 
diabetic and non-diabetic Chinese hamster strains and 
reported that tumours only develop in the non-diabetic 
animals (Bell and Pour, 1987) .
There has been considerable interest in recent 
years in the relationship between pancreatic cancer 
and carbohydrate intolerance. In a prospective study 
of 99 patients suspected of having pancreatic cancer, 
Schwartz and colleagues (1978) measured blood glucose, 
serum insulin, serum c-peptide and plasma glucagon 
during an oral glucose tolerance test. They 
demonstrated an increased incidence of carbohydrate 
intolerance in the 32 patients found subsequently to 
have pancreatic cancer (81%) compared to the 67 
control patients (36%) suggesting that abnormalities 
in carbohydrate metabolism were more widespread in 
patients with pancreatic cancer than had previously 
been realised. Insulin secretion was lower during the
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glucose tolerance test in the pancreatic cancer 
patients than in the controls. Unfortunately, the 
picture here may again be clouded in that patients 
with obstructive jaundice may exhibit abnormalities in 
carbohydrate metabolism during oral glucose tolerance 
tests (Ozawa et al, 1975).
The nature of the abnormality of carbohydrate 
metabolism in these patients remains unclear. While 
Schwartz and colleagues (1978) exhibited low serum 
insulin levels in humans in response to an oral 
glucose tolerance test, in a recent study of 
pancreatic cancer induced in Syrian golden hamsters, 
production of insulin in response to infusions of 
glucose and arginine in an isolated preparation of the 
malignant pancreas was unaffected (Bell et al, 1986).
f) Gallstones and Cholecystectomy
In an autopsy study of 609 cases of pancreatic 
cancer, Bell (1957) noted that 14% of male and 38% of 
female cases had gallstones co-existent with the 
tumour. Despite the fact that the overall incidence 
of cholelithiasis in these autopsy cases (21%) 
exceeded that of a general autopsy population, Bell 
concluded that there was no obvious association 
between pancreatic cancer and gallstones. Wynder and 
colleagues (1973), in a retrospective case-controlled 
study of 142 patients with pancreatic cancer, noted a 
higher incidence of prior cholecystectomy in female
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cancer patients (15%) than in controls (8%), although 
this d i f f e r e n c e  did not reach statistical  
significance. Wynder (1975) subsequently reviewed the 
results of his group's initial 1973 study, and 
cautioned that the association between prior 
cholecystectomy and pancreatic cancer in women was 
based on a relatively small number of patients. 
Haines and colleagues (1982) failed to demonstrate a 
relationship between cholecystectomy and pancreatic 
cancer in patients who underwent cholecystectomy more 
than five years prior to the development of pancreatic 
cancer. In a review of 586 randomly selected patients 
with abdominal malignancy, a Finnish group suggested 
that there was a significantly increased frequency of 
prior cholecystectomy in patients developing 
pancreatic cancer, with the peak incidence of 
pancreatic cancer occurring five years after surgery 
(Hyvarinen and Partanen, 1987).
In a small study from Athens, cholelithiasis was 
associated with an increased risk of pancreatic cancer 
(relative risk = 3.5) (Manousos et al, 1981). In a 
more recent case-controlled study from Stockholm, it 
was concluded that the relative risk of pancreatic 
cancer for subjects who reported suffering from 
gallstone disease was 1.7 compared with hospital 
controls and 2.7 compared with population based 
controls (Norell et al, 1986). The relative risk 
values were 1.2 and 2.9 following exclusion of
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patients who reported gallstones only in the five 
years prior to the diagnosis of pancreatic cancer, and 
this group concluded that the risk of pancreatic 
cancer was increased in patients with gallstone 
disease.
It has been shown, in the hamster, that 
cholecystectomy results in an increase in circulating 
plasma cholecystokinin levels, pancreatic weight, DNA 
content and DNA synthesis rate and in hyperplasia and 
hypertrophy of pancreatic cell populations (Rosenberg 
et al, 1983; Rosenberg et al, 1984). In a Japanese 
study, the incidence of pancreatic cancer induced by 
the nitrosamine N-nitrosobis(2-hydroxypropyl)amine 
(BHP) was increased in animals which had undergone 
cholecystectomy one week prior to the first injection 
of carcinogen (Ura et al, 1986) . This difference did 
not reach statistical significance. When 
cholecystectomy was combined with the administration 
of the secondary bile salt lithocholic acid, the 
incidence of pancreatic carcinoma was significantly 
greater than the control group which received 
carcinogen only.
While cholecystectomy may increase the risk of 
development of experimental pancreatic cancer when 
undertaken immediately prior to exposure to chemical 
carcinogens (the mechanism perhaps involving transient 
increase in cell turnover mediated by increased 
circulating levels of CCK), it remains to be seen
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whether this mechanism would apply to humans who had 
undergone cholecystectomy many years prior to their 
p r e s e n t a t i o n  with pancr e a t i c  cancer. Why 
cholelithiasis should predispose to pancreatic cancer 
is unclear.
g) Gastric Surgery
In 1982, McLean-Ross and colleagues reported on 
the results of a follow-up study of the mortality rate 
and causes of death in 779 patients who had undergone 
peptic ulcer surgery. Eighty-six percent of the 
patients had undergone some form of gastrectomy and 
the remainder vagotomy and drainage. The authors 
found that the life expectancy of patients following 
peptic ulcer surgery was reduced in all age groups 
studied. One of the surprise findings of this study 
was a statistically significant increase in the number 
of patients dying of pancreatic cancer (11 actual 
deaths compared with 3.9 expected, p<0.01). They 
concluded that part of this increase in mortality 
following gastric surgery was related to continued 
cigarette smoking, and this could explain the increase 
in pancreatic cancer cases.
Further evidence to suggest a relationship 
between previous gastric surgery and pancreatic cancer 
was provided by Mack and colleagues (1986). In a 
large case-controlled study, they demonstrated a 
relative risk of developing pancreatic cancer
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following gastric surgery (mainly partial gastrectomy) 
of 7.4 in non-smokers and 8.1 for current or recent 
smokers (the relative risk for smokers without 
gastrectomy was 2.3). A three-fold risk of pancreatic 
cancer following gastric surgery has been reported by 
other groups (Caygill et al, 1985; Offerhaus et al, 
1987). In the Offerhaus study corrections were made 
for cigarette consumption in case and control groups, 
and the relationship persisted. This group postulated 
that the cause for the increase in pancreatic cancer 
might be increased production of carcinogens such as 
nitrates and nitroso-related compounds in the gastric 
remnant. Nitrosamines have been used for many years 
to induce pancreatic cancer in experimental animals 
(Pour and Wilson, 1980).
In a follow-up study of 336 patients who 
underwent gastric surgery for benign peptic ulcer 
disease, a group from the Mayo Clinic reported no 
relationship between pancreatic cancer and previous 
gastric surgery (Marighini et al, 1986). Only one 
patient developed pancreatic cancer 33 years after a 
Billroth II subtotal gastrectomy compared with 1.6 
expected (relative risk = 0.64).
h) Familial Cases
Cases of pancreatic cancer occurring in families 
have appeared sporadically in the literature. 
MacDermott and Kramer (197 3) reported three brothers
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and one sister who all developed pancreatic cancer 
between the ages of 59 and 72 years. Another group of 
four affected brothers, who all smoked cigarettes, was 
reported three years later (Friedman and Fialkow,
1976) . In both of these reports, the affected 
individuals all developed pancreatic cancer in the 
high incidence age groups. Another case report 
published in 1973 described a father and son who 
presented with pancreatic cancer who had both 
previously been exposed to toxic chemicals (Reimer et 
al, 1977). There have been four other case reports of 
familial pancreatic cancer in the 12 years to 1987 
(Danes and Lynch, 1982? Dat and Sontag, 1982; 
Grajower, 1983? Ehrenthal et al, 1987). One of these 
reports documented the familial occurrence of 
pancreatic cancer in three women of consecutive 
generations (Ehrenthal et al, 1987). The women were 
European and Jewish and two died at the young ages of 
29 and 42 years with pathologically proven disease 
(the daughter and grandaughter in the series). Two of 
the women were smokers.
Despite these case reports, it is generally 
accepted that such cases are rare and that the 
association could still be due to chance (MacMahon, 
1982).
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i) Industrial Exposure
Since Potts' original observation of an increase 
in the incidence of scrotal cancer amongst chimney 
sweeps, many investigators have looked for an 
association between occupational chemical exposure and 
human pancreatic cancer.
In a study of 639 men employed in 1938 or 1939 
in a company manufacturing B-naphthylamine and 
benzidine and followed up until 1965, Mancusco and El- 
Attar (1967) reported six cases of pancreatic cancer. 
These six cases accounted for almost one third of 
malignant gastrointestinal tumours recorded in the 
study and represented a mortality rate for pancreatic 
cancer in the cohort of 39/100,000, compared with 7.9 
for men of similar ages in the general Ohio 
population.
Li and colleagues (1969) examined 3,637 of 4,644 
death certificates of members of the American Chemical 
Society who died between 1948 and 1967, and compared 
the mortality rate from pancreatic cancer with the 
mortality rate of a general population of age-matched 
professional men. They reported 56 deaths from 
pancreatic cancer compared to 35 expected but were not 
able to implicate any one chemical substance as 
responsible for this increase. The authors advised 
caution in the interpretation of their results, given 
that 22% of the death certificates were missing, and 
secondly, the relative frequency method used to make
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the comparisons was thought to have the potential for 
erroneous results. Two subsequent studies have failed 
to reveal such an excess of pancreatic cancer cases in 
chemists (Hoar and Pell, 1981? Searle et al, 1981).
There has been one report suggesting an excess 
of pancreatic cancer in British radiologists but the 
excess was small and of marginal statistical 
significance (Smith and Doll, 1981).
In a study of 94 cases of p a n c r e a t i c  
adenocarcinoma, lifetime occupational histories were 
obtained by interviewing the subjects and age and sex- 
matched controls (Lin and Kessler, 1981). The 
proportion of male patients with pancreatic cancer who 
had been employed in the dry cleaning business or in 
jobs involving close exposure to petrol was 
significantly higher than for male controls and the 
risk of pancreatic cancer was increased by a factor of 
five in men in these occupations for more than ten 
years.
Other high-risk occupations have been reported? 
metal industry and aluminium milling workers, 
particularly those exposed to coal tar pitch 
derivatives (Turner and Grace, 1938? Dorken, 1964) 
and coke plant workers (Redmond et al, 1976).
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j) Alcohol Consumption
Alcohol was initially suggested as a risk factor 
for pancreatic cancer by Burch and Ansari in 1968. In 
their study, 65% of 83 pancreatic cancer patients 
admitted to moderate to heavy alcohol consumption for 
at least 15 years, compared to less than 15% of the 
control group. Ishii and co-workers (1968) also 
reported that the risk of pancreatic cancer was twice 
as high in males who drank alcohol every day compared 
to non-drinkers. In a case control study, Durbec and 
colleagues (1983) showed an increased risk of 
pancreatic cancer with high fat diet and alcohol 
intake. In a prospective study of 16,713 Norwegians, 
Heuch and co-workers (1983) found a relative risk of 
developing pancreatic cancer of 5.4 for frequent 
alcohol consumption.
Studies of alcoholics in many countries have 
failed to demonstrate a link between alcohol 
consumption and pancreatic cancer (Hakulinen et al, 
1974; Monson and Lyon, 1975; Robinette, Hrubec and 
Fraumeni, 1979; Schmidt and Popham, 1981). Many 
case-controlled studies have similarly failed to 
demonstrate any such link between alcohol consumption 
and pancreatic cancer (Wynder et al, 1973; MacMahon 
et al, 1981; Haines et al, 1982; Mack et al, 1986) 
while others have suggested a weak link with wine 
consumption in males (Lin and Kessler, 1981).
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Some authors have attempted to overcome the 
positive correlation between cigarette smoking and 
alcohol intake by attempting to standardise for 
tobacco use (Wynder et al, 1973). No association 
between pancreatic cancer and alcohol consumption was 
demonstrated in this study. In a case-control study 
in Baltimore, consumption of wine in both males and 
females seemed to be significantly protective against 
pancreatic cancer (Gold et al, 1985).
Despite the established relationships of alcohol 
and cancers of the mouth, pharynx, oesophagus, larynx 
and liver, the link between pancreatic cancer and 
alcohol consumption is weak and inconsistent and 
suggests that any increased risk is small (Gordis and 
Gold, 1984).
k) Oncogenes and Pancreatic Cancer
As molecular biologists and geneticists become 
more familiar with the human genome and techniques 
with which to explore it, chromosomal abnormalities 
associated with specific disease states are being 
reported with increasing frequency. This is the case 
in pancreatic cancer.
Hirai and colleagues demonstrated that a human 
pancreatic cancer cell line, T3M-4, contained 
activated c-Kirsten(Ki)-ras oncogene resulting in 
amplification and overexpression (Hirai et al, 1985). 
Yamada and co-workers (1986) demonstrated a point
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mutation at codon 12 in the same oncogene in a primary 
pancreatic adenocarcinoma and a lymph node metastasis 
and reported a three to six-fold amplification of the 
oncogene in both samples, suggesting that the point 
mutation had occurred early in the tumour process.
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1.4 Human Pathology
The pathological classification of pancreatic 
cancer proposed by Cubilla and Fitzgerald is generally 
accepted as definitive for descriptive purposes 
(Cubilla and Fitzgerald, 1975; Cubilla and 
Fitzgerald, 1979). In their initial paper (Cubilla 
and Fitzgerald, 1975) they reviewed the histology of 
406 cases of non-endocrine pancreatic carcinoma. Duct 
cell adenocarcinoma accounted for 76% of cases; other 
histological types were much rarer, namely giant cell 
c a r c i n o m a  (5%) , m i c r o a d e n o c a r c i n o m a  (4%) , 
adenosquamous carcinoma (4%), mucinous adenocarcinoma 
(2%), anaplastic carcinoma (2%), cystadenocarcinoma 
(1%) , acinar cell carcinoma (1%), pancreaticoblastoma 
(<1%) and unclassified (7%). The proportion of each 
type of tumour has undergone minor alteration in 
subsequent publications but the general distribution 
remains the same.
Ductal Adenocarcinoma
This histological type of pancreatic carcinoma 
predominates in the elderly (sixth and seventh decades 
of life). Cubilla and Fitzgerald (1979) made a number 
of observations regarding this tumour type which 
remain relevant. It was found most commonly in the 
head of the pancreas (61%) followed by the body (13%) 
and tail (5%); in the remainder the pancreas was 
diffusely involved with tumour. In approximately two-
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thirds of patients, overt metastases were present at 
the time of diagnosis, most commonly in the liver, 
regional lymph nodes, peritoneum, lungs and pleura. 
Less than 10% had tumours apparently confined to the 
gland at diagnosis. In 60% of the patients with head 
of pancreas disease, the tumour diameter exceeded 5 
cm. Lesions in the body and tail were generally 
larger (averaging 10 cm in diameter).
Histologically ductal pancreatic adenocarcinoma 
resembles adenocarcinomata seen in other sites in the 
body such as the gastrointestinal tract, uterus and 
lung. Glands of different sizes and degrees of 
differentiation are found together with a variable 
amount of fibrous tissue. In most tumours, 
appropriate histological stains reveal the presence of 
mucin, either in the cell apex or in extracellular 
pools. Foci of haemorrhage, necrosis and fat necrosis 
are also seen. In cases where the main pancreatic 
duct is occluded, acinar and ductular atrophy occur 
associated with ductular ectasia.
Tumours involving the body and tail of the 
pancreas have been reported to result in a different 
clinical spectrum from head of pancreas cancer. 
Jaundice is less common while thromboembolism and 
metastases (particularly subcutaneous metastases) are 
more frequent (Die Goyanes, Pack and Bowden, 1971; 
Cubilla and Fitzgerald, 1978). In a prospective study 
of 11 patients with pancreatic body and/or tail cancer
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abdominal pain was present in 10 patients and back 
pain in nine (Fitzgerald et al, 1978).
In their initial publication, Cubilla and 
Fitzgerald (1975) also reported on the incidence of 
other associated histological abnormalities found in 
the pancreatic ducts of 195 patients with duct cell 
adenocarcinoma. Mucous cell hypertrophy, pyloric 
gland metaplasia and papillary hyperplasia were all 
more commonly found in patients with pancreatic cancer 
than controls and atypical duct hyperplasia and 
carcinoma-in-situ were only found in the cancer group. 
In an autopsy study, hyperplastic, preneoplastic and 
frankly neoplastic lesions were found in the pancreas 
of 83 military veterans, only two of whom were known 
to have pancreatic cancer, while three were known to 
have metastatic pancreatic carcinoma (Pour, Sayed and 
Sayed, 1982). Ten of these patients were found to 
have neoplastic exocrine lesions including unsuspected 
early pancreatic carcinoma (n = 2) , ductal carcinoma- 
in-situ (n = 1) and ductular carcinoma-in-situ (n = 
7) . No less than 47 patients (57%) had pancreatic 
ductal hyperplasia and 32 (39%) had ductular
hyperplasia; 48% exhibited squamous metaplasia in the 
ductules.
The importance of the diagnosis of in-situ 
carcinoma of the pancreas has recently been emphasised 
in a paper from Australia, which reported two such 
cases both of which were successfully treated by
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surgical excision (Smith, Kneale and Goulston, 1986). 
In the first patient, laparotomy was undertaken to 
relieve obstructive jaundice; per-operative biopsy of 
an area of hard pancreas demonstrated cellular atypia 
in a papillary tumour but no invasion and total 
pancreatectomy was performed. In the second patient, 
pre-operative investigations had revealed an abnormal 
area in the head of the pancreas; per-operative 
biopsy suggested the presence of adenocarcinoma and a 
Whipple procedure was performed. Subsequent 
examination of the excised pancreas failed to reveal 
invasive adenocarcinoma. In neither case was the 
diagnosis made pre-operatively. In-situ carcinoma of 
the pancreas is not included in Cubilla and 
Fitzgerald's classification.
In 1985, Kloppel proposed that pancreatic duct 
cell adenocarcinomata should be subdivided into three 
major grades of m a l i g n a n c y  u sing glan d u l a r  
differentiation, nuclear size, anaplasia and mitotic 
a ctivity as h i s t o l o g i c a l  crite r i a  for the 
classification. The grades of malignancy reported 
correlated with the tumour doubling times in explants 
in nude mice and with the median survival time after 
resection of tumour in 75 patients assessed 
retrospectively. In a subsequent ultrastructural 
study of 51 pancreatic adenocarcinomata, increasing 
grades of malignancy correlated with a progressive 
loss in cell polarity and a loss of association of
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tumour cells with the basement membrane (Kern et al,
1987) .
Giant Cell Carcinoma:
This tumour type occurs in the same age group as 
ductal adenocarcinoma and has a similar sex 
distribution. Body and tail cancers are relatively 
more common. Tumours tend to be relatively large with 
c o n s i d e r a b l e  h a e m o r r h a g e  a n d  n e c r o s i s .  
Histologically, the tumours contain large, polypoid 
mono-nucleated tumour giant cells and malignant 
spindle cells. A small, round, uniform-sized cell 
with little cytoplasm is usually present in sheets or 
clusters. Epithelial glands are often present. The 
prognosis for patients with this tumour is similar to 
that of ductal adenocarcinoma (Cubilla and Fitzgerald, 
1979) .
Microadenocarcinoma;
This is an uncommon and rapidly fatal type of 
pancreatic cancer. It is usually large and necrotic 
and histologically it resembles the carcinoid tumour. 
Metastatic disease is common. Glands are smaller than 
in ductal adenocarcinoma and are often found in 
sheets. Fibrosis is less prominent than in ductal 
adenocarcinoma (Cubilla and Fitzgerald, 1979).
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Adenosquamous Carcinoma:
This tumour type, found most frequently in 
males, comprises two elements; an adenocarcinoma and 
a squamous carcinoma. Glandular areas differ widely 
in degrees of differentiation. Squamous areas have 
abundant cytoplasmic keratin and intercellular 
bridges. Metastases to liver, lymph nodes and 
peritoneum are common (Cubilla and Fitzgerald, 1975; 
Cubilla and Fitzgerald, 1979).
Mucinous Adenocarcinoma:
This tumour was initially reported only in males 
and found most frequently in the head of the pancreas. 
It is characterised histologically by large cystic 
spaces filled with mucin and frequently lined by tall, 
columnar, nonpapillary, glandular epithelium. The 
prognosis for patients with this type of pancreatic 
cancer is poor (Cubilla and Fitzgerald, 1975; Cubilla 
and Fitzgerald, 1979).
Anaplastic Carcinoma:
This subgroup includes those tumours which 
cannot be classified under any of the other headings. 
The pancreas is frequently involved in a diffuse 
manner. Tumours exhibit many different histological 
appearances including a large-cell group which 
resembles anaplastic adenocarcinoma, a group with 
small uniform cells which resembles malignant lymphoma
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and a third type which resembles renal carcinoma 
(Cubilla and Fitzgerald, 1979).
Cvstadenocarcinoma;
This tumour occurs most commonly in young women 
and most frequently involves the tail of the pancreas. 
The tumours are frequently large and present as a 
palpable abdominal mass or following a complication 
such as haemorrhage, rupture or secondary infection. 
The tumour is grey in colour with numerous 
multiloculated cysts which vary in diameter from 
approximately 1 cm to 20-30 cm. The cyst wall 
comprises tall columnar cells with abundant clear 
cytoplasm filled with mucigen granules. Prominent 
intracystic papillary projections of cells are a 
feature of all tumours of this type. Following 
resection, usually of the tail of the pancreas, the 
prognosis for this tumour is much better than for 
ductal adenocarcinoma (Compagno and Oertel, 1978? 
Cubilla and Fitzgerald, 1979; Kaufman et al, 1986).
Acinar Cell Carcinoma:
This tumour occurs in a younger group of 
patients than duct cell adenocarcinoma. Necrosis is a 
prominent feature. Tumour cells frequently form 
acinar structures with a small acinar lumen. The 
cells are large and polyhedral with a basal nucleus 
and abundant cytoplasm containing coarse cytoplasmic
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granules. Areas in the tumour can show formation of 
giant cells, anaplasia and groups of small round cells 
resembling lymphoma. Tumour dissemination is common 
(Cubilla and Fitzgerald, 1979).
Pancreatico-blastoma:
This rare tumour has been reported by a number 
of authors (Moynan, Neerhout and Johnson, 1964; 
Frable, Still and Kay, 1971; Tsukimoto et al, 1973). 
In one case a three year old Peruvian boy was affected 
(Taxy, 1976). The tumour was initially diagnosed as a 
neuroblastoma but following Whipple resection of the 
involved head of pancreas, the 4 x 3 x 2 cm tumour was 
reclassified. Histologically the lesion comprised 
sheets of small cells with clear, scanty cytoplasm. 
Some areas contained spindle cells, chondroid, osteoid 
and bone tissue as well as epithelial components 
(Cubilla and Fitzgerald, 1979).
Unclassified (mixed cell types):
This group, which is distinct from the 
anaplastic group, comprises those tumours which 
contain a number of cell types, thus making 
classification difficult. Some cases show evidence of 
mucin production while most show some attempt to form 
gland or duct-like structures (Cubilla and Fitzgerald, 
1975).
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Metastatic Cancer:
Many tumour types can metastasize to the 
pancreas. The commonest primary sites reported are 
lung, melanoma of the skin and lymphoma (Cubilla and 
Fitzgerald, 1975).
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1.5 Animal Models of Pancreatic Cancer
The natural history of pancreatic cancer in 
humans makes direct scientific observation and 
manipulation difficult. The tumour usually presents 
late, is irresectable and carries a dismal prognosis. 
Largely as a consequence of these factors, workers in 
the field have turned to animal models in an attempt 
to increase our knowledge and understanding of the 
basic biology and biological behaviour of pancreatic 
cancer.
Spontaneous exocrine pancreatic tumours occur in 
many species of animal, but are rare, accounting for 
much less than 1% of tumours reported (Pour and 
Wilson, 1980). The hamster seems to be most 
susceptible to spontaneous exocrine pancreatic cancer; 
1-4% of all tumours in this species are pancreatic 
cancers with a ductal or ductular morphology which is 
similar to that of the human tumour (Fortner, 1957; 
Kirkman, 1962; Pour et al, 1976a).
a) Rat
Chemically induced pancreatic neoplasia was 
first reported in animals during an attempt to find 
safer organic substitutes for inorganic insecticides 
(Wilson, DeEds and Cox, 1941). The compound 2- 
acetylamino-fluorene was fed to albino rats whose 
organs were subsequently examined for carcinogenic 
effects. Nodular hyperplasia was demonstrated in the
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liver and the pancreas; 17 of 39 rats exhibited 
pancreatic lesions and one developed an acinar cell 
carcinoma. Neoplastic lesions were also reported in 
many other organs. Similar findings have been 
reported in Buffalo rats fed the same substance for 
six to seven months (Morris et al, 1961). In the same 
paper, almost all of a group of Buffalo rats fed 2,7- 
fluorenylenebisacetamide develop similar lesions after 
four months of treatment.
Many other chemicals have been tested in rats 
since the initial 1941 report of induced pancreatic 
neoplasia. A low incidence of neoplastic pancreatic 
lesions was reported after long term administration of 
p-dimethylaminoazobenzene in Wistar rats (Hoch-Ligeti, 
1949). In 1955, Hendry and colleagues reported acinar 
cell adenomata in three of 23 albino rats injected 
subcutaneously with 4 '-fluoro-4-aminobiphenyl. 
Intravenous injections of 4-hydroxyaminoquinolone-l- 
oxide to Sprague-Dawley rats yielded a much higher 
incidence of similar adenomatous lesions (Hayashi and 
Hasegawa, 1971; Shinozuka and Konishi, 1974).
All of these substances suffer from the 
disadvantages of low tumour yield, production of 
predominantly benign tumours, long tumour latency and 
lack of organ specificity. In addition, lesions 
produced are acinar cell in type, whereas in human 
pancreatic cancer, ductal morphology predominates, 
although there is debate about the actual cell of
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origin of human pancreatic adenocarcinoma.
Azaserine (o-diazoacetyl-L-serine), an analogue 
of glutamine with antimetabolite purine-synthesis- 
inhibiting properties, was reported to cause toxic 
pancreatic acinar cell injury (Hruban, Swift and 
Slesers, 1965). Using tritiated labelling, azaserine 
was found to localise particularly to the kidney and 
pancreas (Longnecker and Curphey, 1975). Weekly or
t w i c e  w e e k l y  a d m i n i s t r a t i o n  of a z a s e r i n e  
intraperitoneally to Wistar rats, resulted in the 
development of a large number of hyperplastic acinar- 
type nodules and adenomata after 6 months of treatment 
(Longnecker and Crawford, 1974). These atypical 
acinar cell nodules (AACN's) appeared after eight 
weeks of treatment and increased in size and number 
during subsequent months (Longnecker, 1981). In a 
longer term study, rats were injected once or twice 
weekly for six months and sacrificed and autopsied at 
6, 9, 12 and 18 months after initiation of treatment
or when weight loss or obvious morbidity made survival 
unlikely (Longnecker and Curphey, 1975). All rats
autopsied exhibited AACN's and in 25% the pancreas 
contained discrete encapsulated adenomata. Of the 60 
animals injected twice weekly, 23 survived more than 
one year; nine of these exhibited pancreatic 
adenocarcinomata (20%) and three more had lesions 
suspected of being adenocarcinoma. Of the 60 animals 
injected once weekly, 18 were autopsied after one year
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and five exhibited pancreatic adenocarcinomata (8%) . 
Of the 18 animals with adenocarcinoma or suspected 
adenocarcinoma, 16 were male. Five animals had 
developed liver metastases, one pulmonary metastases 
and one diffuse tumour spread in peritoneal fat. 
Tumours also occurred in kidney, breast, neck, liver, 
pituitary gland, subcutaneous tissues and rectum. 
Variations in the susceptibility to the effects of 
azaserine of various strains of rats have been 
reported (Roebuck and Longnecker, 1977). With respect 
to the induction of AACN's, F344 rats were least 
susceptible, W/LEW rats exhibited a 100% response and 
Wistar rats an intermediate response. In addition it 
was noted that male rats developed almost twice the 
number of lesions as female rats. Since these initial 
reports, azaserine has become the standard substance 
used to study various aspects of pancreatic 
carcinogenesis in the rat.
b) Syrian golden hamster
The high rate of spontaneous ductal pancreatic 
tumours in the Syrian golden hamster prompted a number 
of investigators to study this animal in more detail 
with a view to developing a model of pancreatic cancer 
with the same ductal morphology as the human tumour.
In 1974, chemicals of the nitrosamine family 
were reported to induce pancreatic cancer in the 
Syrian hamster (Kruger, Pour and Althoff, 1974? Pour
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et al, 1974a). A large number of related nitrosamines 
have now been studied for their carcinogenic effects 
in the hamster. N-nitroso-dipropylamine (DPN) (Pour 
et al, 1973), N-nitrosomethyl-n-propylamine (MPN) 
(Pour et al, 1974b), N-nitroso-(2-hydroxypropy1)-n- 
propylamine (2-HPPN) (Pour et al, 1974c), N-nitroso- 
(2-oxopropyl)-n-propylamine (OPPN) (Pour et al, 
1974d), and N-nitroso-2,21-dihydroxy-di-n-propylamine 
(DHPN or BHP) (Pour et al, 1975a) all proved to be 
carcinogenic to a greater or lesser extent. 
Adenomatous lesions predominated although the 
incidence of pancreatic cancer was much higher in the 
BHP-treated animals. Tumours were induced in many 
organs in addition to the pancreas suggesting that the 
effect of this group of carcinogens was non-specific. 
In a subsequent study, groups of hamsters were given 
weekly subcutaneous doses of each of the five 
substances mentioned above for life and sacrificed 
when moribund (Pour et al, 1975b). DPN failed to 
produce any carcinogenic effects in the pancreas. 
OPPN, 2-HPPN and MPN were all associated with a low 
incidence of ductal adenomata, BHP induced ductal 
adenomas in all animals, ductal carcinomas in 80-100% 
of animals and acinar cell carcinomas in 17%.
Pour's group then investigated other metabolites 
of the original nitrosamines in an attempt to develop 
carcinogens which had a more specific effect on the 
pancreas. These compounds were manufactured by
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further substitutions on the B-aliphatic side chains 
of the original n i t r o s a m i n e  compounds. N- 
nitrosobis(2-acetoxypropyl)amine (BAP) exhibited a 
similar incidence of tumour and organ specificity to 
BHP (Pour et al, 1975c? Pour et al, 1976b). N- 
nitrosobis(2-oxopropyl)amine (BOP) was found to be 
more toxic than any of the other substances tested, 
resulted in tumour development as early as 13 weeks 
and seemed to have a more specific effect on the 
pancreas (Pour et al, 1975d). In a subsequent study, 
BOP was administered to male and female hamsters, 
either in a single subcutaneous dose (500, 250, 125
and 62.5 mg/kg body weight) or once weekly (10, 5 and
2.5 mg/kg body weight) for life (Pour et al, 1977a). 
The incidence of pancreatic neoplasms was between 50% 
and 80% for those animals injected once and between 
67% and 100% for those animals injected weekly. 
Tumours occurring in other organs (particularly lung 
and liver) were more common in the animals injected 
only once. The incidence of pancreatic adenocarcinoma 
was highest (95%) in male hamsters receiving a weekly 
dose of 5 mg/kg body weight and in female hamsters 
receiving half of this dose. All pancreatic tumours 
in the single injection groups were benign but the 
incidence of liver neoplasm was much higher than in 
the multiple injection groups. Some BOP-treated 
hamsters also developed ascites, diarrhoea, weight 
loss, icterus and vascular thrombosis, similar
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symptoms to those reported in man.
Different dose regimes have been studied in 
attempts to maximise the yield of pancreatic tumours 
and minimise the development of tumours in other 
organs. In a study where hamsters were injected for 
six weeks with 10 mg/kg body weight of BOP, and 
sacrificed at two-weekly intervals, no tumours were 
recorded at 8 weeks, 50% had pancreatic tumours at 10 
weeks and at 16 weeks all animals examined had 
pancreatic tumours (Pour et al, 1977b). The incidence 
of lung tumours was low (only 12% of all animals 
examined) and other tumours only developed in females 
after 18 weeks; all males had died by this stage in 
the experiment. Single low doses of BOP (40, 20, 10, 
5 and 2.5 mg/kg body weight) a d m i n i s t e r e d  
subcutaneously resulted in the development of 
pancreatic and other neoplasms (Pour, Salmasi and 
Runge, 1978). Pancreatic tumours were more frequent 
at higher doses but the incidence of tumours in other 
organs was also higher. Pancreatic tumours were 
induced even at low doses (2.5 mg/kg body weight) 
indicating the high carcinogenic potency of BOP in the 
hamster pancreas.
A large number of substances have now been 
tested for their carcinogenic potential in the Syrian 
hamster although none has exhibited the specificity 
and high tumour induction rates observed with BOP 
(Pour and Wilson, 1980; Pour and Raha, 1981).
Many studies have been carried out on the 
metabolism of the nitrosamine group of chemicals in an 
attempt to understand why they should have such an 
affinity for the pancreas in the Syrian hamster. 
Gingell and colleagues (1976b) administered BHP, BOP 
and HPOP (N-nitroso(2-hydroxypropyl)(2-oxopropyl) 
amine) intraperitoneally to male hamsters and studied 
blood levels and urinary excretion of their 
metabolites. HPOP and BHP were both detected in the 
urine after administration of BHP and BOP, but the 
amount of HPOP obtained was significantly greater 
after BOP administration. BOP was only obtained in 
the urine in very small quantities after BOP 
administration. HPOP appeared in the blood stream 
more rapidly after BOP administration than after BHP. 
The authors suggested that the carcinogenic effects 
seen after BOP or BHP administration, might be 
mediated through the proximate carcinogen HPOP, given 
that the amount of HPOP appearing in both blood and 
urine following BOP and BHP administration correlated 
with the tumour yield of these compounds in the 
hamster pancreas. They also pointed out that the 
cyclic form of HPOP resembled the pyranose form of 
hexose sugars and suggested that this similarity might 
provide a route for HPOP to enter pancreatic cells. 
HPOP had previously been shown to be a metabolite of 
another hamster pancreatic carcinogen, N-nitroso-2,6- 
dimethylmorpholine (Gingell et al, 1976a) and has
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since been shown to possess a carcinogenic potency 
similar to that of BOP (Pour et al, 1979b).
Different routes of administration also 
influence the effect of BOP on the hamster pancreas. 
Oral administration results in more bile duct tumours, 
few pancreatic tumours and no lung or renal tumours 
(Pour et al, 1977c) . Oral and intraperitoneal (IP)
administration of BOP were compared with regard to
excretion of metabolites in the bile and pancreatic
juice in addition to blood levels and urinary 
excretion (Gingell and Pour, 1978). Urinary excretion 
of HPOP and BHP was greater after IP administration 
than after oral administration as were blood 
concentrations. All three substances were detected in 
gallbladder bile although IP administration again 
resulted in higher concentrations. In contrast, only 
HPOP and BHP were detected in pancreatic juice with 
higher levels again following IP administration? BOP 
was not detected in the pancreatic juice after oral or 
IP administration. These results were interpreted as 
further proof that HPOP may be the proximate
carcinogen in BOP carcinogenesis. The authors were 
unable to explain the different tumour spectrum after 
oral BOP.
Further work by Gingell and colleagues (1979) to 
investigate carcinogen metabolism involved IP 
administration of BOP, BHP and HPOP labelled with 
radioactive 14C in hamsters and rats. For BHP in the
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hamster, 74% of radioactivity was excreted in the 
urine and 19% as C02; in the rat 73% was excreted in
urine and 4% as CO2 ; for BOP in the hamster, 12% in
urine and 74% as C02; in the rat 23% in the urine and
55% as C02: for HPOP in the hamster, 57% in the urine
and 24% as C02 . In this study trace amounts of BHP 
and HPOP were detected in pancreatic juice in hamsters 
after BOP administration, which taken with their 
earlier experimental work, led the authors to suggest 
that the effects on the pancreas were mediated through 
blood-borne carcinogens and not through exposure of 
the pancreatic duct to carcinogens in pancreatic juice 
or in refluxed bile. They also suggested that 
metabolic activation of carcinogens seemed to be by an 
oxidative pathway.
It is interesting to note that although 
nitrosamines seem to be metabolised in rats in a 
similar way to hamsters, they do not cause pancreatic 
tumours in rats. BHP causes tumours to develop in the 
nasal cavity, lungs, oesophagus, liver and kidneys of 
rats (Reznik and Mohr, 1976? Mohr, Reznik and Pour, 
1977) and BOP causes tumours to develop in the 
intestines, liver, urogenital tract and respiratory 
tract (Pour, 1978a). A later report from Longnecker 
and his group (1985a), however, reported successful 
induction of pancreatic neoplasms including carcinomas 
(of acinar cell type) in 77% of rats after IP 
administration of a single dose of HPOP, although the
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incidence of tumours in the liver and lungs was as 
high as that in the pancreas.
In 1980, Scarpelli and colleagues postulated 
three mechanisms by which the carcinogens could be 
activated namely (a) activation by liver microsomal 
mixed function oxidase (MFO) and release of active 
carcinogen into the blood stream, (b) activation in 
the liver followed by release of carcinogen into the 
bile and (c) activation of the carcinogens by MFO's in 
the pancreas and release of carcinogen into the 
pancreatic ductules and ducts. In a complex study to 
determine whether hamster pancreas contained the 
necessary MFO enzymes to activate carcinogen they 
investigated the mutagenic effects of BOP and another 
potent hamster pancr e a t i c  carcinogen, 2,6- 
dimethylnitrosomorpholine (DMNM), following activation 
by the post-mitrochondrial fraction of hamster 
pancreas (S-9), on Salmonella typhimurium TA 1535. 
They demonstrated that after activation, both 
carcinogens became more mutagenic to the bacteria. 
Interestingly, DMNM was more mutagenic than BOP 
despite the fact that BOP is the more potent 
carcinogen in the hamster. Mutagenicity was enhanced 
by pre-treatment of the hamsters with B-naphthoflavone 
and 2,3,7,8-tetrachlorodibenzo-p-dioxin, but not by 3- 
methylcholanthrene and this mirrored changes in aryl 
hydrocarbon hydroxylase activity. Mutagenicity was 
inhibited by pre-treatment with alpha-naphthoflavone
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and 2,5-diphenyloxazole and there seemed to be an 
absolute requirement for nicotinamide adenine 
dinucleotide phosphate (NADPH). These findings taken 
together suggest that the enzymes responsible for 
carcinogen activation were indeed pancreatic MFO's.
The relative species-specificity of pancreatic 
carcinogens has intrigued many authors in recent 
years. Azaserine, BOP and streptozotocin have been 
examined for toxic effects on rat and hamster acinar 
cell preparations (Zucker, Chan and Archer, 1986). 
Using inhibition of protein synthesis as a measure of 
cellular toxicity, it was demonstrated that while 
azaserine inhibited synthesis in all tissues examined, 
BOP and its metabolite HPOP had no effect on any. 
Streptozotocin inhibited synthesis in islets and in 
hamster acinar cells. The authors concluded that the 
specificities of the cellular toxicity of the 
carcinogens paralleled their tumorigenic effects. 
Scarpelli's group investigated the capacity of rat 
liver and pancreas to convert the putative proximate 
carcinogen HPOP to a mutagenic agent (Mangino, 
Hollenberg and Scarpelli, 1986). They reported that 
hamster hepatocytes rather than rat hepatocytes 
preferentially converted HPOP to a mutagenic 
metabolite. Pancreatic acinar cells in both animals 
were poor activators of HPOP and they concluded that 
hamster liver activated the carcinogen into a 
mutagenic form.
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In 1987, Curphey and colleagues reported on the 
ability of 11 pancreatic carcinogens to damage the DNA 
of pancreatic acinar cells of rats and hamsters, both 
in vivo and in vitro. Azaserine in vivo and in vitro 
damaged DNA in both rat and hamster pancreatic acinar 
cells in a dose dependent fashion. BOP only damaged 
DNA in hamster pancreatic acinar cells in vivo while 
HPOP damaged DNA in rats and hamsters in vivo but only 
in hamsters in vitro. The authors suggested that 
azaserine may well be carcinogenic to hamster pancreas 
under appropriate conditions and that the acinar cell 
in both species may well be the target for pancreatic 
carcinogens despite the apparent ductal morphology 
seen in the hamster.
c) Other mammals
Mice have not proved to be a useful model for 
human pancreatic cancer although they have proven 
invaluable in studying transplanted human and 
chemically induced tumours.
The rabbit has similarly not been widely 
investigated with regard to pancreatic carcinogenesis. 
In one study, small catheters made from 40% 
dimethylhydrazine were surgically implanted into the 
pancreatic ducts of New Zealand white rabbits (Elkort, 
Handler and Mozden, 1975). The catheters did not seem 
to interfere with pancreatic exocrine or endocrine 
function, but after 18 weeks, metaplasia, hyperplasia
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and dysplasia developed within the pancreatic duct 
epithelium. After a further 48 weeks, these lesions 
had developed into adenomatous periductal lesions and 
adenomas.
Guinea pigs have also been studied for the 
effects of various chemicals on the pancreas. N- 
nitroso-N-methylurea was administered to guinea pigs 
in drinking water five times weekly for life? two of 
26 animals exhibited pancreatic adenocarcinomata after 
548 and 560 days of treatment (Druckery et al, 1968). 
In other studies, the same substance was administered 
intraperitoneally once weekly for life to inbred 
guinea pigs (NIH strain 13) . Approximately one third 
of animals exhibited pancreatic adenocarcinomata after 
28 to 44 weeks of treatment (Reddy and Rao, 1975? 
Reddy, Scarpelli and Rao, 1979). Despite these 
results it is generally believed that the guinea pig 
does not provide a useful model for the investigation 
of pancreatic carcinogenesis. Long latency periods, 
low tumour yields and a high animal loss rate during 
the first six months of treatment make it unsuitable.
d) Guinea Fowl
A recent paper from Bulgaria reported on the 
successful induction of pancreatic adenocarcinoma in 
350 guinea fowls infected with the avian osteopetrosis 
virus strain Pts-56 (Kirev, Toshkov and Mladenov, 
1986). Pancreatic carcinomata were detected four
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months post-infection. By six months almost all birds 
studied exhibited neoplastic changes in the pancreas 
and over 60% exhibited pancreatic carcinomata. 
Further work is being undertaken by this group to 
determine the relevance of these findings in relation 
to human pancreatic cancer.
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1.6 Syrian Golden Hamster Model
a) Anatomy (Takahashi et al, 1977a)
The pancreas of the adult Syrian golden hamster 
is well defined (unlike other rodent pancreata), 
lobulated, pink in colour and has three distinct 
lobes; gastric, duodenal and splenic (Figure 1.1).
The duodenal lobe, the smallest of the three, is 
closely applied to the posterior aspect of the 
duodenum; it accounts for approximately 12% of the 
pancreatic wet weight. It joins the other two lobes 
at an irregularly shaped head situated medial and 
dorsal to the duodenum. The gastric lobe extends 
ventrally from the head region, lies in close 
apposition to the greater curvature of the stomach and 
the pylorus, and is easily seen on opening the 
abdomen. It accounts for 25% of the weight of the 
organ. The splenic lobe, the largest of the three 
(40% of organ wet weight) , extends dorsally from the 
head region and lies behind the stomach. It passes 
the spleen in a caudal position and attaches through a 
thin membrane to the descending colon, in front of the 
left kidney. The tail of the gastric and splenic 
lobes of the pancreas are connected by a long piece of 
omental fat ("fatty string") which lies lateral to the 
forestomach.
Each lobe has a single major pancreatic duct 
(although the gastric lobe sometimes possesses two
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Figure 1.1: Anatomy of the pancreas in the Syrian
golden hamster. The pancreas comprises three lobes; 
gastric, splenic and duodenal. The gastric and 
splenic lobes, situated anterior and posterior to the 
stomach, respectively, are attached by a fatty string 
of tissue. The duodenal lobe lies behind the 
duodenum. Each lobe contains a major duct (splenic 
lobe duct (d) , gastric lobe duct (e) , duodenal lobe 
duct (f). The gastric and splenic lobe ducts join to 
form the common pancreatic duct (c) . The common bile 
duct (b) joins the common pancreatic duct which, 
together with the duodenal lobe duct, forms the common 
duct (a) which enters the posterior aspect of the 
duodenum.
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such ducts). The ducts of the gastric and splenic 
lobes join proximal to the head region to form a large 
main pancreatic duct; this duct joins the common bile 
duct prior to entry into the duodenum. The duct of 
the duodenal lobe joins the common bile duct distal to 
the entry of the main pancreatic duct.
The blood supply of the gland is derived from 
the splenic, right gastroepiploic, pancreatoduodenal 
and superior mesenteric arteries. This is not 
dissimilar to the human situation although there are 
some variations in vascular pattern specific to the 
hamster.
Histologically, the hamster pancreas resembles 
that of other mammals, including the human (Figure 
1.2). The gland is composed of both exocrine and 
endocrine elements. The exocrine tissue is arranged 
into acini draining into ductules and ducts of 
increasing diameter. The cells of the acini are
pyramidal in shape with basal nuclei. The acinar 
cells contain eosinophilic zymogen granules in their 
apical portion (Pour and Wilson, 1980).
The endocrine elements of the pancreas are found 
in Islets of Langerhans (as in man. The islets are 
distributed evenly throughout the gland but can vary 
considerably in size. Islets contain alpha and beta 
cells in similar proportions and numbers to the human. 
Delta cells are also present but are much less 
frequently identified (Pour and Wilson, 1980).
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Figure 1.2: Histological appearance of normal hamster
pancreas. Acini drain into ductules and ducts (top 
right of section). The endocrine elements are found 
in the is l e t s  of L a n g e r h a n s  (H&E; x3 60
magnification).
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b) Physiology (Helgeson et al, 1980a; Helgeson et
al, 1980b)
In their initial paper, Helgeson and colleagues 
(1980a) studied various aspects of pancreatic function 
in starved and fed eight week old male and female 
Syrian golden hamsters. After the animals were 
anaesthetised with IP sodium pentobarbital, the common 
bile duct was ligated and the distal common pancreatic 
duct cannulated. After a period of recovery from the 
anaesthetic, pancreatic juice was collected in pre­
weighed vials for 20 hours; animals were allowed free 
access to water but no food. In a second experiment, 
DNA and protein synthesis rates were measured 
following IP injection of [3H ]phenylalanine or 
[3H]thymidine. Animals were sacrificed 15 minutes 
after the injection and radioactivity in DNA or 
protein was measured.
With regard to pancreatic secretion there was 
little fluctuation in the pH of pancreatic juice 
during the 20 hour study period although fed animals 
exhibited a consistently higher pH than starved 
animals (range of mean pH's: fed animals 9.11-9.46,
starved animals 8.87-9.17). The flow rate of 
pancreatic juice increased steadily from a basal level 
in fed animals of approximately 80 ul/hr/kg body 
weight (BW) to a peak level of approximately 120 
ul/hr/kgBW after 10 hours. This was followed by a 
slight fall in secretion during the night time
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collection period. Flow rates in starved animals were 
generally lower than in the fed animals although the 
pattern of secretion was similar. The protein content 
of the pancreatic juice was five times greater in the 
starved animals than in the fed animals in all 
periods; protein output gradually fell over the study 
period in the fed animals but slowly increased in the 
starved animals before falling during the night. The 
authors suggested that the higher protein content of 
pancreatic juice in the starved animals could be 
explained by cellular debris in the pancreatic ducts 
caused by cell death as a consequence of starvation 
and resultant pancreatic atrophy.
Electrolyte concentrations were measured in the 
pancreatic juice during the study period. Calcium and 
magnesium content gradually decreased with time. 
Bicarbonate and chloride concentration exhibited a 
reciprocal relationship but the combined total 
increased with time. Phosphate and sulphate exhibited 
a similar reciprocal relationship but their combined 
total decreased with time.
DNA synthesis rates were similar in fed and 
starved male hamsters; females had a consistently 
higher synthesis rate than the corresponding male 
group and synthesis rates were higher in the fed 
group. The protein synthesis rate for fed animals was 
twice that of the corresponding starved animals.
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In a subsequent study, Helgeson*s group (1980b) 
investigated the effects of repeated injection of 
secretin and pancreozymin in the cannulated hamster 
pancreatic duct model. The hormones were injected 
every 30 minutes for a total of six doses (secretin 
doses 25 iu/kgBW, pancreozymin doses 2 0 iu/kgBW). The 
pancreatic juice of animals given secretin was of a 
consistently and significantly lower pH than that of 
animals administered pancreozymin. The flow rate of 
pancreatic juice was two to threefold greater in the 
secretin-stimulated than in the pancreozymin- 
stimulated animals during the first three hours in 
both males and females and in the second three hours 
in males. Thereafter the flow rates in the two groups 
were similar. Overall, the flow rate in pancreozymin 
treated animals paralleled that of unstimulated 
animals in the previous experiment, whereas in the 
secretin treated animals the flow rate was initially 
much greater, gradually falling until the last period 
when it rose again. The hourly total protein output 
following administration of secretin or pancreozymin 
was five to ten times greater than that of 
unstimulated animals throughout the experiment. The 
pancreatic juice protein concentration was greater in 
the pancreozymin treated animals, particularly so 
between hours six and ten.
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DNA and protein synthesis were depressed by 
secretin administration whereas pancreozymin did not 
seem to exert any effect.
c) BOP Carcinogenesis
In the original paper d e s c r i b i n g  the 
carcinogenic effects of BOP in the Syrian golden 
hamster, Pour and colleagues (1977a) reported on a 
number of features of the induced pancreatic tumours. 
Only half were visible to the naked eye; tumour 
nodules varied in size from two to 15 mm and were 
frequently multiple. Tumours appeared as early as 13 
weeks after initiation of carcinogenesis in male 
animals and 15 weeks in females.
Histologically the tumours were adenomata, 
intraductal carcinomata and adenocarcinomata of a 
similar histological appearance to those induced by 
other nitrosamines (Pour et al, 1975a? Pour et al, 
1975b? Pour et al, 1975e). In these earlier papers, 
adenomata appeared microscopically to be of ductal 
origin with a wide variation in appearance? the 
majority comprised tubular structures lined by a 
single layer of flattened epithelial cells while 
others consisted of cystic or cystic-papillary 
structures lined by a layer of single flattened 
cuboidal or columnar cells. Hyperplasia and infolding 
of the larger duct epithelium was seen in almost all 
animals. Intraductal carcinomata were characterised
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by proliferation of relatively uniform cells with 
areas of secondary glandular formation and necrosis. 
The frank adenocarcinomata exhibited a wide variation 
in appearance. Some were cystic-papillary in 
appearance, some contained large amounts of mucous, 
and areas comprising transitional or squamous cell 
epithelium and signet ring cells were noted. Some 
poorly differentiated tumours resembled sarcomata and 
some areas of acinar cell carcinoma were reported. 
Some adenocarcinomata invaded adjacent structures and 
metastases to lymph nodes and other organs were 
occasionally seen. Carcinoma-bearing animals 
exhibited marked loss of weight and some developed 
ascites, thromboses and fat necrosis.
In the BOP paper (Pour et al, 1977a) no acinar 
cell tumours were reported but mixed ductal cell and 
islet cell neoplasms were noted in two male hamsters. 
Local invasion of adjacent structures was common and 
metastases were reported in a few animals. Three 
female hamsters developed obstructive jaundice, 
haemorrhagic ascites developed in three females, 
diarrhoea in two males and portal vein thrombosis in 
two females and two males. Fat necrosis was not seen.
In a detailed study, Pour and colleagues (I977d) 
examined the sequential effect of weekly subcutaneous 
injection of BOP (10 mg/kgBW) on the hamster pancreas. 
Male and female eight-week old Syrian golden hamsters 
were divided into three groups; group one received
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carcinogen weekly for six weeks, group two received 
carcinogen weekly for life and group three were 
injected with normal saline as control. Group one 
animals were sacrificed in batches every second week 
from week two, and group two animals every second week 
from week eight. The pancreas from each animal was 
excised with extrahepatic ducts attached, fixed, cut 
into step sections (seven sections for each pancreatic 
lobe) and stained with haemotoxylin and eosin. 
Morphological changes were reported in the common 
duct, in the main and lesser pancreatic ducts, in the 
ductules and, to a lesser extent, in the islets.
From two weeks following initial exposure to 
carcinogen, focal hypertrophy and hyperplasia of 
common duct epithelium was reported. Goblet cell 
metaplasia was also seen at this stage. This was 
followed by stratification of the epithelium during 
the next eight weeks with cellular atypia and an 
increasing number of mitotic figures. Papillary 
proliferation was seen from 12 weeks until the 
termination of the experiment. Benign and malignant 
tumours within the duct were uncommon? two such 
periampullary carcinomata accounted for only 1.7% of 
all malignant neoplasms in the experiment.
Similar changes occurred in the main and lesser 
pancreatic ducts from week four. Epithelial cells 
became enlarged and encroached on the duct lumen, 
often resulting in a pseudobridging effect. Focal
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areas of periductal inflammation and fibrosis were 
seen from six weeks. Progressive hyperplasia and 
heaping up of cells with increasing cellular atypia 
and mitotic figures resulted in areas of carcinoma-in- 
situ and intraductal carcinoma from 10 weeks. Frank 
invasion was seen from 12 weeks.
Ductular hypertrophy and hyperplasia were 
recorded from week two. Thereafter the carcinogen 
seemed to affect the ductules in a different manner 
from the larger ducts; ductular proliferation was 
seen from week six. These proliferating ductules 
formed adenomatous patterns from week eight and 
adenomata from week 10. Occasionally such adenomatous 
ductular proliferation could affect a whole pancreatic 
lobule# As the adenomata became more atypical, a 
pseudocapsule developed, often surrounded by a rim of 
lymphocytes. These lesions eventually breached the 
pseudocapsule and became invasive adenocarcinomata.
Changes in the pancreatic islets were also 
observed during exposure to BOP. Islet cells seemed 
to undergo hyperplasia resulting in an increase in 
islet size to four or five times normal. Similar 
changes in the islets were observed in the control 
animals, although to a much lesser extent. 
Intrainsular ductular formation was consistently 
observed during the carcinogenic process from eight 
weeks. These new ductules proliferated in a similar 
way to the normal ductules resulting in adenoma
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formation from week 10. Islets seemed to atrophy as 
ductular proliferation progressed. Subsequent changes 
were similar to those seen with respect to the 
ductules.
Throughout the carcinogenic process, acinar 
cells underwent degeneration and death, often being 
replaced by proliferating ductules or other atypical 
cells. All pancreatic lesions reported were thought 
to have originated in the pancreatic ductal system. 
It proved difficult to determine the origin of many of 
the adenocarcinomata because of the simultaneous 
development of ductal and ductular lesions in close 
proximity.
In a subsequent study, Pour*s group attempted to 
identify which part of the pancreatic ductal system 
was most susceptible to the effects of BOP (Takahashi 
et al, 1977b). Male and female hamsters were injected 
weekly with BOP (10 mg/kgBW) for five, seven and nine 
weeks and sacrificed in groups for examination two 
weeks after the last injection and every two weeks 
thereafter. In an attempt to determine whether cystic 
ductular changes occurred as a consequence of ductal 
or ductular obstruction, India ink was injected down 
the pancreatic duct of each animal immediately after 
death and the pancreas was photographed and prepared 
histologically as before. At week seven, areas of 
focal necrosis of acinar cells were reported. One 
hamster exhibited focal ductal hypertrophy and
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hyperplasia with moderate periductal inflammation but 
all other ducts and ductules showed no changes and 
contained India ink. At nine weeks, changes of 
epithelial hyperplasia, hypertrophy and stratification 
were noted in the common duct in three animals and 
focal hyperplasia in the pancreatic duct in four of 
six animals. India ink was noted in all ducts and 
ductules including proliferated ductules and a 
secondary ductule which led to a small peripheral 
adenocarcinoma, although there was no ink within the 
adenocarcinoma itself. At 11 weeks there was still no 
ductal obstruction and all proliferated ductular 
structures contained ink. Two small adenocarcinomata 
showed no communication with ductal or ductular 
structures.
Despite the progression of all lesions during 
this experiment, ductal or ductular obstruction was an 
infrequent finding and usually occurred only when a 
large adenocarcinoma occluded one of the main ducts 
within the pancreas. The authors concluded that 
ductular alteration particularly affecting the peri- 
and intrainsular ductules was the most common response 
of the hamster pancreas to the carcinogen BOP. The 
majority of adenocarcinomata induced seemed to be 
ductular in origin. Ductal and ductular occlusion did 
not seem to play an important part in the genesis of 
cystic ductular proliferative lesions. They suggested 
that the cells of the ductular epithelium were the
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primary progenitor cells of induced pancreatic cancer 
in the Syrian hamster model.
In 1978, Pour published the results of further 
observations relating to the role of pancreatic islets 
in the genesis of ductal adenocarcinomata in the 
hamster model (Pour, 1978b). Using biological 
material from previous studies in addition to 
pancreatic tissue from six further groups of hamsters 
injected weekly with BOP (10 mg/kgBW) for up to nine 
weeks and two groups receiving single injections of 
BOP (20 and 40 mg/kgBW) , Pour carefully examined the 
morphology of islets and intra- and peri-insular 
ductules during the carcinogenic process. Carcinogen- 
treated animals exhibited a marked increase in numbers 
of islets associated with hyperplasia and hypertrophy 
of intralobular and interlobular ductal cells; new 
islets were usually hypovascular and composed almost 
exclusively of beta cells.
Pour concluded that ductular cells, particularly 
those of peri-insular and intrainsular origin were 
most susceptible to the effects of carcinogen. The 
carcinogenic process seemed to be initiated with 
hyperplasia of intralobular ductular and interlobular 
ductal cells associated with newly formed islets, 
followed by excess formation of mature and immature 
islet cells and islet cell percursors in the periphery 
of the islets. This was associated with the 
appearance, distension and multiplication of
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periinsular and intrainsular ductules. The 
relationship between islet cell precursor cells and 
proliferating peri- and intrainsular ductular cells 
was emphasised and Pour suggested that they arose from 
a common undifferentiated precursor cell in response 
to the effect of the carcinogen. Subsequent changes 
in these cells result in malignant transformation and 
the establishment of the carcinogenic process.
Further support for this assertion came in 
another paper from Pour's group (Pour, Salmazi and 
Runge, 1978). Single subcutaneous injections of BOP 
(40, 20, 10, 5 and 2.5 mg/kgBW) were administered to
male and female Syrian hamsters. Animals were 
observed for life and sacrificed when moribund. Most 
tumours of the pancreas occurred in the highest dose 
group and seemed to occur most frequently along the 
line of the main pancreatic ducts, where islets were 
most frequently found, although neoplastic change was 
seen in all groups, emphasising the high carcinogenic 
potency of BOP for the hamster pancreas. Periinsular 
and intrainsular ductular proliferation was seen in 
all treated hamsters whereas ductal hyperplasia was 
rarely seen. Similarly, intraductal carcinomata were 
rare indicating that the hyperplastic response of the 
ductal epithelium requires a higher threshold dose of 
carcinogen than proliferating ductular cells.
In a histological study of three human 
pancreatic cancers, Pour and colleagues (1979a)
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demonstrated similar morphological changes in the 
affected pancreata to those seen in the Syrian hamster 
BOP model. All three human cases exhibited ductular 
and ductal hyperplasia and preneoplastic and 
neoplastic changes similar to those found in the 
animal model. Nesidioblastosis was also a common 
feature in association with hyperplastic and atypical 
intrainsular ductules. This paper concluded that 
cells of small ducts and ductules represented a source 
of human as well as experimental pancreatic tumours.
Flaks and colleagues (1980a) have questioned 
Pour's conclusions with regard to the cell of origin 
of experimental pancreatic cancer in hamsters. They
| pointed out that having initially claimed a ductal
i
| histogenesis for experimental pancreatic cancer in
jhamsters, Pour and colleagues subsequently indicated
i
' that ductular cells were the cells of origin followed 
by work suggesting that precursor cells arose from 
intrainsular ductules associated with newly formed 
islets. This confusion has been heightened by work 
from others which suggested that BHP induces 
exclusively ductal neoplasms (Levitt et al, 1977? 
Levitt et al, 1978). Flaks' group injected hamsters 
subcutaneously with BHP (250 mg/kgBW) weekly and 
sacrificed the animals in groups after two, four and 
six weeks of treatment and thereafter at three weekly 
intervals. Grossly visible pancreatic tumours were 
apparent from 12 weeks and all animals had tumours by
the end of the experimental period. No pancreatic 
lesions were seen until nine weeks of treatment. 
After 12 weeks, increasing numbers of abnormal acini 
were noted and as treatment progressed these acini 
became distended with a decrease in the size of the 
acinar cells. In the later stages of the experiment 
the acini were replaced by small ductule-like 
structures. From 15 weeks cystic foci became 
increasingly evident progressing into cystadenomata. 
Ductal changes were limited to luminal dilatation and 
ductal cell hyperplasia and there was no evidence that 
neoplasms arose from the ductal epithelium. Flaks 
group therefore disagreed with Levitt's results
j regarding a ductal cell of origin for the tumours.
I They also failed to demonstrate new islet formation or
!
| that intrainsular ductules had a role in pancreatic 
carcinogenesis. They suggested that the cell of 
origin of the cystic focus was the precursor of 
hamster pancreatic tumours and that further work was 
required to clarify the now confused situation.
Further work from Flaks' group has attempted to 
identify the cell of origin of experimental pancreatic 
cancer in the hamster model by looking in detail at 
the various morphological changes which occur during 
the carcinogenic process. In a study of the cystic 
lesions seen in the pancreas during carcinogenesis 
induced by BHP, using high resolution light microscopy 
and electron microscopy, it was suggested that the
cystic lesions, consisting of cells similar to those 
found in pancreatic adenomata and adenocarcinomata, 
were indeed true precursors of these tumours (Flaks, 
Moore and Flaks, 1980b). They noted, however, that 
cells possessing acinar cell characteristics could 
also be found in the cystic lesions and that they too 
might have an important role in the development of 
pancreatic tumours.
In a subsequent study, Flaks1 group looked at 
lesions seen at an earlier stage during the 
carcinogenic process than the cystic lesions reported 
in their earlier paper (Flaks, Moore and Flaks, 1981). 
These pseudoductules, which seemed to arise from 
replacement of acini, appeared to develop from acinar 
cells which dedifferentiated in response to the 
carcinogen. The authors suggested that the primary 
target for BHP might indeed be the acinar cell of the 
pancreas.
Acinar cell changes were studied in two 
subsequent papers from Flaks' group (Flaks, Moore and 
Flaks, 1982a and 1982b). Acinar cells appeared to 
undergo a process of dedifferentiation leading to the 
development of a population of cells closely 
r e s e m b l i n g  c e n t r o a c i n a r  and d u c t u l a r  cells. 
Interestingly, they reported that ductular cells and 
centroacinar cells were not themselves affected by 
BHP. These findings supported the assertion that the 
acinar cell was the target for BHP carcinogenesis.
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In 1983, Moore and co-workers suggested that 
cystic lesions were not true precursors of malignant 
pancreatic tumours induced by BOP and di-hydroxy-di-n- 
propyl nitrosamine (DHPN) (Moore et al, 1983a; Moore 
et al, 1983b). They proposed that the important 
carcinogenic sequence was ductal or ductular 
proliferation, epithelial atypia and dysplasia and 
carcinoma. This sequence appeared to be different 
from the ductular proliferation, benign multilocular 
cyst, cystadenoma sequence studied in depth by Flaks' 
group and shed doubt on the significance of Flaks' 
findings. Increase in the activity of glucose-6- 
phosphate dehydrogenase was established by Moore's 
group as a useful histochemical marker for early 
atypical proliferation.
In 1983, in a further attempt to determine 
whether ductal adenocarcinoma arose from acinar cells 
in the hamster model, Scarpelli's group reported on 
the effects of the administration of BOP during 
ethionine-induced pancreatic regeneration (Scarpelli, 
Roa and Subbarao, 1983). BOP was adminstered when the 
maximal number of acinar cells were in the S-phase of 
the cell cycle. Hamsters were fed with a methionine 
deficient diet and injected intraperitoneally once 
each day with DL-ethionine for two weeks to induce 
pancreatic degeneration, followed by a single IP 
injection of L-methionine to induce pancreatic 
regeneration. Pancreatic tumour induction was
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augmented significantly in those animals injected with 
carcinogen during pancreatic regeneration. Despite 
the fact that the cells in the pancreas most affected 
during regeneration were acinar cells, neoplastic 
lesions induced were exclusively ductular and ductal 
in morphology. The authors hypothesised that either 
the acinar cells were unable to metabolise BOP to an 
active carcinogenic form or that exposure to BOP led 
to a phenotypic alteration of acinar cells to duct­
like cells which subsequently underwent malignant 
change. They concluded that acinar cells were 
intimately involved in the pathogenesis of pancreatic 
ductal adenocarcinoma in the hamster model.
In a further study to determine the cell of 
origin of BOP induced hamster pancreatic cancer, Bell 
and Ray (1987) stained normal and neoplastic hamster 
pancreata with antiserum against the epithelial cell 
marker cytokeratin. In normal pancreas the monoclonal 
antiserum against cytokeratin stains centroacinar, 
ductular and ductal epithelium but did not stain 
acinar cells. In pancreata exposed to BOP the 
antiserum strongly stained cells of all BOP associated 
lesions including cysts, pseudoductules, hyperplasia, 
dysplasia and adenocarcinomata. Acinar cell staining 
was not seen in any pancreas exposed to BOP. The 
authors concluded that BOP-induced lesions arose from 
ductal epithelium and not from acinar cells.
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d) Modifying the Carcinogenic Process
Since the establishment of the Syrian golden 
hamster model, investigators have attempted to 
elucidate the aetiology of pancreatic cancer by 
identifying factors which alter the development of 
tumour in response to carcinogens.
In 1978, Pour's group published the results of a 
study which investigated the effects of operative 
biliary diversion on BOP carcinogenesis in hamsters
i
j(Pour and Donnelly, 1978). The rationale for these 
experiments lay in the widely supported hypothesis 
that pancreatic cancer, most frequently reported as
|
occurring in the head of the organ in humans, was
ii
caused by reflux of bile into the pancreatic duct.
|
Hamsters underwent laparotomy and ligation and
division of the common bile duct above the junction 
I .
with the pancreatic duct. Thereafter, a small hole
I
|Was made in the gallbladder fundus and the whole 
gallbladder was inserted through the duodenal wall 
into the gut lumen, five to ten millimetres distal to 
the opening of the common duct. Bile was thus
J diverted from the lower end of the common bile duct
[
and away from its junction with the pancreatic duct.
I
In t w o  h a m s t e r s  t h e  i n t e g r i t y  of t h e  
cholecystoduodenal anastomosis was confirmed by 
operative cholangiography. Hamsters then received BOP 
(5 mg/kgBW/week) for 20 weeks. Only animals which 
were deemed to be in a normal condition one week after
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surgery were included in the study.
The mean survival of treated hamsters was 3 2 + 4  
weeks and at death all treated hamsters had developed 
pancreatic ductal adenocarcinomata. The distribution 
of neoplasms in the pancreas was similar to that 
previously reported and, in addition, over 90% of 
tumours exhibited ductular morphology. The authors 
concluded that bile diversion did not alter the 
pattern of experimental pancreatic carcinogenesis in 
the hamster. The distribution of tumour in the 
pancreas was proportional to the size and weight of 
the pancreatic segments in which the tumours 
developed? bigger segments generated more tumours. 
They suggested that the high frequency of head of 
pancreas cancer in humans could have a similar simple 
explanation.
In a subsequent study using the carcinogen BHP, 
biliary diversion using the same surgical technique as 
Pour did not alter the extent or distribution of 
pancreatic tumours in treated hamsters (Andren- 
Sandberg, Dawiskiba and Ihse, 1982).
In a further attempt to determine whether reflux 
of intestinal contents into the pancreatic duct 
increased the development of carcinogen-induced 
pancreatic cancer, Pour's group conducted an 
experiment where the neck of one of the pancreatic 
lobes was ligated, the distal part of the same lobe 
was divided, and both cut ends inserted into the
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I
I colonic lumen through a small hole, thus fashioning a
! partial pancreatico-colostomy (Pour et al, 1983b). 
The integrity and function of this anastomosis was
: established in ten pilot animals examined two weeks 
after surgery. BOP was administered as a single 
subcutaneous dose (20 mg/kgBW) shortly after surgery 
and animals were sacrificed 4 6 weeks after injection.
While the overall tumour yield was much less in 
this study than that reported in animals receiving 
carcinogen in weekly doses, partial pancreatico- 
colostomy did not alter the distribution, frequency or
jmorphology of BOP induced lesions in the anastomosed
iI
| pancreatic lobe. Interestingly, the frequency of
| lesions in a group of control animals not undergoing
I
! surgery was significantly greater than operated or
!
| sham-operated animals, confirming a previous finding
1
i that surgery seems to exert a protective effect when
I
carcinogen is administered shortly after the operation 
(Pour et al, 1983a) . The authors concluded that 
reflux of intestinal contents, including bile, did not 
have an aetiological role in the development of 
pancreatic cancer in the hamster.
Partial pancreatectomy (70% of organ excised) in 
hamsters given a single subcutaneous dose of BOP does 
have an effect on tumour development depending on when 
the carcinogen is administered in relation to the time 
of surgery (Pour et al, 1983a). The highest tumour 
yield occurred in animals injected with BOP one week
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after surgery and it was lowest in those injected with 
BOP 30 m i n u t e s  a f t e r  s u r g e r y  ( p < 0 .01) . 
Pancreatectomised animals given BOP one week after 
surgery developed significantly more cancer in the 
residual duodenal lobe and head of the gland than non- 
operated control animals in the same regions of the
I pancreas. The authors concluded that the higher 
incidence of tumour in the animals injected one week 
later occurred because the carcinogen was adminstered 
at a time when the pancreas was undergoing
fI
regeneration; they cited previously published work in 
rats which showed that post-partial pancreatectomy, 
DNA synthesis was maximal after 36 hours (Lehv and
I
I Fitzgerald, 1968; Konishi et al, 1978) and that by
i two months, pancreatic segments reach a size 21-78%
I greater than the segments of non-pancreatectomised
t
rats (Pearson, Scott and Torrance, 1977). Pour's 
group assumed for their experiment that the same 
regenerative process would occur in hamster pancreata. 
They also observed that most tumours developed at the 
excision line (which was oversewn) and postulated that 
local inflammatory or degenerative processes could 
have an influence on response to carcinogen.
In an attempt to look in more detail at the 
effects of pancreatic degeneration and regeneration on 
BOP carcinogenesis, Pour's group investigated the 
effects of experimentally induced pancreatitis, 
following temporary pancreatic duct ligation, at
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various times during this disease (Pour et al, 1983c). 
Pilot studies identified that the optimal duration of 
duct ligation for inducing pancreatitis, with minimal 
mortality, was 48 hours. BOP was administered 
subcutaneously in one dose (20 mg/kgBW) 30 minutes 
before duct ligation in one group of animals and at 
three days (peak time for cellular degeneration), one 
week (peak time for cellular regeneration) and eight 
I weeks (healing phase) after duct ligation in three 
,other groups. A fifth group underwent duct ligation 
| four weeks after injection of BOP and again at four 
|weekly intervals thereafter (recurrent pancreatitis 
, group). BOP produced significantly fewer tumours than
! control groups when administered during cellular
1
degeneration (day 3 group) and during healing (week 8
i
■ group). When administered before duct ligation or 
| during cellular regeneration (week 1 group) BOP did
i
; not seem to influence the tumour pattern compared to
|
i controls. The incidence and size of pancreatic|
jcarcinomata was significantly higher in the recurrent 
pancreatitis group than controls.
T h e  a u t h o r s  w e r e  s u r p r i s e d  t h a t  BOP 
administration during the regenerative phase of acute
iI.
| pancreatitis did not increase tumour yield, but 
suggested that difficulties in identifying one week as 
the time of maximal ductal cell regeneration in the 
pilot studies, which often occurred with the phase of 
degeneration, might have resulted in carcinogen being
103
administered before or after the real regenerative 
phase. In addition, the mortality in the one week 
animals was extremely high (only 16% survived to the
I
end of the experiment compared to 65% of one of the
|
f
comparable control groups). On-going inflammation and
i
i
r e g e n e r a t i o n  in the animals with r e c u r r e n t  
^pancreatitis was suggested as a possible cause for the 
increase in pancreatic cancer in this group.
Cholecystectomy has been suggested as a risk 
jfactor for the development of pancreatic cancer in 
humans (Wynder et al, 1973). Cholecystectomy in 
hamsters has been shown to increase circulating levels
i
of cholecystokinin and increase pancreatic weight, DNA
t
content and synthesis rate and protein content
j
I (Rosenberg et al, 1983). In a subsequent study the
s
, same group of authors demonstrated, using morphometric
fand autoradiographic techniques, that cholecystectomy
|
jresulted in hyperplasia and hypertrophy of the 
pancreas (Rosenberg et al, 1984). In the light of 
.evidence quoted above that regenerating pancreatic 
.tissue is more at risk from the effects of carcinogen, 
these observations might explain the increased risk of 
pancreatic tumours in cholecystectomised humans,
i
I although there is no published evidence in man to 
.support this thesis, particularly given the time delay 
between cholecystectomy and the development of 
pancreatic cancer many years later.
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Cholecystectomy alters bile acid composition by 
reducing the circulating pool of primary bile salts 
and increasing the proportion of secondary bile salts 
(Hepner et al, 1974; Pomare and Heaton, 1979). 
Exogenous dietary administration of the secondary bile 
salts lithocholic acid (LCA) and deoxycholic acid
; (DCA) during BHP carcinogenesis, both significantly
j
enhance the development of pancreatic cancer in the
I
hamster (Makino et al, 1986). In the same study
|
administration of phenobarbital did not alter the
[
[
iincidence of pancreatic carcinomata.i
i
! In 1986, Ura et al studied the effects of
iI
| combining cholecystectomy with dietary administration 
of LCA in the BHP hamster model. The incidence of
f
i
pancreatic cancer was significantly increased only in
[
’those animals subjected to cholecystectomy and LCA 
jsupplemented diet. Cholecystectomy increased the 
| yield of pancreatic cancer from 28% to 56% but this 
, did not reach statistical significance. LCA dietary 
supplementation alone did not increase the incidence 
of pancreatic cancer compared to those animals 
| receiving standard feed. The dose of BHP used in 
lura's study was only 250 mg/kgBW/dose for five dosesi
E
| compared to 500 mg/kgBW/dose for five weeks in
\
\
| Makinofs study; this might explain the failure of 
Ura's study to demonstrate any effect of LCA.
Throughout 1983, Pour's group published the 
results of a series of experiments looking at the
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effects of dietary factors on experimental pancreatic 
carcinogenesis in the hamster model. Hamsters fed a 
protein free diet for 28 days developed significantly 
fewer pancreatic tumours compared to controls 
regardless of when the carcinogen was administered 
during the dietary period (Pour et al, 1983d). In
!
addition to inhibition of tumour development, hamsters 
.injected with BOP on day 18 of the protein free diet 
I did not develop any benign or malignant tumours in the 
pancreas, suggesting that dietary protein may also be
I
important in the initiation of BOP-induced pancreatic
I
cancers.
!
| Diets high in unsaturated fat have been shown to
enhance both the initiation and the promotion of BOP-
I
induced pancreatic cancer in hamsters (Birt, Salmasi
f
and Pour, 1981). In a later study, Birt and Pour
i
J  (1983a) reported an increase in the yield of renal 
|adenocarcinomata, pulmonary adenomata and benign 
.biliary cystic adenomata in animals exposed to BOP and
,a high-fat diet. In a further study hamsters were fed
|
diets low or high in fat and protein in combination 
jfor eight weeks before or after a single subcutaneous 
|BOP injection (10 mg/kgBW) (Birt et al, 1983b). When 
|BOP was administered after the special diets, 
pancreatic cancer yield was highest in those animals 
fed a high fat/high protein diet, less in those fed a 
high fat/low protein diet, and least in those on the 
low fat/high protein and low fat/low protein diets.
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In those animals where BOP was administered before the 
special diets the development of pancreatic cancer was 
inhibited in the low fat/low protein group and 
greatest in the high fat/high protein group (although 
; not as great as in the high fat/high protein group 
;given BOP after the special diet). Animals fed high 
jfat diets either before or after BOP injection had on 
average a 25% greater calorie intake and a 25% greater 
intake of other dietary substances including protein
'compared to animals in the low fat groups. Whether
I
|this observation is important in explaining the
1
differences reported is not clear. The authors
j
concluded that both dietary fat and protein influenced
I
experimental pancreatic carcinogenesis.
ii
| In 1987, Woutersen and colleagues in an attempt
1
I to develop a short four month protocol of BOP
I
f
: treatment which would allow more careful study of the 
pre-neoplastic lesions seen during carcinogenesis,
i
f
| reported that diets high in saturated fat resulted in
(a greater yield of large ductal complexes, ductal
i
I hyperplasia and ductal atypia. Dietary fat did not 
I seem to influence main pancreatic ductal changes. 
(They concluded that saturated fat in the diet enhancedI
rf
pancreatic carcinogenesis in the hamster.
i
A subsequent study into the effects of different 
levels of dietary protein alone produced confusing
I
results (Pour and Birt, 1983e). Hamsters were fed
I
diets with low or high protein content (given as
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casein) before or after BOP treatment. The low 
protein diet inhibited carcinogenesis only in female 
hamsters whereas the high protein diets did not affect 
the development of pancreatic cancer in any way. The 
authors were unable to offer a convincing explanation 
for these unexpected results.
Alcohol has been proposed as a possible
!
aetiological factor in human pancreatic cancer and its
i|
^effects have been studied in the BOP-hamster model. 
When administered in the animals' drinking water in a
iI
|concentration of 25% weight/volume, ethanol inhibited 
pancreatic cancer induced by a single subcutaneous
j
jinjection of BOP administered two weeks after
commencing alcohol ingestion (Tweedie et al, 1981).
!
. In a subsequent study, 5% ethanol administered in 
drinking water either before or before and after a 
single subcutaneous injection of BOP, failed to havei
!
any effect on the development of pancreatic cancer
(Pour et al, 1983f) . The authors of the second of
these papers suggested that the effect of ethanol 
could be d o s e - r e l a t e d  and that the h i g h e r  
concentration could be exerting some sort of toxic 
; effect on the pancreas which somehow interfered with 
the carcinogenic process.
Other dietary components which might exert a 
protective influence with regard to the development of 
pancreatic cancer in humans, have been examined for 
their effect on BOP-induced pancreatic carcinogenesis
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in the hamster model. Natural and synthetic retinoids 
have been shown to inhibit the later stages of 
carcinogenesis in animal models of skin, breast and 
bladder cancer (Bollag, 1972? Moon et al, 1977? 
Becci et al, 1978) . In a large study of the effects 
of four synthetic retinoids, Longnecker and co-workers 
(1986) demonstrated a significant reduction in the 
yield of pancreatic cancer in male hamsters fed N-4- 
propionyloxyphenylretinamide or retinylidene dimedone.
[
A lower yield of pancreatic cancer was seen in 12 of
i
the 14 retinoid-fed groups although this did not reach
i
significance in the remainder. The authors urged
i
.caution in the interpretation of these results 
particularly since the overall yield of pancreatic
iI
neoplasms in the animal groups was relatively low.
tj
| Dietary cabbage supplementation of a high-fat
diet produced more BOP-induced pancreatic cancer int
i
^hamsters than a low-fat, cabbage-supplemented diet or
I a high-fat diet without supplementary cabbage, in a
I
.study published in 1987 (Birt et al, 1987). The 
authors of this paper suggested that further work was
I
.required before the general public should be urged to
; increase their consumption of green vegetables in an
\\
attempt to reduce cancer risk.
Interest in the effect of dietary changes on 
experimental pancreatic carcinogenesis and the 
implication of diet in the aetiology of human 
p a n c r e a t i c  c a n c e r  has s t i m u l a t e d  f u r t h e r
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|investigations into possible mechanisms for these 
observations. Cholecystokinin, a peptide hormone
i
t
released from the duodenal mucosa in response to a
i
diet rich in fat and protein, has been studied for its
|
effect in the hamster model. Howatson and Carter
i
j (1985) reported that a six week course of CCK, 
administered subcutaneously in a gelatin carrier twice 
daily on three days each week around the time of
I .....................
weekly BOP administration, significantly increased the
i
i
yield of pancreatic cancer in a group of hamsters 
after 15 weeks of carcinogen, when compared to animals
i
.injected with BOP alone. In the same paper they
'demonstrated that 15 consecutive days of twice daily[
CCK administration and the same schedule of CCKi
[
injections as used in the carcinogen part of the study
ri
significantly increased pancreatic DNA content and 
pancreatic wet weight compared to control animals. 
|The authors postulated that CCK acted as a co­
carcinogen or promotor of pancreatic carcinogenesis by 
influencing pancreatic cell turnover and in so-doing, 
increased the susceptibility of the dividing cells to
I
the effects of BOP.
Not all investigators have agreed with these 
findings. Johnson and co-workers (1983) reported that 
CCK administered before or simultaneously with BOP 
.exerted an inhibitory effect on pancreatic tumour 
development. Caerulein, an analogue of CCK has also 
been studied for its effects in the hamster model.
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Andren-Sandberg and colleagues (1984) failed to 
demonstrate an effect of caerulein administration on 
experimental pancreatic carcinogenesis while a later 
study reported a statistically significant increase in 
pancreatic cancer in hamsters injected with weekly 
caerulein and the nitrosamine carcinogen BHP (Satake 
et al, 1986). Differences in experimental design, 
p a r t i c u l a r l y  with regard to the timing of
i
t
jCCK/caerulein administration in relation to carcinogen
[
administration, make interpretation of these 
conflicting results difficult.
Secretin, another gastrointestinal peptide 
hormone, released in response to acid in the duodenum,
1
stimulates pancreatic secretion primarily by
i
stimulating ductal rather than acinar cells. In a
|
study of similar design to their CCK study, Howatson
!
and Carter (1987) demonstrated a significant increase 
in pancreatic cancer yield in hamsters injected with 
secretin in addition to BOP providing further evidence 
for a link between the effects of diet and pancreatic 
cancer.
Exogenous administration of epidermal growth 
factor (EGF) during the carcinogenic process in the 
BOP hamster model promotes the development of 
pancreatic cancer (Chester et al, 1986). After 19 
weeks of carcinogen and four weeks (weeks five to 
eight) of EGF, 75% of EGF treated hamsters exhibited 
histological pancreatic cancer compared to only 44% of
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these receiving BOP (p = 0.016). Interestingly the 
incidence of bronchial carcinoma increased in the EGF 
treated animals.
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1.7 Cholecvstokinin. Secretin and the Pancreas
a) Cholecvstokinin
The main actions of cholecystokinin were 
initially described earlier this century by two 
independent groups of workers? instillation of fat 
into the proximal intestine of the hog stimulated 
gallbladder contraction (Ivy and Oldberg, 1928) and a 
substance released from the duodenal mucosa stimulated 
pancreatic secretion (Harper and Raper, 1943). 
Subsequent purification of these two substances 
demonstrated that they were an identical peptide 
comprising 33 amino acids (Jorpes and Mutt, 1962? 
Jorpes, Mutt and Toczko, 1964? Jorpes, 1968), the C- 
terminal tetrapeptide of which is identical to 
gastrin. Ivy and Oldberg confirmed the hormonal 
nature of CCK in a series of carotid-to-carotid cross­
perfusion studies (Ivy and Oldberg, 1928).
Since these original observations, CCK has been 
shown to exhibit considerable molecular heterogeneity, 
occurring in several different forms (CCK-58, CCK-39, 
CCK-33, CCK-8, CCK-5, CCK-4 and probably CCK-21 and 
CCK-12) . The sulphated form of CCK (sulphated on the 
tyrosine residue of position 7 in CCK-33) is more 
potent with respect to gallbladder contraction than 
the desulphated form (Amer, 1969). PRO-CCK, a 95 
amino acid precursor of the CCK family and PRE-PRO-CCK 
of 115 amino acid residues have both been described
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and characterised (Gubler et al, 1984? Beinfeld, 
1985? Deschenes et al, 1985).
Cholecystokinin is present throughout the 
gastrointestinal tract (Ogden et al, 1982) and in the 
central and peripheral nervous systems (Brownstein and 
Rehfeld, 1985). Interestingly, different CCK 
receptors have been described in the brain and 
pancreas? the pancreas possessed 3 00 times more 
binding sites than the brain (Innis and Snyder, 1980). 
Sulphated CCK had a higher affinity for both types of 
receptor in this study.
In 1928, ingestion of fat was shown to cause 
gallbladder contraction (Boyden, 1928). Since then it 
has been shown by many investigators that CCK is 
released in response to the presence of fat and 
protein digestion products in the gut lumen. L- 
isomers of the amino acids, particularly tryptophan 
and phenylalanine, and straight-chain fatty acids are 
particularly potent in this respect (Lin, 1975? Marx 
et al, 1987). Postprandial release of CCK in response 
to food or intraduodenal fat occurs after 5 minutes in 
humans, 2 0 minutes in pigs and after 2 hours in dogs 
(Lilja et al, 1982). In a study using ultrasonography 
to assess gallbladder contraction, Wiener and 
colleagues (1981) demonstrated that intraduodenal 
instillation of a medium-chain triglyceride increased 
plasma CCK to maximal levels within 16 minutes and 
reduced gallbladder volume to minimum in 18 minutes.
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Infusion of exogenous CCK in humans to physiological 
plasma levels has been shown to stimulate pancreatic 
secretion and gallbladder contraction (Kerstens et al, 
1985). Interestingly, in rats, only intact proteins 
but not amino acids, fats or carbohydrate seem to 
stimulate CCK release (Liddle et al, 1986).
In addition to the stimulation of gallbladder 
contraction and pancreatic enzyme secretion, CCK has
!
been shown to exert a number of other effects. It 
stimulates bicarbonate release and insulin secretion
I
from the pancreas, intestinal motility, the 
contraction of the resting stomach and pylorus and
[
i
bile production in the liver, amongst others; it
j
inhibits lower oesophageal sphincter contraction and
|
contraction of the sphincter of Oddi (all cited in 
Marx et al, 1987).
i
I In 1967, Rothman and Wells found that synthesis
l
i
of pancreatic enzymes in the rat was stimulated by
!
,CCK. Although their study was not designed to 
demonstrate trophic influences on the pancreas, they 
|did note that pancreatic weight was significantly 
I increased in the CCK group. Other investigators have 
.confirmed the trophic effect of CCK (Barrowman and 
Mayston, 1973; Brants and Morisset, 1976; Howatson[[
^and Carter, 1985). Chronic administration of CCK was 
.associated with increases in pancreatic protein, RNA 
and DNA content and in stimulation of [14C]thymidine 
incorporation into DNA in a study by Mainz and co­
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Iworkers (1973). Caerulein (an amphibian skin 
decapeptide structurally and functionally related to 
CCK) was shown to be trophic to rat pancreas, and when 
administered with exogenous secretin, the trophic 
effect was greater than expected by simple summation
i
of the effects of each individually (Solomon et al,
I
i1978). The potentiated trophic effect on the pancreas 
of combined administration of caerulein and secretin 
was confirmed by Dembinski and Johnson (1980).
|
Subsequent workers have confirmed these early
I
^observations although there have been some interesting 
species differences and variations in response 
depending on dose schedules and CCK preparations used.
j
itf
b) Secretin
i
[ The study of endocrinology started in 1902 when
!
Bayliss and Starling described the secretion of
|
pancreatic juice in response to the infusion of
i
hydrochloric acid into a devervated loop of small 
intestine. The 27 amino acid sequence of secretin was 
not described or synthesised for another 60 years 
(Bodanszky et al, 1966; Mutt et al, 1965).
Secretin is found predominantly in the duodenum 
jand proximal small intestine (Curtis, Rayford and 
Thompson, 1976; Straus and Yalow, 1978). More 
recently, immunoreactive secretin has been discovered 
in the central nervous system of rats and pigs 
(O'Donohue et al, 1981).
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Despite a search for dietary and other 
stimulants of secretin release, duodenal acidification 
with hydrochloric acid remains the only consistent 
such agent (Rayford et al, 1976); secretin release is 
proportionate to the amount of acid in the duodenum. 
In the dog, perfusion of an isolated segment of 
jejunum with hydrochloric acid or sodium oleate 
stimulated secretin release (Fujimura et al, 1984a; 
Fujimura et al, 1984b). In the rat, acid perfusion of 
the distal ileum increased plasma secretin and 
pancreatic bicarbonate secretion (Shinomura et al, 
1983).
In addition to the stimulation of pancreatic 
bicarbonate secretion, secretin stimulates the
I production of colonic mucin, gastric pepsin secretion 
and increases serum parathormone; it inhibits colonic
}
; contraction, gastric acid secretion, gastric emptying, 
lower oesophageal sphincter tone and gastrointestinal 
motility (cited in Doyle, Luis and Rayford, 1987).
Secretin has also been reported as having a 
trophic effect on the pancreas. Eight-hourly 
subcutaneous injections of secretin (25 ug/kgBW) for 
5, 10 and 15 days resulted in a significant increase
in pancreatic weight only in the 15 day treatment
I group in a study by Solomon and co-workers (1978).
| Pancreatic DNA content in the secretin-treated animals 
was not increased in this study although there was a 
significant increase in RNA and lipase content at 15
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days. Protein content was also increased in the 
secretin treated rats, but this did not reach 
statistical significance. The authors concluded that 
secretin caused pancreatic hypertrophy alone, given 
the lack of increase in DNA content. In 1980, 
Dembinski and Johnson reported that chronic IP
j
; injection of 50 U/kgBW of secretin eight-hourly for 
seven days in rats, resulted in a significant increase 
in pancreatic DNA and RNA concentration compared to
|
|control animals. Pancreatic DNA synthesis was also 
significantly increased in the secretin-treated group.
i
tThe authors concluded in this study that secretin 
s t i m u l a t e d  both pancr e a t i c  h y p e r t r o p h y  and 
hyperplasia.
[
In 1981, in a study of the effects of endogenous
[F
secretin on the pancreas, Johnson reported that fiveI
I
|days of c o n tinuous duodenal p e r f u s i o n  with 
^hydrochloric acid (known to stimulate the release of 
| secretin) resulted in an increase in pancreatic weight 
|and in pancreatic DNA content in Sprague-Dawley rats.
^e concluded that endogenous secretin had a similar
I
|trophic effect on the pancreas as exogenous hormone. 
Unfortunately, Johnson was unable to assay secretin to
fi
ensure that duodenal perfusion with acid had resulted 
in stimulation of secretin secretion.
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1.8 Somatostatin and Analogues
a) Physiology
Somatostatin, a tetradecapeptide with a 
molecular weight of 1637 was first described by 
Brazeau and colleagues (1973) during a search for an 
ovine hypothalamic growth hormone (somatotropin)
i
^release inhibiting hormone (SRIF or GHRIH). Brazeau1s 
group were able to purify, sequence and synthesize
I|
. SRIF and renamed it somatostatin. Schally and 
colleagues (1976) isolated and characterised
iI
somatostatin from porcine hypothalami and confirmed
i
.that its amino acid sequence was identical to
I
somatostatin of ovine origin. Identical substances 
have since been isolated and purified from pigeon
I
pancreas (Speiss et al, 1979), from the pancreatic
i
j islets of anglerfish (Noe et al, 1979) and from the 
pancreas of Sprague-Dawley rats (Benoit et al, 1980). 
Somatostatin-2 8 has been identified in porcine 
I intestine (Pradayrol et al, 1980) and in ovine 
|hypothalamus (Esch et al, 1980). Even larger forms of 
somatostatin have been identified and sequenced 
(Bethge, Diel and Usadel, 1982).
In 1975, Polak and colleagues described the 
presence of GHRIH-like immunoreactivity in the D-cells 
of the pancreatic islets and in cells in all parts of 
the upper gastrointestinal mucosa. GHRIH staining 
cells were localised mainly to the midzone of mucosal
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glands, but also to cells in the basal region of the
glands and the tips of the villi. Since then,
somatostatin has been found in the nervous system, in 
various body fluids, in most of the tissues of the 
body and in some tumours (Efendic, Hokfelt and Luft, 
1978; Larsson, 1981; Bethge et al, 1982) . In the 
gastrointestinal tract, which contains approximately 
70% of the body's total somatostatin (Patel et al,
1981), somatostatin has been demonstrated in the
antrum, body and fundus of the stomach, the duodenum, 
jejunum, ileum, colon and pancreas, with particularly 
high activity in the pancreas and the stomach 
(McIntosh et al, 1978). In man, its half-life in 
plasma is short; between 1.69 minutes (Bethge et al, 
1981) and 3 minutes (Bauer et al, 1982).
In the gastointestinal tract somatostatin 
release is influenced by vagal tone, prostaglandins, 
circadian rhythm, cholinergic and adrenergic receptors 
and fluctuations in the migrating motor complex; 
post-prandial plasma levels are increased by meals, 
intraluminal acid and bile, and circulating nutrients, 
and are modulated by vagal tone, prostaglandins, and 
cholinergic, adrenergic, histaminergic and opiate 
receptors. Somatostatin release is stimulated by CCK, 
gastrin, gastric inhibitory polypeptide (GIP), 
secretin, bombesin, substance P and vasoactive 
intestinal polypeptide (VIP) (Newman, Lluis and 
Townsend, 1987).
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The a c t i o n s  of s o m a t o s t a t i n  in the 
gastrointestinal tract are numerous. It inhibits 
salivary gland, gastric acid, pepsin and intrinsic 
factor secretion (Arnold and Lankisch, 1980), and 
increases gastric mucous production (Johansson and 
Aly, 1982). It inhibits the release of all known 
gastrointestinal hormones including gastrin, secretin, 
CCK, motilin, enteroglucagon, GIP, VIP and pancreatic 
polypeptide (Arnold and Lankisch, 1980). It inhibits 
the release of insulin and glucagon from the pancreas 
(Koerker et al, 1974) and when administered 
exogenously, decreases the release of the thyroid 
hormones T3 and T4 (Lins, Efendic and Hall, 1979). 
Amino acid residues 7 to 10 are essential for 
biological activity (Bauer et al, 1982).
The effects of somatostatin on the exocrine 
pancreas are less clear. Pharmacological doses of 
somatostatin in dogs resulted in competitive 
inhibition of the effects of secretin but not CCK 
(Konturek et al, 1976) , and when administered as a 
bolus in rats seemed to stimulate pancreatic secretion 
(Arnold and Lankisch, 1980); it was suggested that 
identical amino acids comprising the 5-8 positions in 
the secretin molecule and the 10-13 positions in the 
somatostatin molecule might explain this phenomenon. 
The majority of studies, however, report an inhibition 
of the secretion of protein, bicarbonate and volume of 
pancreatic juice in response to somatostatin
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administration (Arnold and Lankisch, 1980).
b) Somatostatin Analogues
The half-life of somatostatin in plasma in man 
is only three minutes (Bauer et al, 1982). 
Therapeutic application is therefore difficult; 
continuous infusions have been required to arrest 
upper gastrointestinal haemorrhage from peptic ulcers 
(Kayasseh et al, 1980; Magnusson et al, 1985) and 
from oesophageal varices (Jenkins et al, 1985). This 
short half-life and multiple inhibitory effects have 
prompted the search for analogues of somatostatin with 
longer durations of action and more specific 
inhibitory effects.
Des[Ala1 ,Gly2 ,Asn5 ]-somatostatin was shown to 
inhibit the release of insulin, and to a lesser extent 
growth hormone, without inhibiting glucagon release 
(Sarantakis et al, 1976). D-Cys14-somatostatin and 
[D-Trp8 ,D-Cys14]-somatostatin, selectively inhibit 
growth hormones and glucagon more than insulin release 
(Brown, Rivier and Vale, 1977; Gordin et al, 1977). 
Since these initial reports, other somatostatin 
analogues have been developed with more selective 
inhibitory actions (Schally, Coy and Meyers, 1978) . 
SMS 201-995 (Sandoz) is an octapeptide analogue of 
somatostatin [H-(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys-Thr- 
ol, acetate]. It has a plasma half-life of 45 minutes 
following the termination of an intravenous infusion
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and is a more potent inhibitor of growth hormone, 
glucagon, insulin and gastric acid secretion than 
somatostatin. In rats, it has been shown to prevent 
the development of acute pancreatitis (Baxter et al, 
1985a), stimulate the reticuloendothelial system 
(Baxter et al, 1985b) and reduce the effect of
endotoxaemia (Baxter et al, 1985c).
c) Somatostatin Analogues and Pancreatic Cancer
The inhibitory effects of somatostatin and its 
analogues on various aspects of pancreatic endocrine 
and exocrine function prompted some investigators to 
examine its effects on the growth and development of 
pancreatic tumours. Redding and Schally (1984), using 
hamster-ductal and rat-acinar pancreatic cancers 
t r a n s p l a n t e d  into other hamsters and rats 
respectively, demonstrated that chronic administration 
of a number of somatostatin analogues could inhibit 
tumour growth. [L-5-Br-Trp8]-somatostatin-14, which 
is equipotent with somatostatin with respect to 
gastric acid secretion suppression, significantly 
decreased tumour weight and volume in rat and hamster 
tumour-bearing animals. A cyclical hexapeptide 
analogue of somatostatin (cyclo-Pro-Phe-D-Trp-Lys-Thr- 
Phe) inhibited hamster ductal pancreatic cancer growth 
but had no effect in rats. Somatostatin-28 had no 
effect on tumour growth in the rat model. This work 
prompted the authors to suggest that pancreatic cancer
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in humans might respond to similar hormonal 
manipulation.
In a study of a human pancreatic cancer cell 
line (MIA PaCa-2), Liebow and co-workers (1986) 
demonstrated that somatostatin could eliminate growth 
stimulation of the tumour cells by EGF in cell 
culture. They had previously demonstrated that 
m e m b r a n e - b o u n d  and c ytosolic receptors for 
somatostatin existed in this cell-line and that 
b i n ding of s o m a t ostatin d e p h o s p h o r y 1 ated a 
phosphotyrosyl-membrane protein whose phosphorylation 
had been promoted by EGF (Hierowski et al, 1985).
They suggested that this mechanism might explain 
somatostatin's inhibitory effect on pancreatic cancer 
and prompt further investigation into possible 
therapeutic applications of this information.
In 1987, Paz-Bouza, Redding and Schally reported 
the results of an investigation into the effects of 
somatostatin analogues on BOP-induced ductal 
pancreatic adenocarcinoma in the Syrian hamster. The 
cyclical analogue RC-160 (D-Phe-Cys-Tyr-D-Trp-Lys-Val- 
Cys-Trp-NH2 with a disulphide bond between the two Cys 
amino acids) was administered in slow release 
microcapsules (liberating 5 ug/day of RC-160) to 
female hamsters after 18 weeks exposure to BOP. 
Treated hamsters exhibited a striking decrease in 
tumour weight and volume and an increased percentage 
survival after 45 days of treatment compared to
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controls.
As yet, there has been no p u b l i s h e d  
investigation into the effect of somatostatin or its 
analogues on pancreatic carcinogenesis in animal 
models.
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1.9 Summary and Aims of Thesis
Cigarette smoking is the most consistent factor 
so far implicated in the aetiology of human pancreatic 
cancer. Nitrosamines, which we know to be present in 
cigarette smoke, can induce exocrine pancreatic cancer 
in animal models, although, to date, none of the 
specific nitrosamine carcinogens so far detected in 
cigarette smoke have been shown to induce such 
malignant change. Given the morphological similarity 
between nitrosamine-induced hamster and human 
pancreatic cancer, and the likely implication of 
nitrosamine-containing cigarette smoke in the 
aetiology of the human tumour, the nitrosamine-hamster 
model of pancreatic cancer would appear to be 
reasonably valid for investigating aspects of 
pancreatic carcinogenesis.
There is increasing evidence to suggest that 
dietary factors may explain some of the differences in 
the incidence of pancreatic cancer throughout the 
world. Diets with a high fat and protein content have 
been implicated most frequently in the increasing 
incidence of pancreatic cancer. The influence of some 
d i e t a r y  factors on e x p e r i m e n t a l  p a n c r e a t i c  
carcinogenesis has been investigated in animal models, 
and generally has confirmed that diets with a high fat 
and protein content increase the susceptibility of the 
pancreas to the effects of carcinogens.
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Given that dietary fat and protein are amongst 
the most powerful stimulants of the release of various 
gastrointestinal hormones, which have been shown by 
many investigators to influence pancreatic physiology 
and morphology, the question arises as to whether the 
effects of diet on pancreatic cancer susceptibility 
might be mediated through some of these hormones. 
Cholecystokinin and secretin have previously been 
shown to increase the susceptibility of animal 
pancreata to the effects of carcinogens. Whether they 
can be implicated in the human situation is less 
clear.
Somatostatin, an inhibitory gastrointestinal 
hormone, has been shown to inhibit both the release 
and the effects of secretin and CCK. Unfortunately 
somatostatin has a short half-life and this has 
prompted the development of many somatostatin 
analogues. Some investigators have demonstrated that 
s o m e  s o m a t o s t a t i n  a n a l o g u e s ,  u s u a l l y  in 
pharmacological doses, can inhibit the progression of 
induced animal pancreatic cancer. They have 
speculated that some of the longer acting analogues 
may have a role in treating established human 
pancreatic cancer.
There is little published information on the 
effect of somatostatin analogues administered during 
the carcinogenic process in animal models. In 
addition, there is little information on the
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interaction between somatostatin analogues and some of 
the other gastrointestinal hormones in this respect. 
As a consequence, the aims of this thesis were:
1) to establish the nitrosamine (BOP) - hamster 
model of pancreatic carcinogenesis in our laboratory?
2) to investigate the effects of intravenously 
infused physiological doses of secretin, CCK-8 and the 
long-acting somatostatin analogue SMS 201-995, alone 
and in combination, on exocrine pancreatic juice 
output in the Syrian golden hamster?
3) to determine the effects of subcutaneous 
injections of secretin, CCK-8 and SMS 201-995, alone 
and in combination, on pancreatic wet weight and 
pancreatic DNA content, in the Syrian golden hamster?
4) to determine the effects of subcutaneous 
injections of secretin, CCK-8 and SMS 201-995, alone 
and in combination, on BOP carcinogenesis in the 
Syrian golden hamster.
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CHAPTER 2
Induction of pancreatic adenocarcinoma in the Syrian 
golden hamster: intraperitoneal versus subcutaneous
administration of N-nitrosobis(2-oxopropyl)amine (BOP)
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2.1 Introduction
The nitrosamine-hamster model of pancreatic 
cancer has been used by many authors to study various 
aspects of carcinogenesis since its development by 
Pour in the 1970's. In order to determine that the 
model could be reproduced in our own laboratories 
using the dosing schedules previously described, a 
pilot study was undertaken.
When the model had been used previously in the 
University Department of Surgery at Glasgow Royal 
Infirmary, considerable morbidity had been experienced 
by the animals as a consequence of repeated 
subcutaneous injections of the carcinogen N-nitrosobis 
(2- o x o p r o p y 1 ) amine (BOP) (D. Bell, personal 
communication) . This morbidity took the form of 
extensive skin ulceration and infection. In addition, 
there was no available published data on the effect of 
intraperitoneal injection of carcinogen on the 
pancreas. It was decided therefore to embark on a 
small comparative study of intraperitoneal versus 
subcutaneous administration of carcinogen, to compare 
the degree of morbidity experienced by the animals in 
the two groups and to determine whether the 
morphological changes developed in the pancreata were 
comparable.
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2.2 Materials and Methods
Sixty male WO(GD) strain Syrian golden hamsters 
(Wrights of Essex) were divided into two groups of 3 0 
animals each. All animals were kept in standardized 
animal facility conditions with a 12 hour light dark 
cycle, 21% humidity and caged in groups of four. All 
animals were fed standard small rodent diet (Rat and 
Mouse No. 1 Modified Maintenance Diet, Special Diet 
Services, Witham, Essex) and water ad libitum.
N-nitrosobis(2-oxopropyl)amine (BOP: Ash
Stevens Inc., Detroit, USA) was administered once 
weekly to all animals in a dose of 5mg/kg body weight 
(kgBW) per injection. Group A received carcinogen 
intraperitoneally and Group B subcutaneously (SC). 
The site for SC administration was rotated through 
right thigh, left thigh, right flank and left flank in 
an attempt to minimise morbidity from skin ulceration 
due to repeated injection of carcinogen at one site.
Carcinogen was made up into solution with normal 
saline (0.9%) to a concentration of lmg/ml of 
solution, within one hour of administration, as BOP is 
known to degrade if left in solution for longer 
periods. A filter mask was worn during weighing of 
carcinogen and making up of the solution, and any 
spillage was immediately cleaned with liberal amounts 
of water. All staff handling the animals receiving 
carcinogen wore gloves and animal waste was 
incinerated.
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Animals in both groups were weighed weekly on 
the day prior to injection. The carcinogen dose 
administered was calculated on the basis of the animal 
weight on the previous day, and rounded up or down to 
the nearest 0.05ml.
Animals were sacrificed in groups after five, 
10, 15 and 20 weeks of carcinogen administration. A
full post-mortem examination was performed at time of 
sacrifice and gross lesions in the pancreas and other 
organs sought. The pancreas was then excised with the 
duodenum attached to the duodenal lobe and a segment 
of spleen attached to the splenic lobe to allow 
identification of the lobes. The entire excised 
pancreas was fixed in 4% formal saline solution.
After fixation, the pancreas was cut and blocked 
in paraffin wax. Three blocks were cut from the 
gastric and splenic lobes and one from the duodenal 
lobe. Three serial sections 4um thick were cut from 
each block, mounted on chrome alum microscopic slides 
and stained with haematoxylin and eosin (H&E). Gross 
lesions in the pancreas were excised, fixed and 
stained separately.
All sections were examined for the presence of 
abnormalities when compared to normal hamster 
pancreas. In particular, evidence of acinar cell 
death, acinar-ductular (A-D) transformation, cystic 
ductular complexes, ductular carcinoma-in-situ (CIS), 
ductular microcarcinoma, ductal dysplasia, ductal CIS
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and frankly invasive adenocarcinoma was sought.
Acinar cell death was recorded when a cell 
appeared to lose its staining characteristics, when 
the nucleus appeared pyknotic or when an acinus 
appeared distorted and small, indicating the death of 
a number of cells in the acinus. Acinar cell death 
was often accompanied by an increase in the number of 
ductular or centroacinar cells. The loss of solid 
acinar structure and its r e p l a c e m e n t  by or 
degeneration into a cystic structure lined by a thin 
rim of cellular material was recorded as AD 
transformation. When three or more areas of AD 
transformation appeared together the lesion was 
described as a cystic ductular complex. The term 
ductular CIS was used to describe a lesion composed 
entirely of atypical, dysplastic ductules. These 
ductules varied greatly in size and shape and were 
composed of cells with pleomorphic nuclei with 
frequent mitotic figures. These lesions were usually 
encapsulated by a zone of inflammatory cells and 
involved only one pancreatic lobule. A ductular 
microcarcinoma was essentially a large ductular CIS 
which had breached the boundaries of a lobule.
The first change seen in larger ducts in 
response to BOP was the development of ductal 
hyperplasia. The neatly arranged unilayer of cells 
lining the duct became heaped up and the cells seemed 
to lose their polarity. A more disordered appearance
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associated with nuclear pleomorphism and the 
appearance of the occasional mitotic figure was 
recorded as ductal dysplasia. Ductal CIS was 
characterised by intraluminal proliferation of 
atypical epithelium, often of papillary type, with 
crossbridging across the duct lumen and large numbers 
of mitotic figures and pleomorphic nuclei. An 
increase in surrounding inflammatory cells was also a 
feature.
Invasive adenocarcinoma exhibited all the 
characteristics of malignancy in any organ, namely a 
high mitotic rate, nuclear pleomorphism, disordered 
architecture and invasion.
The presence of a lesion in any section of any 
one pancreas was recorded as positive for that 
pancreas. In addition, in an attempt to gauge the 
extent of any particular histological lesion in the 
pancreata, results have been expressed as present or 
absent in each block in any group.
The nature of the histological lesions reported 
by the author was confirmed in a series of 100 
histological blocks examined blindly by Dr. David J. 
Harrison, Senior Lecturer in the Department of 
Pathology, University of Edinburgh. The number of 
lesions present in the SC and IP groups at each time 
point was compared using Fisher's exact test. Animals 
weights were compared using a two sample analysis of 
variance.
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2.3 Results
Table 2.1 depicts changes in mean body weights 
in the two groups of animals over the 2 0 week 
experiment. Mean body weight in the two groups 
increased from 89.3g (IP) and 93.lg (SC) at week 0 to 
a maximum of 126.2g (IP) and 125.9g (SC) at week 15. 
Mean body weight thereafter fell in both groups, 
presumably as a result of the development of malignant 
lesions in the pancreas. The body weights of the two 
groups were significantly different at week 0 
(p<0.05). There was no statistical difference between 
animal weights in the two groups at any other time 
point during the experimental period.
Three animals in the intraperitoneal group 
exhibited weight loss in excess of 10% of body weight 
in one week, which, under the terms of the animal 
project licence necessitated humane sacrifice at week 
four (n=l) and week eight (n=2) . All three animals 
were found at post-mortem examination to have a 
necrotic testis and associated abscess. It is likely 
that this was caused by accidental administration of 
BOP into a retracted abdominal testis during 
intraperitoneal injection. There was no injection 
morbidity in the SC group and the remaining hamsters 
in the IP group.
After five weeks of carcinogen injection, six 
animals in each group were sacrificed. Full post­
mortem examination failed to reveal any gross lesions
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Table 2.1: Mean body weights of two groups of
hamsters injected with the carcinogen BOP 
either SC or IP, during a twenty week 
experiment.
Week Intraperitoneal Group Subcutaneous Group
n mean body weight 
(SD)
n mean body weight 
(SD)
0 30 89.3g (6.3g) 30 93.lg (8.lg)*
5 29 110.5g (9•6g) 30 115.3g (9.5g)
10 21 122.Og (12.8g) 24 124.8g (13.2g)
15 14 126.2g (19.3g) 18 125.9g (14.7g)
20 7 112.8g (11.3g) 11 119.7g (20.0g)
(n = number of animals, SD = standard deviation of the
mean *P<0 .05)
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in any organ. On histological examination the 
pancreata of both groups of animals exhibited evidence 
of patchy acinar cell death and prominence of small 
pancreatic ductules (Fig. 2.1). There was no 
discernable difference between the two groups with 
respect to the severity or extent of these changes. 
There was also some evidence of mild periductal 
inflammation in a minority of sections in both groups. 
One section in the IP group exhibited mild ductal 
hyperplasia and another mild goblet cell metaplasia in 
a major pancreatic duct. These changes were not seen 
in the SC group largely because few of the sections in 
this group contained large ducts for examination.
Histological changes seen in the hamster 
pancreata after 10 weeks of carcinogen treatment are 
shown in Table 2.2. There was no evidence of ductular 
or ductal CIS, m i c r o c a r c i n o m a  or invasive 
adenocarcinoma in any section in either group. Acinar 
cell death was a prominent feature in almost all 
sections examined in both groups. Acinar-ductular 
transformation was seen in almost all animals but was 
not widespread throughout each pancreas. Cystic 
complexes were small, comprising usually not more than 
three or four small cyst-like structures (Fig. 2.2). 
Periductal inflammation became very prominent at this 
stage, particularly affecting the larger ducts. A 
cellular inflammatory infiltrate was seen in many 
sections, particularly where acinar cell death and
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IFigure 2.1: Hamster pancreas after 5 weeks IP
injection of BOP showing evidence of patchy acinar 
cell death and prominence of interlobular ductal 
cells. (H&E; x280 magnification).
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Table 2.2: Histological lesions present in hamsters
after 10 weeks treatment with BOP.
Animals 
SC IP
Histological 
Blocks 
SC IP
(n=6) (n=6) (n=3 6) (n=42)
Ductal hyperplasia 1 2 1 3
Ductal dysplasia 0 1 0 1
A-D transformation 5 5 10 18
Cystic complexes 4 3 7 4
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Figure 2.2: Hamster pancreas after 10 weeks SC
injection of BOP showing a small cystic ductular 
complex. The solid appearance of adjacent acini is 
contrasted by the development of cystic structures 
lined by a single layer of flattened epithelium. 
(H&E; x280 magnification).
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subsequent proliferation of cells of ductular and 
centroacinar origin was prominent.
The histological changes seen after 15 weeks of 
carcinogen treatment in the two groups of animals are 
shown in Table 2.3. Ductal hyperplasia was present in 
some sections in both groups, as after ten weeks of 
carcinogen treatment. Ductal dysplasia (Figs. 2.3 & 
2.4) and ductal CIS became a new feature at this 
stage. Cystic complexes affected all pancreata 
examined and were present in over half of the blocks 
examined in both groups (Fig. 2.5). Ductular CIS 
(Fig. 2.6) was significantly more prominent in the SC 
group both with regard to affected animals and 
affected sections. Microcarcinoma (Fig. 2.7) was 
p r e s e nt  in one pancr eas  in each group but 
adenocarcinoma was present only in the IP group.
Histological changes seen after 20 weeks of 
carcinogen treatment in the two groups of animals are 
shown in Table 2.4. Ductal hyperplasia affected 
significantly more animals and blocks in the SC group, 
although this is unlikely to be important given the 
extent and severity of more advanced pre-malignant 
changes at this stage. Ductal dysplasia was more 
widespread in both groups but the amount of ductal CIS 
did not seem to increase. Cystic complexes, which 
tended to be even bigger than those seen at 15 weeks, 
affected nearly all pancreata examined. Ductular CIS 
affected similar numbers of hamsters in each group but
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Table 2.3; Histological lesions present in hamsters 
after 15 weeks treatment with BOP
Animals Histological
Blocks
SC IP SC IP
(n=6) (n=7) (n=34) (n=48)
Ductal hyperplasia 2 3 2 3
Ductal dysplasia 3 2 4 4
Ductal CIS 3 2 5 2
Cystic complexes 6 7 20 25
Ductular CIS 6 3* 13 5+
Microcarcinoma 1 1 2 1
Adenocarcinoma 0 2 0 2
(* = p<0.05 versus SC group, Fisher1 s Exact Test)
(+ = p<0.005 versus SC group, Fisher's Exact Test)
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Figure 2.3: Hamster pancreas after 15 weeks SC
injection of BOP showing ductal dysplasia in two peri- 
insular ducts. The cells lining the ducts have lost 
their order and polarity and there are a number of 
m i t o t i c  f i g u r e s  in e v i d e n c e .  (H&E? xl4 0 
magnification).
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Figure 2.4: Hamster pancreas after 15 weeks SC
injection of BOP showing ductal dysplasia in a major 
pancreatic duct. The cells lining this duct have 
become disordered with a loss, in some areas, of 
cellular polarity. Nuclear pleomorphism is evident 
and there are a number of mitotic figures. (H&E; 
x280 magnification).
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Figure 2.5: Hamster pancreas after 15 weeks SC
injection of BOP showing a cystic ductular complex 
adjacent to an islet of Langerhans (top centre of 
section). (H&E; xl40 magnification).
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Figure 2.6: Hamster pancreas after 15 weeks SC
injection of BOP showing ductular carcinoma-in-situ. 
This lesion is composed of atypical dysplastic 
ductules and is surrounded by a halo of inflammatory 
cells. (H&E; xl40 magnification).
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Figure 2.7: Hamster pancreas after 15 weeks SC
injection of BOP showing ductular microcarcinoma. The 
lesion involves adjacent lobules of the pancreas and 
is surrounded by a halo of inflammatory cells. There 
is a small dysplastic duct in the centre of the 
section. (H&E; xl40 magnification).
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Table 2.4: Histological lesions present in hamsters
after 2 0 weeks treatment with BOP
Animals Histological
Blocks
SC IP SC IP
(n=8) (n=7) (n=55) (n=4'
Ductal hyperplasia 5 0# 5 0*
Ductal dysplasia 5 4 5 4
Ductal CIS 3 3 5 5
Cystic complexes 8 6 25 24
Ductular CIS 7 5 19 8*
Microcarcinoma 3 2 4 2
Adenocarcinoma 5 2 15 5*
(# = p<0.02 versus SC group, Fisher1s Exact Test)
(* = p<0.05 versus SC group, Fisher's Exact Test)
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was significantly more widespread in the SC group. 
Microcarcinomata were present in similar numbers in 
both groups. Invasive adenocarcinoma (Figs. 2.8 &
2.9) affected more hamsters in the SC group than in 
the IP group.
Although no formal estimation of islet size and 
number was made at any time point in this experiment, 
it was not apparent that any obvious changes had 
occurred in response to BOP administration.
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Figure 2.8: Hamster pancreas after 20 weeks SC
injection of BOP showing invasive adenocarcinoma I. 
The tumour in this section exhibits both ductal and 
ductular morphology. (H&E; xl40 magnification).
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Figure 2.9: Hamster pancreas after 20 weeks SC
injection of BOP showing invasive adenocarcinoma II. 
The tumour in this section exhibits predominantly 
ductular morphology. The large duct on this 
histological section (top left) exhibits severe ductal 
dysplastic change. There is an islet of Langerhans in 
the top right corner of the section (H&E; xl40 
magnification).
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2.4 Discussion
In this experimental study, the histological 
changes seen in both groups of animals after exposure 
to BOP corresponded very closely to those reported in 
the many early papers by Pour and his colleagues.
The first changes seen were acinar cell death 
and prominence of small pancreatic ductules after five 
weeks of treatment. Focal hypertrophy and hyperplasia 
of large ductal epithelium, reported as occurring 
within two weeks of carcinogen exposure (BOP 
lOmg/kgBW) by Pour (1977d) was seen in only one animal 
in the IP group in this experiment.
The predominant histological abnormalities seen 
after 10 weeks of carcinogen administration were 
acinar-ductal transformation and the development of 
small cystic ductular complexes. The nature of these 
particular lesions remains the subject of much debate. 
Ductal and ductular obstruction was initially thought 
to result in the development of these cystic 
structures. However, in a study using India ink 
injection of the main pancreatic ducts, Pourfs group 
demonstrated that ink was able to get through the main 
ducts and fill the cystic complexes (Takahashi et al, 
1977b). Whether the injection pressure used overcame 
natural obstructing forces is unclear, given that no 
data relating to injection pressure were presented.
In a more recent electron-microscopic and 
immunohistochemical study, Pour (1988) suggested that
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the earliest changes in the pancreas seen following a 
single injection of BOP (20mg/kgBW) were hyperplasia 
and hypertrophy of centroacinar cells. These abnormal 
centroacinar cells developed long cytoplasmic 
processes which seemed to separate acinar cells 
resulting in their degeneration and death. Certainly, 
centroacinar cell proliferation was only seen in areas 
where acinar cells had undergone degeneration. After 
a period, the abnormal centroacinar cells formed into 
pseudoductular complexes which were lined by a single 
layer of elongated cells - the cystic complexes 
reported by many authors and seen in this thesis. The 
presence of increasing numbers of inflammatory cells 
during the carcinogenic process could be explained by 
a need to remove cell debris caused by death of 
increasing numbers of acinar cells. At no stage did 
acinar cells seem to transform into ductular cells. 
Interestingly, some of the cells in these 
pseudoductular structures became cytologically 
abnormal with pleomorphic nuclei and plump microvilli, 
consistent with malignant progression.
After 15 weeks of carcinogen exposure the range 
of histological abnormalities seen in both groups of 
animals in the current study increased to include 
lesions which are generally recognised to be truly 
pre-malignant or malignant, namely ductular CIS, 
microcarcinoma and frankly invasive adenocarcinoma. 
Ductal dysplasia and ductal CIS which both seem to
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have the potential to p r o g r e s s  to invasive 
adenocarcinoma became obvious at this stage. These 
changes agree with previously published work with the 
BOP model.
Despite the similarities in the nature of 
histological changes seen in the animals injected SC 
and those injected IP, the extent and severity of 
these changes appeared to be worse in the SC group, 
particularly after 20 weeks of treatment and 
particularly with respect to the development of 
d u c t u l a r  CIS, m i c r o c a r c i n o m a  and invasive 
adenocarcinoma. Ductal histological changes were 
similar in both groups.
A possible reason for the differences between 
the two groups of animals with respect to the extent 
of the histological lesions developed in response to 
BOP might lie in the way that the carcinogen is 
handled after IP or SC administration. The fact that 
lesions seem to be more frequent in the SC group would 
suggest that direct contact of the carcinogen with the 
pancreas (as might occur in the IP group) in an 
unmetabolised form does not play in important role in 
the development of the various histological changes 
reported. To date, there has been no published work 
comparing the relative effects of IP and SC BOP in the 
Syrian hamster. From work reported in Chapter 1 of 
this thesis, it has been generally accepted that BOP 
acts, regardless of the route of administration, after
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absorption into the bloodstream and oxidative 
metabolism into active compounds, of which HPOP seems 
to be the most likely candidate.
In a recent study, Mangino and colleagues (1990) 
attempted to look at the carcinogen metabolising 
capacity of isolated hamster pancreatic acinar and 
ductal cells and hepatocytes. They demonstrated that 
hamster hepatocyte preparations metabolized BOP to 
HPOP and BHP with a much higher capacity than either 
hamster pancreatic acinar or ductal cells. In 
conditions most favourable to BOP metabolism, the 
ratio of activation products formed by hepatocytes was 
14.5 times that formed by acinar cells. Hepatocytes 
were also shown to activate BOP 106 times more rapidly 
than ductal cells, as determined from the yield of 
activation products, or 156 times more rapidly if the 
ratio for covalently bound metabolites was used for 
comparison. Pancreatic acinar cells had a higher 
capacity for BOP activation than ductal cells.
These results led the authors to conclude that 
alkylation of BOP in other organs, most probably the 
liver, occurs before any effect on the pancreas was 
seen. It is unclear whether BOP appearing at the 
liver via the portal circulation (as is likely in IP 
injected animals) is handled in a different way to BOP 
appearing at the liver via the systemic circulation.
In some of Pour’s earlier work, great emphasis 
was placed on the importance of increased numbers of
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pancreatic islets and of the importance of peri- 
insular ductules in the carcinogenic process. In the 
current study, changes in the number and size of 
islets were not apparent. Involvement of peri-insular 
ductules was difficult to determine at the level of 
magnification used, although some of the larger ductal 
lesions seen histologically occurred close to or 
within islets.
Pour and Bell (1989) recently reported on a 
study of endocrine cell proliferation in hamster 
p a n c r e a s  after 6 weeks of BOP treatment. 
Immunohistochemical staining of pancreatic tissue 
demonstrated an increase in the number of insulin, 
glucagon and somatostatin secreting cells after weeks 
12 and 33. Almost all of these extra endocrine cells 
were found outside islets, predominantly in 
hyperplastic ductal or ductular epithelium. At 12 
weeks the number of insulin- and glucagon-secreting 
cells far outnumbered the somatostatin-secreting 
cells. At 33 weeks the number of somatostatin- 
secreting cells increased dramatically. The role of 
these extra endocrine cells in the carcinogenic 
process still require explanation and further work on 
the effect of BOP on the endocrine elements in the 
pancr e a s  might shed light on the c o nfusing  
relationship between pancreatic cancer and diabetes.
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CHAPTER 3
Part 1
The effect of step-wise increasing doses of 
cholecystokinin octapeptide (CCK-8), secretin and a 
somatostatin analogue (SMS 201-995) on pancreatic 
juice output and composition in the Syrian golden 
hamster.
Part 2
(a) The effect of simultaneous infusions of 
cholecystokinin octapeptide (CCK-8) and SMS 201-995 on 
pancreatic juice output
(b) The effect of simultaneous infusions of secretin 
and SMS 201-995 on pancreatic juice output
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3.1 Introduction
It is well recognised that cholecystokinin and 
secretin stimulate pancreatic exocrine secretion in 
both man and animals, under physiological and 
pharmacological conditions. From our knowledge of the 
actions of somatostatin, it might be expected that SMS 
201-995 would inhibit such exocrine secretion.
In order to determine that cholecystokinin 
octapeptide, secretin and SMS 201-995 were active in 
the Syrian golden hamster and to determine the effect 
of various doses of these peptides on pancreatic 
exocrine secretion, a series of dose response curves 
were generated for each peptide based on the effects 
of intravenous infusions on pancreatic exocrine 
secretion in the Syrian golden hamster.
Some gastrointestinal hormones can act together 
to affect gastrointestinal function. Having 
identified doses of CCK-8, secretin and SMS 201-995 
which stimulate or suppress pancreatic secretion when 
infused intravenously into anaesthetised hamsters, 
infusion studies of combinations of CCK-8 or secretin 
and SMS 201-995 were undertaken to determine what 
effects their interaction have on pancreatic 
secretion.
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Part 1
3.2 Materials and Methods
Male WO(GD) Syrian golden hamsters (Wrights of 
Essex) 10 - 14 weeks of age were kept in standardised 
animal facility conditions with a twelve hour light- 
dark cycle and 21% humidity. Animals were caged in 
groups of four and fed standard small rodent diet and 
water ad libitum.
Hamsters were fasted singly in cages but with 
free access to water for 16 hours prior to the 
commencement of an infusion. Animals were weighed on 
the morning of the experiment.
Hamsters were anaesthetised intraperitoneally 
with pentobarbitone sodium BP (Sagatal, May and Baker 
Ltd., Dagenham: 60mg per ml) administered in a dose
of 0.1ml per 100 grammes body weight. Anaesthesia was 
maintained throughout the duration of each infusion by 
further injections of pentobarbitone sodium.
A surgical tracheostomy was fashioned and an 
intravenous cannula inserted into the right internal 
jugular vein. Normal saline was infused at a rate of 
0.375ml per hour using 5ml glass syringes on an 
infusion pump (B. Braun Medical Ltd.). A laparotomy 
was performed through a midline abdominal incision. 
The pylorus was identified and ligated to exclude 
gastric contents from the duodenum. The common duct 
was identified at the point of entry into the 
posterior aspect of the duodenum (Fig. 1.1). A small
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incision was made in the common duct and a cannula 
(Portex Ltd. 2FG, outer diameter 0.63mm, inner 
diameter 0.5mm) introduced and passed up into the 
common bile duct. The cannula was then withdrawn 
slowly, such that the tip of the cannula came to rest 
at the lower end of the common duct. The cannula was 
then firmly ligated in place by passing a suture 
around the cannula at the lower end of the duct. The 
common bile duct was then ligated in continuity just 
below the entry point of the cystic duct, to exclude 
bile. A large trocar and cannula was then passed 
through the animal's flank and the trocar removed. 
The cannula collecting pure bile-free pancreatic juice 
was then fed through the larger cannula passing 
through the body wall and left to drain externally. 
The abdominal incision was closed with a continuous 
Vicryl suture (Ethicon (UK) Ltd, Edinburgh). Animal 
temperature was monitored with a rectal thermometer 
and maintained at 36°C using an overhead heating lamp.
An equilibration period allowed bile-stained 
pancreatic juice (present in the distal common bile 
duct prior to ligation of same) to drain out through 
the pancreatic cannula. Pure pancreatic juice was 
then collected in pre-weighed tubes placed below the 
hamster. An initial basal sample was collected for 
one hour. Subsequent samples were collected over one 
hour (CCK-8, sulphated CCK fragment 26-33 amide, Sigma 
Chemical Company Ltd., Dorset, UK.) or 30 minutes
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(Secretin, porcine secretin, approximately 98% pure, 
Sigma Chemical Company Ltd., Dorset, UK. ; SMS 201- 
995, Sandoz Pharma Division, Basle, Switzerland). A 
20 minute time period was allowed after the 
commencement of a new infusion concentration prior to 
collection of pancreatic juice. This allowed the new 
infusate to travel down the jugular vein cannula to 
the animal. Jugular vein cannulae were cut into 
lengths calculated to clear fluid infused at 
0.375ml/hour in 2 0 minutes, prior to insertion.
I n f u s a t e s  w e r e  m a d e  up into v a r i o u s  
concentrations with distilled water, snap frozen in 
liquid nitrogen and stored at -268°C prior to use. 
Final dilutions were made on the day of the experiment 
into a volume of normal saline twice the infusate to 
be given over the time period and based on the body 
weight of the animal on that day. All substances were 
infused at a rate of 0.375ml/hour.
At the end of each time period, the pre-weighed 
tubes containing collected pancreatic juice were 
reweighed. The amount of juice produced was 
calculated by subtracting the weight of the tube prior 
to collection of pancreatic juice, from the weight of 
the tube and contents after the collection period. 
Amounts of pancreatic juice collected over time 
periods shorter than one hour were multiplied up to 
give values for hourly collection.
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At the end of each experiment, a solution of 
light green dye was injected into the pancreatic 
cannula. The abdominal wound was re-opened and the 
pancreas examined to ensure complete staining of the 
gland.
Bicarbonate Estimation
The bicarbonate content of the pancreatic juice 
was estimated using the Natelson Microgasometer (Model 
600; Scientific Industries International Inc. (UK) 
Ltd., Loughborough) (Figure 3.1). Mercury was 
advanced to the tip of the gasometer pipette. 0.01ml 
of pancreatic juice was aspirated into the gasometer 
and sealed in place with 0.02ml of mercury. Lactic 
acid (0.03ml) was then aspirated into the gasometer 
followed by 0.01ml of caprylic acid and 0.01ml of 
mercury. Water (0.1ml) was aspirated into the 
gasometer followed by mercury to the 0.12ml mark on 
the reaction chamber. The reaction chamber stopcock 
was closed and the gasometer piston turned until all 
the reagents have been drawn into the reaction 
chamber. The gasometer was agitated for one minute to 
allow the lactic acid to react with the sample and 
release C02. The gasometer piston was then wound back 
until the fluid meniscus returned to the 0.12ml mark 
and the initial pressure (P^) was read off the 
manometer? the temperature was also recorded. The 
piston was then wound back until the mercury column
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Figure 3.1: Natelson Microgasometer (Model
Scientific Industries International Inc. (UK) 
Loughborough).
6 00 ; 
Ltd. ,
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reached the top of the manometer. After opening the 
reaction chamber stopcock, 0.03ml of sodium hydroxide 
was then drawn into the gasometer pipette followed by 
mercury to the 0.12ml mark. The stopcock was closed 
and the piston wound back until all reagents reached 
the reaction chamber. The stopcock was then closed 
and the sample agitated again for one minute. Sodium 
hydroxide reacts with C02 thus extracting it from the 
sample. The piston was then wound back until the 
meniscus of the reagent mix reached the 0.12ml mark. 
The second pressure (P2) was then read on the 
manometer and C02 content calculated by subtracting P2 
from P ^  An adjustment was then made for temperature 
calculated from standard charts.
Protein Assay
Pancreatic juice protein content was measured 
u si n g a B io - R a d  p r o t e i n  assay kit (Bio-Rad 
Laboratories Ltd., Watford, UK.). This assay is based 
on the colour change induced in a dye in response to 
various concentrations of protein. Absorbance maximum 
for an acidic solution of Coomassie Brilliant Blue G- 
250 used in the assay shifts from 465nm to 595nm when 
binding to protein occurs. Spectrophotometric 
measurement of absorbance at 595nm wavelength allows 
estimation of protein content to be made.
Samples were diluted with water to required 
concentrations. Lyophilized bovine serum albumin
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standards were diluted to 0.2 - 1.4 mg/ml. 0.1ml of 
standard and diluted sample solutions were placed in 
dry test tubes. 0.1ml of sample buffer was placed in 
a "blank” test tube. 5 ml of diluted dye reagent was 
added to the samples, the standards and the buffer 
blank. Test tubes were then agitated on a vortex 
mixer. After 10 minutes, absorbance at 595nm for the 
dye-sample complex is measured. Allowance is made for 
the absorbance of the buffer blanks and the true value 
obtained for absorbance for each sample and standard. 
A series of 10 normal calf serum samples were measured 
during each test run to act as quality control. From 
the bovine serum albumin standard samples, a standard 
curve was drawn for each assay run and the protein 
content of the pancreatic juice samples were read from 
the curve.
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3.3 Results
a) CCK-8 Infusions
Pancreatic juice weight (mg/hour) and pancreatic 
juice output (mg/kgBW/hour) during the infusion of 
CCK-8 in six hamsters (mean body weight 116.8g, range 
105.9 - 127.7g) are shown in Figures 3.2 and 3.3. The 
median basal pancreatic juice output over the first 
hour when saline was infused was 92.1mg/kgBW (Q1:Q3 = 
75.5:96.2). This rose steadily to 345mg/kgBW/hour 
(Q 1 : Q 3 = 3 2 1 . 2 : 3 6 8 . 6 )  d u r i n g  i n f u s i o n  of
0.4ug/kgBW/hour of CCK-8 and 460.7mg/kgBW/hour (Q1:Q3 
= 316.9:574.8) during infusion of 0.8ug/kgBW/hour of 
CCK-8. Pancreatic juice output was significantly 
different from the basal (normal saline) values during 
infusion with 0.1, 0.2 and 0.4ug/kgBW/hour of CCK-8
(all p<0.05, Wilcoxon Rank Test).
Pancreatic juice bicarbonate concentration 
(mmol/1) is shown in Figure 3.4 and total pancreatic 
juice bicarbonate output (umol/kgBW/hour) in Figure 
3.5. Basal estimations were not possible in any 
animal due to the small amount of pancreatic juice 
secreted during the first hour. Median bicarbonate 
concentration during infusion of 0.lug/kgBW/hour of 
CCK-8 was 32.7mmol/l (Q1:Q3 = 30.6:41.2, n = 4). This 
rose to a maximum of 60.3mmol/l (Q1:Q3 = 52.9:72.0, n 
= 6) during infusion of 0.2ug/kgBW/hour CCK-8 falling 
thereafter. Median total bicarbonate output was 
8.Ommol/kgBW/hour (Q1:Q3 = 7.5:13.1, n = 4) during
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Figure 3.2: Pancreatic juice weight (mg/hour) in six
hamsters during infusion of increasing doses of CCK-8 
(values expressed as median and interquartile range).
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Figure 3.3: Pancreatic juice output (mg/kgBW/hour) in
six hamsters during infusion of increasing doses of 
CCK-8 (values expressed as median and interquartile 
range).
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C C K -8  INFUSION DOSE ( yug/Kg BW/hour)
F i g u r e  3.4: P a n c r e a t i c  j u i c e  b i c a r b o n a t e
concentration (mmol/1) in six hamsters during infusion 
of increasing doses of CCK-8 (values expressed as 
median and interquartile range).
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Figure 3.5: Pancreatic juice total bicarbonate output
(umol/kgBW/hour) in six hamsters during infusion of 
increasing doses of CCK-8 (values expressed as median 
and interquartile range) .
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infusion of 0.lug/kgBW/hour of CCK-8 and rose 
gradually to a maximum of 24.8mmol/kgBW/hour (Q1:Q3 = 
23.7:25.9, n = 6) during infusion of 0.8ug/kgBW/hour 
of CCK-8.
Pancreatic juice protein concentration (mg/ml) 
is shown in Figure 3.6 and total pancreatic juice 
protein output (mg/kgBW/hour) in Figure 3.7. Basal 
estimations were only possible in three hamsters due 
to small sample sizes. Median basal pancreatic juice 
protein concentration during infusion of saline was 
72.6mg/ml (Q1:Q3 = 15.4:74.4, n = 3). This rose to a 
maximal value of 90.1mg/ml (Q1:Q3 = 78.1:99.7, n = 6) 
during infusion of 0.lug/kgBW/hour of CCK-8, falling 
thereafter. Median basal total pancreatic juice 
p ro t e i n  output dur in g saline infusion  was 
6.9mg/kgBW/hour (Q1:Q3 = 1.8:7.2, n = 3) rising
gradually to 29.Omg/kgBW.hour (Q1:Q3 = 22.4:35.2, n =
6) during infusion of 0.4 ug/kgBW/hour CCK-8.
The coefficient of variation for the control 
calf serum protein samples was 5.6%.
b) Secretin Infusions
Pancreatic juice weight (mg/hour) and pancreatic 
juice output (mg/kgBW/hour) during the infusion of 
secretin in six hamsters (mean body weight 103.9g, 
range 86.0 - 124.3g) are shown in Figures 3.8 and 3.9. 
The median basal pancreatic juice output over the 
first hour when saline was infused was 370.2mg/kgBW
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Figure 3.6: Pancreatic juice protein concentration
(mg/ml) in six hamsters during infusion of increasing 
doses of CCK-8 (values expressed as median and 
interquartile range).
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Figure 3.8: Pancreatic juice weight (mg/hour) in six
hamsters during infusion of increasing doses of 
secretin (values expressed as median and interquartile 
range).
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Figure 3.9: Pancreatic juice output (mg/kgBW/hour) in
six hamsters during infusion of increasing doses of 
secretin (values expressed as median and interquartile 
range) .
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(Q1:Q3 = 216.0:654.9). This rose to 875.2mg/kgBW/hour 
(Q1:Q3 = 4 3 0.1:1227.8) during infusion of
0.04ug/kgBW/hour of secretin and 1064mg/kgBW/hour 
(Q1:Q3 = 5 0 2.2:1315.0) during infusion of
0.32ug/kgBW/hour of secretin. Pancreatic juice output 
was significantly different from the basal values 
during infusion with 0.04ug/kgBW/hour of secretin 
(p<0•05, Wilcoxon Rank Test).
Pancreatic juice bicarbonate concentration is 
shown in Figure 3.10 and total pancreatic juice 
bicarbonate output in Figure 3.11. Median basal 
bicarbonate concentration during infusion of saline 
was 39.7mmol/l (Q1:Q3 = 36.8:49.2). This rose to a 
maximum of 55.9mmol/l (Q1:Q3 = 53.7:64.7) during 
infusion of 0.04ug/kgBW/hour of secretin, falling 
slowly thereafter. Median basal total bicarbonate 
output was 19.4mmol/kgBW/hour (Q1:Q3 = 12.8:26.0). 
This rose to a maximal value of 70.4mmol/kgBW/hour 
(Q1:Q3 = 3 7 . 0 : 7 9 . 0 )  d u r i n g  i n f u s i o n  of
0.04ug/kgBW/hour of secretin and fell thereafter.
Pancreatic juice protein concentration is shown 
in Figure 3.12 and total pancreatic juice protein 
output in Figure 3.13. Median basal pancreatic juice 
protein concentration during infusion of saline was 
98. 9mg/ml (Q1:Q3 = 84.8: 106.0, n = 4). This fell 
gradually thereafter during infusion of various doses 
of secretin. Median basal total pancreatic juice 
protein output during saline infusion was
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F i g u r e  3.10: P a n c r e a t i c  j u i c e  b i c a r b o n a t e
concentration (mmol/1) in six hamsters during infusion 
of increasing doses of secretin (values expressed as 
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Figure 3.11: Pancreatic juice total bicarbonate
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infusion of increasing doses of secretin (values 
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Figure 3.12: Pancreatic juice protein concentration
(mg/ml) in six hamsters during infusion of increasing 
doses of secretin (values expressed as median and 
interquartile range).
179
DO.c
m
C71
tr 100 ~
£  8 0 -ocn
60 -
LU
^  40 -
o
S  20-
0 20 0 24 0-28 0 3 20 04 0 0 8  012 0 16
SECRETIN INFUSION DOSE ( /ug/Kg B W /h o u r)
Figure 3.13: Pancreatic juice total protein output
(mg/kgBW/hour) in six hamsters during infusion of 
increasing doses of secretin (values expressed as 
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51.3mg/kgBW/hour (Q1:Q3 = 26.5:70.5, n = 4) rising to 
a maximum value of 61.7mg/kgBW/hour (Q1:Q3 =
50.6:99.7, n = 4) during infusion of 0.04ug/kgBW/hour 
of secretin.
The coefficient of variation for the control 
calf serum protein samples was 8.0%.
c) SMS 201-995 Infusions
Bicarbonate and protein estimations were not 
possible due to the small volumes of pancreatic juice 
secreted in this group of six hamsters (mean body 
weight 110.4g, range 99.7 - 116.6).
Pancreatic juice weight (mg/hour) and pancreatic 
juice output (mg/kgBW/hour) are shown in Figures 3.14 
and 3.15. Median basal pancreatic juice output during 
saline infusion was 212.Omg/kgBW/hour (Q1:Q3 = 
121.1:334.7). This was suppressed during infusion of 
5ug/kg/hour of SMS 201-995 to 70.2mg/kgBW/hour (Q1:Q3 
= 63.8:102.8, p<0.05 Wilcoxon Rank Test) and remained 
at this level during infusion of higher doses.
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Figure 3.14: Pancreatic juice weight (mg/hour) in six
hamsters during infusion of increasing doses of SMS 
201-995 (values expressed as median and interquartile 
range).
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Figure 3.15: Pancreatic juice output (mg/kgBW/hour)
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3.4 Materials and Methods
The experimental design used was essentially 
similar to that used in Part 1. In addition to the 
cannula inserted in the right internal jugular vein, a 
second cannula was inserted into the left femoral 
vein. Normal saline was infused through each cannula 
at a rate of 0.2ml per hour using 5ml glass syringes 
on an infusion pump. The surgical procedure described 
in detail in Part 1 was performed in all animals.
Pancreatic juice samples were collected as 
previously described after an equilibration period. 
The basal sample was collected over one hour; all 
subsequent samples were collected over 30 minutes. A 
20 minute equilibration period was allowed between 
doses to allow the new infusate to travel down the 
intravenous cannula. Both cannulae were cut into 
lengths calculated to clear fluid infused at 
0.2ml/hour in 20 minutes, prior to insertion into the 
animal.
Infusates were made up as previously described. 
All substances were infused at a rate of 0.2ml/hour.
Al) Increasing doses of CCK-8 with a background 
infusion of SMS 201-995
Normal saline was infused for the first hour 
through both cannulae (basal value), SMS 201-995 was 
then infused through one cannula in a dose of
184
5ug/kgBW/hour while normal saline was infused through 
the second cannula for the next 3 0 minutes (background 
value). Thereafter SMS 201-995 was infused through 
one cannula for the remainder of the experiment in a 
dose of 5ug/kgBW/hour while step-wise increasing doses 
of CCK-8 were infused through the second cannula (0.1 
- 0.8ug/kgBW/hour).
A2) Increasing doses of SMS 201-995 with a background 
infusion of CCK-8
Normal saline was infused for the first hour 
through both cannulae (basal value). CCK-8 was then 
infused through one cannula in a dose of 
0.8ug/kgBW/hour while normal saline was infused 
through the second cannula for the next 30 minutes 
(background value). Thereafter CCK-8 was infused 
through one cannula for the remainder of the 
experiment in a dose of 0.8ug/kgBW/hour while step­
wise increasing doses of SMS 201-995 were infused 
through the second cannula (2.5 - 20ug/kgBW/hour).
Bl) Increasing doses of secretin with a background 
infusion of SMS 201-995
Normal saline was infused for the first hour 
through both cannulae (basal value). SMS 2 01-995 was 
then infused through one cannula in a dose of 
5ug/kgBW/hour while normal saline was infused through 
the second cannula for the next 30 minutes (background
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value). Thereafter SMS 201-995 was infused through 
one cannula for the remainder of the experiment in a 
dose of 5ug/kgBW/hour while step-wise increasing doses 
of secretin were infused through the second cannula 
(0.04 - 0.32ug/kgBW/hour).
B2) Increasing doses of SMS 2 01-995 with a background 
infusion of secretin
Normal saline was infused for the first hour 
through both cannulae (basal value). Secretin was 
then infused through one cannula in a dose of 
0.3ug/kgBW/hour while normal saline was infused 
through the second cannula for the next 30 minutes 
(background value). Thereafter secretin was infused 
through one cannula for the remainder of the 
experiment in a dose of 0. 3ug/kgBW/hour while step­
wise increasing doses of SMS 201-995 were infused 
through the second cannula (2.5 - 20ug/kgBW/hour).
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3.5 Results
Al) Increasing doses of CCK-8 with a background 
infusion of SMS 201-995
Pancreatic juice output during this infusion 
experiment in six hamsters (mean body weight 108.9g, 
range 99.7 - 121. Og) is shown in Figure 3.16. Median 
basal output during saline infusion only was 
374.9mg/kgBW/hour (Q1:Q3 = 280.6:524.5). Median
background output during infusion of saline through 
cannula 1 and SMS 201-995 through cannula 2 was 
482.Omg/kgBW/hour (Q1:Q3 - 429.9:527.0). Pancreatic 
juice output decreased during CCK-8 infusion to a 
minimum median value of 159.Omg/kgBW/hour (Q1:Q3 ■
132.2:290.1) during infusion of CCK-8 0.2ug/kgBW/hour 
before slowly increasing as the dose of CCK-8 
increased.
A2) Increasing doses of SMS 201-995 with a background 
infusion of CCK-8
Pancreatic juice output during this infusion 
experiment in six hamsters (mean body weight 114.Og, 
range 102.8 = 121.8g) is shown in Figure 3.17. Median 
basal output during saline infusion only was 
116.6mg/kgBW/hour (Q1:Q3 = 94.7:142.1). Median
background output during infusion of saline through 
cannula 1 and CCK-8 through cannula 2 was 
272.6mg/kgBW/hour (Q1:Q3 = 239.5:431.3). Pancreatic 
juice output then rose to a maximum of
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Figure 3.16: Pancreatic juice output (mg/kgBW/hour)
in six hamsters during infusion of increasing doses of 
CCK-8 with a background infusion of SMS 201-995.
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Figure 3.17: Pancreatic juice output (mg/kgBW/hour)
in six hamsters during infusion of increasing doses of 
SMS 201-995 with a background infusion of CCK-8.
189
343.Omg/kgBW/hour (Q1:Q3 = 256.8:461.4) during 
infusion of SMS 201-995 at 2.5ug/kgBW/hour before 
falling to basal values during infusion of SMS 201-995 
at 5ug/kgBW/hour. There was a tendency for median 
pancreatic juice output to increase slowly as the dose 
of SMS 201-995 was increased.
Bl) Increasing doses of secretin with a background 
infusion of SMS 201-995
Pancreatic juice output during this infusion 
experiment in four hamsters (mean body weight 123.8, 
range 85.8 - 146.6g) is shown in Figure 3.18. Median 
basal output during saline infusion only was 
239.8mg/kgBW/hour (Q1:Q3 = 221.8:586.6). Median
background output during infusion of saline through 
cannula 1 and SMS 201-995 through cannula 2 was 
444.9mg/kgBW/hour (Q1:Q3 = 412.2:702.4). Pancreatic 
juice output then fell to a minimum median value of 
74.5mg/kgBW/hour (Q1:Q3 = 46.7:115.4) during infusion 
of secretin 0.04ug/kgBW/hour before slowly increasing 
as the dose of secretin increased.
B2) Increasing doses of SMS 201-995 with a background 
infusion of secretin
Pancreatic juice output during this infusion 
experiment in six hamsters (mean body weight 123.4g, 
range 95.8 - 142.2g) is shown in Figure 3.19. Median 
basal output during saline infusion only was
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Figure 3.18: Pancreatic juice output (mg/kgBW/hour)
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Figure 3.19: Pancreatic juice output (mg/kgBW/hour)
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i
192
160.2mg/kgBW/hour (Q1:Q3 = 137.4:269.5). Median
background output during infusion of saline through 
cannula 1 and secretin through cannula 2 was 
278.8mg/kgBW/hour (Q1:Q3 = 226.4:313.8). Pancreatic 
juice output increased to a maximum median value of 
303.5 mg/kgBW/hour (Q1:Q3 = 206.1:341.0) during
infusion of SMS 201-995 at a dose of 2. 5ug/kgBW/hour 
before falling to below basal values during infusion 
of SMS 2 01-995 at a dose of lOug/kgBW/hour.
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3.6 Discussion
There have been few studies of the effects of 
exogenous infusion of gastrointestinal hormones on 
exocrine pancreatic secretion in the Syrian hamster.
In 198 0, Parviz Pour's group published two 
papers on various aspects of pancreatic secretion in 
the Syrian hamster (Helgeson et al, 1980a and b). The 
first of these two papers studied basic unstimulated 
pancreatic secretion. The authors cannulated the 
pancreas in a similar way to that used in this study, 
but recovered the animals after closure of the 
abdomen. They reported, both in starved and fed 
animals, that pancreatic juice output increased 
steadily over the first 10-12 hours (until late 
evening) after which output levelled off or decreased 
slowly. Pancreatic juice pH did not change 
appreciably during the 20 hour study period. 
Pancreatic juice protein concentration and total 
pancreatic juice protein output fell steadily over the 
20 hours of the study in fed animals; protein 
concentration in the starved animals, which was on 
average five times that of the fed animals, fell with 
time but the total protein output rose during the 
first 10 hours before subsequently falling.
In the second paper from Pour's group using the 
same pancreatic duct cannulation technique, secretin 
(25iu/kgBW) or pancreozymin (20iu/kgBW) were 
administered as six half-hourly injections at the
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start of the sample collection period. Pancreatic 
juice secretion and composition were measured during 
the following 2 0 hours. The pH of pancreatic juice 
secreted was significantly lower in the secretin- 
stimulated animals than the pancreozymin-stimulated 
animals at all measured time points. Pancreatic 
secretion in the secretin-stimulated animals was, on 
average, two to three times that of the pancreozymin- 
stimulated animals during the first three hours in 
both male and female hamsters and during the second 
three hour period for males only. Thereafter flow 
rates were similar for both groups. The protein 
content of pancreatic juice was higher in the 
pancreozymin injected hamsters than the secretin 
injected animals at all time points, averaging at 
least 40% higher over the 20 hours of study. The 
total protein output of the two groups was similar in 
the first six hours of study. The hourly protein 
output was five to 10 times greater than in the 
unstimulated hamsters reported in their initial study.
The values for basal pancreatic juice output in 
the CCK-8 and SMS 2 01-995 groups in the current study 
were similar to those reported in Helgeson's initial 
paper. The values obtained for basal pancreatic juice 
output in our secretin group were considerably higher, 
for no apparent reason. Pancreatic juice output 
during infusion of secretin and CCK-8 in the current 
study was considerably higher than that reported in
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Helgeson's second paper; this was almost certainly 
due to the different methods of administration of 
secretin and CCK-8.
Maximal pancreatic secretion in both the 
secretin and CCK-8 groups compares well with work 
reported by Howatson and Carter (1985, 1987) using
CCK-3 3 and a different secretin preparation. It would 
seem therefore that the effects of CCK-8 and secretin 
seen in the current study represent a true effect of 
the infused hormone on pancreatic secretion.
In the present study, secretin and CCK-8 both 
seem to exert a positive effect on pancreatic juice 
total bicarbonate output, with secretin, not 
surprisingly exerting a greater effect than CCK-8. 
Pancreatic juice protein output was increased 
dramatically by CCK-8 infusion but not by secretin 
infusion. These observations confirm those made by 
Ali, Rutishauser and Case (1990). Using a similar 
technique to that used in the current study, hamster 
pancreatic juice was collected in response to 
infusions of secretin (0.01 - 3.0 ug/kg/hour), CCK-8 
(0.05 - 2.5 ug/kg/hour) or bombesin (1.0 - 8.0
ug/kg/hour). Maximum rates of pancreatic juice 
protein secretion in response to CCK-8 were achieved 
at a dose of 0.5ug/kg/hour (similar to the current 
study). Similarly, maximal pancreatic juice 
bicarbonate output occurred in response to a dose of 
lug/kg/hour (higher than the current study). Values
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for total pancreatic juice output in Ali's paper are, 
on average, considerably higher than those recorded in 
the current study. The reason for this may lie in 
that Ali's group cleared the pancreatic cannula of 
bile by injecting each animal with 1.0 U/kg of natural 
secretin prior to the commencement of each infusion. 
In addition, there were other small but significant 
differences in experimental technique with regard to 
infusion rates (16.7ul/min compared to 6.25ul/min in 
the current study) and fluids used for infusion.
SMS 201-995 significantly depressed pancreatic 
juice output during intravenous infusion in the 
current study. Pancreatic secretion was not 
completely abolished however suggesting that other 
positive influences on pancreatic secretion (e.g. 
neural stimulation via the vagus nerve), were not 
affected by SMS 201-995. In a recent publication, 
infusion of low doses of somatostatin-14 suppressed 
pancreatic secretion in eight human subjects whose 
pancreatic duct had been cannulated during biliary 
surgery (Gullo et al, 1988). At a dose of
0.05ug/kg/hour (shown to produce blood levels similar 
to those measured after a meal), somatostatin-14 did 
not exert any effect on pancreatic secretion. Higher 
doses (0.15, 0.45 and 1.35ug/kg/hour) caused a
significant and dose-dependent suppression in 
pancreatic juice, protein and bicarbonate output. The 
inhibitory effect on protein output was greater at all
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doses than the inhibition of bicarbonate output. As 
in the current study, pancreatic secretion was not 
completely abolished even at the highest infusion 
dose.
SMS 201-995 was infused into four dogs in a 
Japanese study published in the same year (Misumi et 
al, 1988). Using infusion doses of SMS 201-995 of one 
to 12 0 ng/kg/hour, pancreatic juice output (collected 
from Thomas duodenal cannulae) was measured between 
and after meals, and after stimulation of pancreatic 
secretion with intravenous infusions of secretin and 
CCK-8. SMS 201-995 inhibited pancreatic juice output 
and the endogenous secretion of CCK, pancreatic 
polypeptide and motilin in all three experimental 
situations, in a dose-dependent manner. It was 
unclear from this study whether the suppression of 
pancreatic secretion occurred as a direct effect of 
SMS 201-995 on the pancreas or through suppression of 
other gastrointestinal hormones.
Contrary results to the above two studies were 
reported by Muller and coworkers (1988). Using an 
isolated rat stomach and pancreatic preparation they 
measured both endocrine and exocrine pancreatic 
secretion and gastrin secretion from the stomach. 
Somatostatin-14 was administered by linear gradient or 
infused intravenously in the presence of caerulein, 
secretin, electric vagal activity or acetylcholine. 
No effect on pancreatic exocrine secretion was
198
detected in any of the experiments although pancreatic 
endocrine secretion of insulin in response to glucose 
was significantly suppressed.
Conway and colleagues (1988) demonstrated that 
subcutaneous injections of SMS 201-995 in dogs 
significantly reduced pancreatic blood flow without 
altering systemic haemodynamics. All vessels to the
pancreas were divided except the pancreaticoduodenal 
artery and vein. A flow probe was placed around the 
pancreaticoduodenal artery. Interestingly, reductions 
in pancreaticoduodenal blood flow did not seem to 
depend on the doses of SMS 201-995 administered 
(0.002mg/kg, 0.02mg/kg, 0.2mg/kg). The absence of
systemic haemodynamic effects suggested that SMS 2 01- 
995 exerted a local effect on pancreatic blood flow. 
This observation might explain why Muller's group 
failed to detect any effect of somatostatin on an 
isolated perfused preparation and may be of relevance 
when other aspects of the current study are examined.
After an initial increase in pancreatic juice 
output, infusion of SMS 201-995 in experiment (Al) 
reduced pancreatic juice output despite subsequent 
infusion of CCK-8. During infusion of CCK-8 in a dose 
of 0.8ug/kgBW/hour the median pancreatic juice output 
value increased slightly compared to the two previous 
values, perhaps indicating that further increases in 
CCK-8 infusion dose would overcome the suppressive 
effect of SMS 201-995.
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Infusion of CCK-8 in experiment (A2) increased 
pancreatic juice output as expected, although not to 
the level seen in the CCK-8 infusion study reported 
earlier in this chapter. CCK-8-stimulated pancreatic 
juice output was not affected by the initial SMS 2 01- 
995 infusion dose (2.5ug/kgBW/hour) but was suppressed 
to basal values at higher doses. Interestingly, 
pancreatic juice output under the influence of both 
CCK-8 and SMS 2 01-995 together was higher at all dose 
points above 2.5ug/kgBW/hour SMS 201-995 than that 
obtained when SMS 201-995 was infused alone in the 
experiments described above.
It has been suggested that CCK exerts its effect 
on pancreatic secretion via membrane bound receptors, 
which, after internalization and activation of 
phospholipase-C, activate the d i a c y l g l y c e r o l  
intracellular messenger system (Williams & Hootman, 
1986; Williams, 1987 ; Case, 1989 and 1990) or 
inositol 1,4,5-triphosphate (Case, 1989 and 1990). 
Somatostatin, on the other hand, is thought to act via 
the cyclic AMP messenger system negatively coupled to 
adenylate cyclase through a unique inhibitory guanine 
nucleotide binding (or G^) protein (Williams & 
Hootman, 1986; Williams, 1987). This difference 
might explain why SMS 201-995 was not able to suppress 
CCK-8 stimulated pancreatic juice secretion to the 
levels achieved by infusion of SMS 201-995 alone.
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CCK has also been shown in acinar cell 
preparations to decrease the binding of somatostatin 
to its cell membrane receptor sites (Matozaki et al, 
1986) . Whether CCK-8 acts in this way to reduce the 
efficacy of infused SMS 201-995 is open to 
speculation.
Recent work has suggested that there are at 
least two (Matozaki et al, 1989) and possibly three 
(Yu et al, 1990) distinct receptors for CCK in
pancreatic acinar cells; one with high affinity but 
low capacity for CCK and one with low affinity but 
high capacity. The third receptor site detected by Yu 
and colleagues accounted for only 17% of tracer 
uptake. The functions of each of these receptor sites 
for CCK are, as yet, not known.
In e x p e r i m e n t  (Bl) s e c r e t i n - s t i m u l a t e d  
pancreatic juice output was suppressed to basal values 
by infusion of SMS 201-995 in a dose of 5ug/kgBW/hour 
and subsequently suppressed to sub-basal values by 
higher doses of SMS 201-995. As in the CCK-8 
experiment (Al), median pancreatic juice output was 
not suppressed as much when secretin and SMS 201-995 
were infused together as when SMS 2 01-995 was infused 
alone.
In experiment (B2) median pancreatic juice 
output increased during infusion of SMS 2 01-995 before 
subsequently falling to sub-basal values following the 
introduction of the secretin infusion. Infusion of
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increasing doses of secretin resulted in only a small 
increase in pancreatic juice output, not reaching 
basal values.
Secretin differs from CCK in that it exerts its 
effects on pancreatic secretion through the same 
cyclic AMP intracellular messenger system as 
somatostatin, without the negative coupling of the 
guanine nucleotide binding protein (Williams & 
Hootman, 1986; Williams, 1987). The fact that both 
hormones act via adenylate cyclase, albeit in opposite 
ways, might explain why SMS was more suppressive to 
pancreatic juice output in the presence of a secretin 
infusion compared to a CCK-8 infusion; competitive 
inhibition of adenylate cyclase activity by SMS 201- 
995 may be relevant in suppressing secretin-stimulated 
secretion but be of no relevance in suppressing CCK-8- 
stimulated secretion.
The role of the endocrine pancreas in exocrine 
secretion has been the subject of much investigation 
and speculation. It is generally held that local 
insulin secretion in the pancreas is necessary for 
exocrine pancreatic enzyme secretion. Insulin was 
shown to have a direct regulatory effect on pancreatic 
acinar cell CCK receptors and CCK-induced acinar cell 
secretion in a paper by Otsuki and Williams (1983) . 
The role of somatostatin in this regard has been the 
subject of a recent report by Garry and colleagues 
(1989). In an isolated rat perfusion model, they
202
studied the interaction between insulin, somatostatin 
and amylase secretion. In a complex series of 
experiments they concluded that somatostatin inhibited 
the secretion of amylase via its inhibition of the 
action of insulin. In addition, they concluded that 
somatostatin may act directly on pancreatic exocrine 
function by influencing specific acinar somatostatin 
receptors. Exogenous insulin was shown to potentiate 
the effect of CCK on amylase secretion, emphasising 
the complex nature of the relationship between peptide 
gastrointestinal hormones, insulin and pancreatic 
function. Whether SMS 201-995 influenced pancreatic 
secretion and altered the effects of both secretin and 
CCK-8 in the current study is not known.
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CHAPTER 4
The effect of chronic subcutaneous administration of 
cholecystokinin octapeptide (CCK-8), secretin and 
somatostatin analogue (SMS 201-995) on the pancreas in 
the Syrian golden hamster.
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4.1 Introduction
In the previous chapter, it was demonstrated 
that IV infusion of the peptides CCK-8, secretin and 
SMS 2 01-995 influenced pancreatic exocrine secretion 
in the Syrian golden hamster. In addition, the 
relationship between IV infusion of SMS 2 01-995 and 
secretin or CCK-8 in combination with respect to 
pancreatic secretion was determined.
The next phase of the study was designed to 
determine whether SC injections of the same peptide 
hormones, alone and in combination, influenced other 
aspects of pancreatic morphology and physiology, in 
particular pancreatic wet weight and DNA content. 
Several experimental studies have suggested that a 
number of CCK preparations, and, to a lesser degree, 
secretin preparations, are trophic to the pancreas in 
experimental animals. Given the negative effect of 
SMS 201-995 on pancreatic secretion in the hamster 
model, this somatostatin analogue might be expected to 
exert a negative effect on these aspects of pancreatic 
physiology.
The selection of appropriate doses of peptides 
to be used in this part of the study proved to be 
difficult, given the lack of published data on CCK-8 
and SMS 201-995 with respect to the pancreas. The 
work described in the previous chapter identified 
doses of hormones which, when infused intravenously 
stimulated or suppressed pancreatic secretion. In
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addition, the dose relationships between CCK-8 or 
secretin and SMS 2 01-995 with respect to pancreatic 
secretion were determined.
While it is obvious that a single SC injection 
of any of the peptides in the doses identified as 
having an effect when infused intravenously, will 
result in a total daily hormonal burden to the hamster 
equivalent to approximately four percent of the 
intravenous dose (if infused for 24 hours), previous 
published work from this Department demonstrated that 
doses so identified were sufficient to result in 
effects on pancreatic wet weight and DNA content, and 
subsequently on pancreatic carcinogenesis when the 
hormones were administered twice daily for three days 
each week (Howatson & Carter, 1985; Howatson & 
Carter, 1987). In the first of these two papers 
cholecystokinin (20% natural CCK, GIH Research Unit, 
Karolinska Institute) was administered SC in a dose of 
30 Ivy Dog Units (IDU)/kg BW, twice daily for three 
days each week for six weeks. This regimen resulted 
in a significantly greater (p<0.001) mean pancreatic 
wet weight in the CCK-treated group (466.4 + 77mg per 
lOOg body weight) compared to the control group (295.6 
± 61mg per lOOg body weight). There was no difference 
in total pancreatic DNA content between the two 
treatment groups. In the second paper, secretin 
(KabiVitrum, Stockholm, Sweden) was administered in a 
dose of 2 0 clinical units (CU)/kg body weight twice
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daily for three days each week for six weeks. No 
significant effect on pancreatic wet weight or total 
DNA content between treatment and control groups was 
demonstrated, although in the final part of this set 
of experiments, secretin (in the same doses described 
in the trophism experiment) did promote pancreatic 
carcinogenesis.
Some further support for the use of an SC 
administered dose of CCK-8 of 0.8ug/kgBW in trophism 
experiments was provided by Pfeiffer et al (1982). 
This is the only published paper to provide any data 
on the trophic effect of CCK-8 on the hamster 
pancreas; it reported a trophic effect of twice daily 
SC injection in a dose of 0.5 - 1.5ug/kgBW. The dose 
of CCK-8 to be used in this chapter of the thesis lies 
within the dose range used in Pfeiffer's study.
Given that the ultimate aim of this thesis was 
to determine whether the hormones under investigation 
could influence pancreatic carcinogenesis, it was not 
thought necessary to administer the hormone each day 
for the duration of the experiments. Administration 
of secretin and CCK for three days in the week with 
carcinogen injection during this three-day period when 
the target organ for the carcinogen, namely the 
pancreas, was most likely to be under the influence of 
the hormones has been shown to yield positive results 
in previous work from this laboratory (Howatson & 
Carter, 1985 & 1987).
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4.2 Materials and Methods
All animals used in these experiments were male 
WO(GD) Syrian golden hamsters (Wrights of Essex) 8-10 
weeks of age. Hamsters were kept in standardised 
animal facility conditions with a twelve hour light- 
dark cycle, and 21% humidity and caged in groups of 
five. All animals were fed standard small rodent diet 
and water ad libitum.
Animals were weighed on day one of each week and 
injected twice daily at 8am and 4pm on days two, three 
and four with peptide substances suspended in a 10% 
gelatin solution to prolong absorption (Petersen et 
al, 1978).
One hundred and twelve animals were studied. 
Seven groups containing 16 animals each were 
sacrificed in subgroups of eight after one and six 
weeks of treatment. The seven groups of animals 
studied at each time point were:
a) Control - 10% gelatin solution only, twice daily
b) CCK-8 (0.8ug/kg body weight, twice daily)
c) SMS 201-995 (5ug/kg body weight, twice daily)
d) CCK-8 and SMS 201-995 (0.8 ug/kg body weight and
5 ug/kg body weight respectively, twice daily)
e) Secretin (0.3ug/kg body weight, twice daily)
f) SMS 201-995 (lOug/kg body weight, twice daily)
g) Secretin and SMS 201-995 (0.3 ug/kg body weight
10 ug/kg body weight respectively, twice daily) 
Hamsters were sacrificed by intraperitoneal
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overdose of pentobarbitone sodium. A full post-mortem 
examination was performed and the pancreas excised 
with the duodenum and a piece of spleen to allow 
identification of the three lobes of the gland. The 
spleen and duodenum and all extraneous connective 
tissue fat and lymph nodes were dissected from the 
pancreas and the organ weighed. A small block was 
excised from the tail of the splenic lobe of each 
pancreas and fixed in formal saline solution. These 
blocks were examined histologically for malignant or 
pre-malignant lesions after processing and staining 
with haematoxylin and eosin. The remainder of each 
gland was snap frozen in liquid nitrogen and stored at 
-8 0°C for assay at a later date.
DNA Assay - Hoechst 33258 Reacyent (Cesarone, Bolognesi 
and Santi, 1979; Perkin-Elmer, 1986) 
Appendix 1 gives details of the preparation of 
the reagents for the assay.
Assay Procedure:
1. Tissue Preparation
(a) Take 3 x 50mg tissue pieces from pancreas
(b) Add 10ml EDTA/PBS buffer (Solution 6;
Appendix 1)
(c) Homogenise for 3 0 seconds
(d) Sonicate for 30 seconds (Sample dilution x 10)
(e) Take 0.1ml of sample solution and add 1.9ml
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EDTA/PBS buffer (Solution 5? Appendix 1) 
(Sample dilution x 200)
(f) Add 2ml Hoechst 33258 Reagent (lug/ml) and 
after one hour analyse DNA content as below
2. Fluorescence Spectrophotometry (Perkin Elmer LS-5
Spectrophotometer)
(a) Switch on machine at wall
(b) Fluorescence lights
(c) FIX SCL lights
(d) Set slits at either side of machine to 10mm
(e) Set excitation to 365nm (Press 3,6,5 then EX 
then GO TO A).
(f) Set emission to 458nm (Press 4,5,8 then EM 
then GO TO A).
(g) Allow indicator lights to stop flashing
(h) Lift front of turret to place cuvettes 
containing solutions for analysis
(i) Open shutter by pressing switch on left hand 
side of instrument (light off)
(j) With reagent blank cell in position allow 
reading to settle and press AUTOZERO - wait 
for zero reading
(k) With test cells in position allow reading to 
settle and press INT - record reading at end 
of integration period (when light stops 
flashing)
(1) Compare readings of samples to standard curve
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For each pancreas examined, six values for DNA 
content were obtained (three paired values). Paired- 
sample assay reproducibility was calculated using 
analysis of variance. Mean values for each set of six 
readings were used for comparing the groups. Groups 
were compared using the Mann-Whitney test for non- 
parametric, unpaired data.
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4.3 Results
There was no evidence of the development of BOP- 
associated histological changes or any other 
histological abnormality in any of the pancreatic 
sections examined.
Figure 4.1 shows the pancreatic wet weights of 
the seven groups of animals at the end of week 1 of 
treatment with CCK-8, secretin or SMS 201-995. 
Appendix 2 gives the raw data for each animal. There 
were no statistically significant differences between 
any of the groups.
Figure 4.2 shows the pancreatic wet weights at 
the end of week 6 of treatment in another seven groups 
of animals. Appendix 3 gives the raw data for each 
animal. Again there were no statistically significant 
differences between any of the groups.
Figure 4.3 shows the DNA contents of the 
pancreata at the end of week 1 of treatment with the 
hormones. Appendix 4 gives the raw data for each 
pancreas analysed. There were no statistically 
significant differences between any of the groups.
Figure 4.4 shows the DNA content of the 
pancreata at the end of week 6 of treatment with the 
hormones. Appendix 5 gives the raw data for each 
pancreas analysed. There were no statistically 
significant differences between any of the groups.
The mean analysis of variance for paired samples 
in 16 DNA assay runs was 2.8% (range 1.7% - 5.3%).
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Figure 4.1: Pancreatic wet weights (mg/kgBW) of
hamsters injected subcutaneously with CCK-8, secretin 
or SMS 201-995 in seven groups after one week of 
treatment.
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or SMS 201-995 in seven groups after six weeks of 
treatment.
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201-995 in seven groups after one week of treatment.
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4.4 Discussion
The earliest report of the trophic effect of 
exogenously administered gastrointestinal hormones on 
animal pancreas was published by Rothman & Wells in 
1967. They demonstrated that pancreatic weights in 
rats given CCK were significantly greater than in 
control rats; secretin and methacholine exhibited no 
such effect on pancreatic weight. This increase in 
pancreatic weight in response to CCK was confirmed by 
Mainz, Black and Webster (1973); they also reported 
an increase in pancreatic protein and DNA content and 
an increase in the uptake by the pancreas of tritiated 
thymidine and its incorporation into DNA. 
Interestingly, another pancreatic secretagogue, 
bethanechol chloride, an acetylcholine analogue, 
failed to exert any effect on pancreatic DNA content 
or synthesis suggesting for the first time that the 
trophic effects of substances on the pancreas were not 
necessarily linked to their ability to stimulate 
pancreatic secretion. In a similar experiment, 
Barrowman and Mayston (1974) administered 12.5 units 
of CCK per lOOg body weight per day for nine days and 
demonstrated a slight but significant increase in 
pancreatic weight in treated rats.
Using a dose of 20% pure CCK which was 
submaximal for pancreatic secretory stimulation, 
administered in gelatin three times daily for 15 days, 
Petersen and co-workers (1978) demonstrated a 57%
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increase in pancreatic wet weight in treated rats 
compared with control animals given the depot gelatin 
vehicle only; this increase was highly significant. 
Interestingly, secretin administration in this paper 
increased pancreatic wet weight in another group of 
rats by only 9% although this was significant at the 
1% level.
In a later paper, Grossman's group demonstrated 
that caerulein, a decapeptide analogue of CCK derived 
from frog skin could exert a similar trophic response 
in rat pancreas (Solomon et al, 1978). When 
administered thrice daily for five, ten or 15 days in 
different doses, caerulein exhibited significant dose- 
and time-dependent increases in pancreatic wet weight 
and content of DNA, RNA, protein, trypsinogen and 
amylase. Such increases were only apparent in 
secretin-treated animals after 15 days of treatment. 
A d m i n i s t r a t i o n  of caerulein and secretin in 
combination resulted in increases in all measured 
parameters of pancreatic trophism, greater than the 
sum of the effects of the two peptides when 
administered individually. Similar effects have been 
demonstrated in the Syrian golden hamster pancreas in 
response to caerulein and secretin (Townsend et al, 
1981).
In 1980, Dembinski and Johnson looked into the 
relationship between secretin and caerulein with 
respect to their effects on pancreatic trophism in
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more detail. Secretin and caerulein administered 
eight-hourly resulted in significant increases in 
pancreatic DNA synthesis and in DNA and RNA content. 
When both hormones were administered together, DNA and 
RNA content was greater than the sum of the values for 
either hormone administered alone. On the basis of 
these findings they postulated that the important 
effect of secretin on the pancreas may be in the 
potentiation of the trophic effects of CCK.
The potentiation of the effect of secretin on a 
CCK nonapeptide analogue was not confirmed in a later 
paper by Haarstad et al (1986). This nonapeptide 
which is almost equipotent with caerulein was infused 
continuously into rats and induced similar increases 
in pancreatic wet weight, DNA, RNA and protein content 
as previous authors have reported for subcutaneous 
administration of other CCK-like peptides. Secretin 
infusions produced similar results.
In an attempt to determine whether endogenous 
secretin and CCK had any effect on pancreatic size, 
Johnson (1981) infused hydrochloric acid and an amino 
acid solution into the duodenums of Sprague-Dawley 
rats for 5 days. He reported an increase in both the 
secretin- and CCK-treated rats in pancreatic weight, 
and DNA, RNA and protein content. DNA synthesis, as 
demonstrated by incorporation of tritiated thymidine 
into DNA, was only increased in the rats infused with 
acid. Johnson concluded that endogenous secretin and
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CCK both have a trophic effect on the rat pancreas. 
Unfortunately, Johnson was unable to measure CCK or 
secretin levels in the animals in response to the 
infusions of acid and amino acid. It is not possible 
to be sure therefore that the effects on the rat 
pancreas demonstrated were mediated by either CCK or 
secretin and as such, his conclusions with respect to 
cause and effect were not entirely valid.
In 1982, Pfeiffer and co-workers examined the 
effect of twice daily subcutaneous injections of CCK 
octapeptide (CCK-8) for ten days in the Syrian 
hamster. They reported that pancreatic weight and 
RNA:DNA ratios were significantly increased over 
controls over a dose range of CCK-8 of 50-150ng/100g 
body weight per day. Satake and co-workers (1986) 
investigated the effects of caerulein in the Syrian 
hamster. Subcutaneous injections of caerulein twice 
daily for ten days resulted in increases in pancreatic 
weight, amylase content, DNA and the pancreatic 
weight/DNA ratio. Caerulein seemed to have both a 
hyperplastic and hypertrophic effect on the pancreas. 
Using autoradiography with tritiated thymidine 
labelling, DNA synthesis was shown to increase most 
notably in acinar cells and only slightly in islet and 
ductal cells.
It came as some surprise that CCK-8 did not seem 
to exert any effect on the hamster pancreas with 
respect to pancreatic wet weight (a function of
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protein content) and DNA content (a function of 
cellular proliferation) in our experiment. When 
similar work was previously undertaken in our 
Department using a different CCK preparation (and 
consequently different dose), this was not the case 
(Howatson & Carter, 1985) . Doses of CCK which 
maximally stimulated pancreatic exocrine secretion, 
exhibited a trophic effect on the pancreas when 
administered subcutaneously in a gelatin vehicle. The 
current secretin results are similar to those reported 
by Howatson & Carter in their second paper (1987). 
They reported no difference between control and 
treatment groups after six weeks with respect to 
either pancreatic wet weight or total DNA content.
One of the notable features of the published 
literature on the subject of pancreatic trophism has 
been the wide variety of trophic substances used, 
marked variations in dosage administered and striking 
differences in the dosage schedules used. Tables 4.1 
and 4.2 summarize the differences in a number of 
publications. In addition to the different peptide 
preparations used in these papers, it is very 
difficult to compare doses used when they have been 
expressed in so many different units. In Satakefs 
work the dose of caerulein used was 20ug/kgBW twice 
daily for ten days compared to a maximum of 5ug/kgBW 
three times daily for 15 days in Solomon's paper and 
only 0.75ug/kgBW three times daily for seven days in
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Table 4.1: Summary of cholecystokinin doses and
preparations used in previously published 
work investigating the trophic effect of 
the hormone on animal pancreas
Cholecystokinin 
Authors Preparation Dose Duration
Petersen et al 
(1978)
Solomon et al 
(1978)
20% natural 
CCK
Caerulein
Dembinski & Johnson Caerulein 
(1980)
Pfeiffer et al 
(1982)
Howatson & Carter 
(1985)
Satake et al 
(1986)
CCK-8
(Kinevac)
20% natural 
CCK
Caerulein
Haddock (this work) CCK-8
(Sigma)
37.5 IDU/ 
kgBW tid
0.2/1.5 
ug/kgBW 
tid
90/180/ 
320/750 ng/ 
kgBW tid
0.5-1.5ug/ 
kgBW bd
15 d
5/10/ 
15 d
7 d
10 d
3 0 IDU/kg 42 d
BW bd
(3 d each week)
2 0ug/kgBW 
bd
0.8ug/kg 
BW bd
(3 d each week)
10 d
7/42 d
(IDU = Ivy Dog Units; tid = three times daily; 
bd = twice daily; d = days)
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T a b l e  4 . 2 : Summary of secretin doses and preparations 
used in previously published work 
investigating the trophic effect of the 
hormone on animal pancreas
Authors
Secretin 
Preparation Dose Duration
Petersen et al 
(1978)
Solomon et al 
(1978)
Dembinski & Johnson 
(1980)
Howatson & Carter 
(1987)
Haddock (this work)
not
specified
Squibb
Squibb
25 ug/kg 
BW tid
2 5 ug/kg 
BW tid
50 U/kg 
BW tid
Kabi Vitrum 2 0 CU/kg 
BW bd
15 d
5/10/ 
15 d
7 d
42 d
(3 each week)
Sigma 0.3 ug/kg 7/4 2 d
BW bd 
(3 each week)
(U = Units; CU = Clinical Units; tid = three times 
daily; bd = twice daily; d = days)
223
Dembinski and Johnson's work. The dose of secretin 
per injection used in the current work was less than 
2% of that used by Petersen et al (1978) and Solomon 
et al (1978) .
The majority of authors so far cited have used a 
continuous dosing schedule when administering the 
peptides, i.e. the hormones have been administered 
regularly for a continuous number of days. In the 
current work, a more intermittent schedule was used 
after Howatson & Carter (1985, 1987) . They were able 
to demonstrate detectable effects on the pancreas of 
CCK but not secretin when administered intermittently, 
although they used different preparations of secretin 
and CCK than those currently under investigation. 
Pfeiffer and co-workers used CCK-8 in their 
investigation in a dose not dissimilar to that under 
investigation. The peptide was administered for ten 
consecutive days, unlike the present study where the 
CCK-8 was administered for only three days out of 
seven or 18 days out of 42. It is possible that this 
intermittent method of administration of peptides in 
very low doses (as in the current work) might have 
allowed pancreatic cells to recover from the effect of 
the peptides during the days when not administered, 
resulting in an overall lack of detectable effect on 
the hamster pancreata. A paper by Lutcke and 
colleagues (1987) offers some support for this 
observation. During a continuous infusion of
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caerulein into rats, tritiated thymidine incorporation 
into DNA increases only after 18 hours of infusion, 
reaches maximum values at 3 6 hours and falls to 
control values after 72 hours.
While there has been some published work on the 
effect of somatostatin and its analogues on exocrine 
pancreatic secretion there have been practically no 
papers on the effects of these substances on cell 
proliferation and none addressed to such an effect in 
the pancreas. Lehy and co-workers (1979) demonstrated 
that somatostatin inhibited incorporation of tritiated 
thymidine into gastric, duodenal and jejunal mucosa in 
vitro. It also decreased cell division in gastric 
mucosa. This observation might lend support to 
extending somatostatin's inhibitory action with 
respect to secretion of other gastrointestinal 
hormones to having a direct negative effect on other 
cellular functions.
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CHAPTER 5
The effect of chronic subcutaneous administration of 
cholecystokinin octapeptide (CCK-8), secretin and 
somatostatin analogue (SMS 201-995) and N- 
nitrosobis(2-oxopropyl)amine (BOP) in the Syrian 
golden hamster.
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5.1 Introduction
In p r e v i o u s l y  p u blished work from this 
Department, preparations of CCK and secretin have been 
shown to promote pancreatic carcinogenesis when 
administered subcutaneously (Howatson & Carter, 1985 & 
1987) . In the case of CCK, the dose of hormone 
administered with BOP when administered alone, proved 
to be trophic to the pancreas in a previous 
experiment. This was not the case with secretin where 
an influence on the carcinogenic process was observed 
without detectable trophism.
Given that BOP is thought to initiate the 
carcinogenic process at a subcellular level and it is 
possible that small doses of peptide hormone, 
administered in doses which do not affect pancreatic 
wet weight or DNA content (as reported in the 
preceding chapter of this thesis) , might be able to 
influence the carcinogenic process. For this reason 
the next phase of the study included administration of 
the carcinogen BOP in addition to the hormones in the 
doses administered in the previous chapter.
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5.2 Materials and Methods
All animals used in these experiments were male 
WO(GD) Syrian golden hamsters (Wrights of Essex) 8-10 
weeks of age. Hamsters were kept in standardised 
animal facility conditions with a twelve hour light- 
dark cycle, and 21% humidity and caged in groups of 
five. All animals were fed standard small rodent diet 
and water ad libitum.
Animals were weighed on day one of each week and 
injected twice daily at 8am and 4pm on days two, three 
and four with peptide substances suspended in a 10% 
gelatin solution to prolong absorption. Carcinogen 
(BOP) was administered subcutaneously between the 
morning and evening doses of peptide substances on day 
three, as described in Chapter 4 of this thesis.
Two hundred and ten animals were studied. Seven 
groups containing 3 0 animals each were sacrificed in 
subgroups of 10 at 10, 12.5 and 15 weeks. The seven 
groups were:
a) Control - 10% gelatin solution only
b) CCK-8 (0.8ug/kg body weight)
c) SMS 2 01-995 (5ug/kg body weight: SMS-LD)
d) CCK-8 and SMS 201-995 (0.8ug/kgBW and
5ug/kgBW respectively)
e) Secretin (0.3ug/kg body weight)
f) SMS 201-995 (lOug/kg body weight: SMS-HD)
g) Secretin and SMS 201-995 (0.3ug/kgBW and
lOug/kgBW respectively)
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Hamsters were sacrificed by intraperitoneal 
overdose of pentobarbitone sodium. A full post-mortem 
examination was performed and the pancreas excised 
with the duodenum and a piece of spleen to allow 
identification of the three lobes of the gland. 
Pancreata were cut into blocks prior to fixation; 
five blocks were cut from each of the splenic and 
gastric lobes and two from the duodenal lobe. Three 
blocks from the gastric and splenic lobes and one from 
t h e  d u o d e n a l  l o b e  w e r e  f i x e d  in P L P D  
(paraformaldehyde, lysine, sodium periodate and 
potassium dichromate). Fixed blocks were washed in 
tap water for three hours. Three serial sections were 
cut from each block prior to staining with 
haematoxylin and eosin. All other blocks were frozen 
in liquid nitrogen. The large lymph node behind the 
head of the pancreas was excised separately and fixed 
in PLPD and stained as other blocks. Any nodules or 
grossly visible lesions were excised and fixed 
separately.
All histological sections were examined by the 
author and assessed for the presence of acinar cell 
death, acinar-ductular transformation, cystic ductal 
complexes, ductular carcinoma-in-situ, ductular 
microcarcinoma, ductal dysplasia, ductal carcinoma-in- 
situ and frankly invasive adenocarcinoma. The 
presence of a lesion in any section of any one 
pancreas was recorded as positive for that pancreas;
229
no attempt was made to count the number of lesions in 
each pancreas.
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5.3 Results
The histological findings are shown in Tables 
5.1 and 5.2 (10 weeks), 5.3 and 5.4 (12.5 weeks) and
5.5 and 5.6 (15 weeks). Results are expressed as the 
presence or absence of the particular histological 
abnormality in each animal in Tables 5.1, 5.3 and 5.5. 
In Tables 5.2, 5.4 and 5.6 the results are expressed
as the presence of the particular abnormality in each 
histological block examined, in an attempt to gauge 
the extent of histological change in each pancreas. 
Values in parenthesis at the bottom of each table 
represent the total number of animals or blocks 
affected by carcinoma-in-situ, microcarcinoma or 
adenocarcinoma (no animal or block registering more 
than one lesion).
After ten weeks of treatment with BOP, the 
pattern of histological change seen in the control 
group of hamsters was similar to those reported in the 
initial studies of carcinogenesis in Chapter 2 of this 
thesis. In addition to ductal hyperplasia, acinar- 
ductular transformation and cystic complexes, one 
control animal exhibited ductal dysplasia. Ductal 
hyperplastic change was seen more frequently in all 
six of the treatment groups compared to the control 
group, although the number of hamsters affected was 
only significantly greater in the CCK-8, SMS-HD and 
secretin/SMS-HD groups (Table 5.1). Ductal dysplastic 
change was significantly more frequent in the secretin
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Table 5.1: Histological lesions present in hamsters
in each of seven groups after 10 weeks 
treatment with BOP (results expressed as 
lesion present or absent in each animal).
Secre-
Secre- CCK-8+ tin +
Control CCK-8 tin SMS-LD SMS-HD SMS-LD SMS-HD
(n=10) (n=10) (n=10) (n=10), (n=10) (n=10) (n=9)
Ductal 
hyper- 3 
plasia
8* 6 6 9# 5 9 +
Ductal 
dys- 1 
plasia
3 8 + 1 4 2 3
Ductal 0 
CIS
0 1 0 0 0 0
Cystic 2 
complexes
4 6 0 6 3 2
CIS 0 0 1 1 0 0 0
Micro- 0 
carcinoma
0 0 1 0 0 0
Adeno- 0 
carcinoma
0 0 0 0 0 0
(* = p<0.05 versus control, Fisher's Exact Test)
(# = p<0.01 versus control, Fisher's Exact Test)
( + = p<0.005 versus control, Fisher's Exact Test)
Table 5.2: Histological lesions present in hamsters
in each of seven groups after 10 weeks 
treatment with BOP (results expressed as 
lesion present or absent in each 
histological block).
Secre-
Secre- CCK-8+ tin +
Control CCK-8 tin SMS-LD SMS-HD SMS-LD SMS-HD 
(n=7 0) (n=7 0) (n=70) (n=70) (n=70) (n=70) (n=63)
Ductal
hyper- 3 9 8 8 11* 5 9*
plasia
Ductal
dys- 1 5 14A 1 6 3 5
plasia
Ductal 0 0 1
CIS
Cystic 4 4 12* 0 14@
complexes
CIS
Micro- 0 
carcinoma
Adeno- 0 
carcinoma
(0) (0) (3) (2) (0) (0) (0)
(* = 
(@ = 
(# = 
( + = 
(A =
p<0.05 versus control, Fisher's Exact Test)
p<0.02 versus control, Fisher's Exact Test)
p<0.01 versus control, Fisher's Exact Test)
p<0.005 versus control, Fisher's Exact Test)
p<0.0005 versus control, Fisher's Exact Test)
Figures in parenthesis denote the number of sections
in each group affected with either CIS, microcarcinoma
or adenocarcinoma
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Table 5.3: Histological lesions present in hamsters
in each of seven groups after 12.5 weeks 
treatment with BOP (results expressed as 
lesion present or absent in each animal).
Secre-
Secre- CCK-8+ tin +
Control CCK-8 tin SMS-LD SMS-HD SMS-LD SMS-HD
(n=10) (n=10) (n=10) (n=10) (n=9) (n=9) (n=10)
Ductal
hyper- 7 2* 5 2*
plasia
Ductal
dys- 8 5 8 3*
plasia
Ductal 1 1 4 0 0 2
CIS
Cystic 9 8 9 10 7 8 9
complexes
CIS
Micro- 2 1 1
carcinoma
Adeno- 1 
carcinoma
(5) (2) (4) (3) (1) (4) (1)
(* = p<0.05 versus control, Fisher's Exact Test)
(# = p<0.01 versus control, Fisher's Exact Test)
(+ = p<0.005 versus control, Fisher's Exact Test)
Figures in parenthesis denote the number of animals in
each group affected with either CIS, microcarcinoma or
adenocarcinoma
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Table 5.4: Histological lesions present in hamsters
in each of seven groups after 12.5 weeks 
treatment with BOP (results expressed as 
lesion present or absent in each
histological block).
Secre-
Secre- CCK-8+ tin +
Control CCK-8 tin SMS-LD SMS-HD SMS-LD SMS-HD
(n=71) (n=71) (n=70) (n=70) (n=64) (n=65) (n=70)
Ductal
hyper- 9 2* 5 2* 10 11 10
plasia
Ductal
dys- 12 15 16 7 15 7 10
plasia
Ductal 1 1 6  0 0
CIS
Cystic 27 14@ 24 27 16 27 35
complexes
CIS
Micro- 3 
carcinoma
Adeno- 1 
carcinoma
(8) (5) (6) (3) (2) (5) (1@)
(* = p<0.05 versus control, Fisher's Exact Test)
(@ = p<0.02 versus control, Fisher's Exact Test)
Figures in parenthesis denote the number of sections 
in each group affected with either CIS, microcarcinoma 
or adenocarcinoma
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Table 5.5: Histological lesions present in hamsters
in each of seven groups after 15 weeks 
treatment with BOP (results expressed as
lesion present or absent in each animal).
Secre-
Secre- CCK-8+ tin +
Control CCK-8 tin SMS-LD SMS-HD SMS-LD SMS-HD
(n=10) (n=8) (n=9) (n=10) (n=10) (n=9) (n=10)
Ductal
hyper- 1 2 3 1 8+ 2 7#
plasia
Ductal
dys- 9 7 8 10 6 7 5
plasia
Ductal 2 2 2
CIS
Cystic 9 8 9 10 9 9 10
complexes
CIS
Micro- 1 
carcinoma
Adeno- 0 1 4* 4* 1 4* 4*
carcinoma
(6) (4) (6) (8) (4) (9) (7)
(* = p<0.05 versus control, Fisher's Exact Test)
(# = p<0.01 versus control, Fisher's Exact Test)
(+ = p<0.005 versus control, Fisher's Exact Test)
Figures in parenthesis denote the number of animals in
each group affected with either CIS, microcarcinoma or 
adenocarcinoma.
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Table 5.6: Histological lesions present in hamsters
in each of seven groups after 15 weeks 
treatment with BOP (results expressed as 
lesion present or absent in each
histological block).
Secre-
Secre- CCK-8+ tin +
Control CCK-8 tin SMS-LD SMS-HD SMS-LD SMS-HD
(n=71) (n=57) (n=68) (n=75) (n=70) (n=64) (n=75)
Ductal
hyper- 1 2  3 1 11+ 2 9
plasia
Ductal
dys- 24 18 19 25 8! 11* 10+
plasia
Ductal 2 3 6 13+ 0 4 1
CIS
Cystic 35 35 44* 35 44 28 48
complexes
CIS 8 5 6 14
Micro- 1 
carcinoma
Adeno- 0 2 9! 17i 2 7 + 4
carcinoma
(9) (7) (13) (33!) (8) (16) (14)
(* = p<0.05 versus control, Fisher's Exact Test)
(# = p<0.01 versus control, Fisher's Exact Test)
(+ = p<0.005 versus control, Fisher's Exact Test)
(! = p<0.002 versus control, Fisher's Exact Test)
Figures in parenthesis denote the number of sections
in each group affected with either CIS, microcarcinoma
or adenocarcinoma
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group than in the control group. Significantly more 
blocks were affected by cystic complexes in the 
secretin and SMS-HD groups, by ductal hyperplasia in 
the SMS-HD group and by ductal dysplasia in the 
secretin group, than in controls (Table 5.2).
No hamsters exhibited adenocarcinoma at this 
stage in the experiment although two animals in the 
SMS-LD group (one with carcinoma-in-situ, one with 
microcarcinoma) and one in the secretin group (with 
carcinoma-in-situ) exhibited pre-malignant change 
(Table 5.1) .
After 12.5 weeks of treatment hamster pancreata 
in all groups exhibited the full spectrum of 
histological changes seen in response to BOP 
treatment. Significantly fewer of the secretin and 
CCK-8 animals exhibited ductal hyperplasia than the 
control group (both p<0.05) and fewer animals in the 
SMS-LD group developed ductal dysplasia (p<0.05). 
There were no other obvious differences between the 
groups with regard to the frequency of the various 
histological changes seen (Table 5.3). Fewer blocks 
were affected by ductal hyperplasia in the CCK-8 
(p<0.02) and SMS-LD groups than controls (Table 5.4). 
Adenocarcinoma was demonstrated only in the control, 
CCK-8 and secretin groups, although animals in all 
seven groups exhibited carcinoma-in-situ.
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At 15 weeks significantly more animals in the 
SMS-LD and secretin/SMS-HD groups exhibited ductal 
hyperplasia than the control group (Table 5.5). The 
only other statistically significant difference 
between the groups in this table occurred with respect 
to the development of adenocarcinoma. This lesion 
affected significantly more animals in four of the 
groups (secretin, SMS-LD, C C K - 8 / S M S - L D  and 
secretin/SMS-HD) than in the control group. When the 
blocks were examined, ductal hyperplasia was 
significantly more common in the SMS-HD group 
(p<0.005), ductal CIS in the SMS-LD group (p<0.005) 
and cystic complexes in the secretin group (p<0.05; 
Table 5.6). Ductal dysplasia was significantly less 
common in the SMS-HD, CCK-8/SMS-LD and secretin/SMS HD 
groups. Adenocarcinoma affected more blocks in the 
secretin (p<0.002), CCK-8/SMS-LD (p<0.005) and, most 
particularly, the SMS-LD (p<0.002) groups compared to 
the controls. When all malignant and pre-malignant 
l e s i o n s  ( n a m e l y  CIS, m i c r o c a r c i n o m a  a n d  
adenocarcinoma) were considered together, only the 
SMS-LD group exhibited a significant increase in 
lesion frequency over the control group (p<0.002).
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5.4 Discussion
The pattern of histological changes seen in 
these experiments in response to subcutaneous 
injection of BOP is similar to those reported by 
Parviz Pour in many publications. Despite these 
publications, Pour and other workers in the field 
remain unclear as to the significance of the different 
lesions seen early in the carcinogenic process.
In a recent electron m i c r o s c o p i c  and 
immunohistochemical study of the early stages of BOP- 
induced pancreatic carcinogenesis, Pour (1988) 
concluded that the pseudoductular structures developed 
from centroacinar cells. Hypertrophy and hyperplasia 
of these cells with the formation of small cellular 
processes which insinuate between acinar cells were 
the initial changes seen during the neoplastic 
process. Acinar cells became separated and detached 
from the glandular lumen and vasculature resulting in 
their degeneration and replacement by centroacinar 
cells. It remains unclear from this work whether the 
tubular and pseudoductular structures which then 
developed were true precursors of malignant change, or 
simply represented a parallel change to the more 
subtle cellular and subcellular effects of the 
carcinogen. It is interesting to note that a point 
mutation in codon 12 of the c-Ki-ras oncogene, which 
has previously been reported in human pancreatic 
cancer, has recently been reported in BOP induced
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hamster pancreatic cancer (Fujii et al, 1990). This 
subcellular effect of BOP seems more likely to be of 
relevance in the development of pancreatic cancer than 
progression from areas of pseudoductular changes.
In the current work it is difficult to detect a 
pattern of histological change in the different groups 
during the early part of the carcinogenic process. 
Given that the significance of many of these changes 
with respect to the ultimate development of pancreatic 
adenocarcinoma is unclear, the significance of minor 
differences between the groups with respect to early 
carcinogen-induced histological lesions is even less 
clear. For example, animals in all groups developed 
cystic changes and although there were some 
statistically significant differences between the 
control group and the secretin and SMS-HD groups at 10 
weeks (when the number of affected sections were 
analysed), the relevance of this is uncertain. 
Similarly, statistically significant differences with 
respect to the development of ductal hyperplasia and 
ductal dysplasia at different stages in the 
experiment, is unclear.
There have been many published studies which 
suggest that cholecystokinin and its analogues 
increase the susceptibility of the hamster pancreas to 
the effects of the carcinogen BOP. It was interesting 
to note that in the present study no such effect was 
detected. It may well be that detectable effect was
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lacking for the same reasons that CCK-8 failed to 
stimulate pancreatic hypertrophy or hyperplasia 
reported in the previous chapter of this thesis, 
namely that the dose was too small or the intermittent 
dosing schedule allowed pancreatic cells to recover 
between injections. This latter possibility seems 
less likely given that the carcinogen was injected 
between doses of CCK-8, when any hormone effect would 
have been expected to be at its greatest. It is of 
course possible that while the octapeptide analogue is 
potent with respect to stimulating pancreatic 
secretion, other parts of the complete CCK molecule 
are necessary to influence BOP induced pancreatic 
carcinogenesis.
Despite the above, there have been some 
conflicting reports of the effect of CCK and its 
analogues in influencing the susceptibility of the 
hamster pancreas to BOP and other carcinogens. In 
1983, Johnson and colleagues reported that CCK 
inhibited the development of pancreatic cancer in the 
hamster model. Another group from Sweden reported 
that caerulein exerted no effect on the chemical 
induction of hamster pancreatic cancer (Andren- 
Sandberg, Dawiskiba and Ihse, 1984). Our own 
laboratory reported that CCK enhanced the development 
of hamster pancreatic cancer when a similar dosing 
schedule to that used in the current study was used 
(Howatson and Carter, 1985).
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In a paper published in 1988, Pour and his 
colleagues attempted to explain some of these 
discrepancies. In the first of two experiments they 
administered CCK-3 3 to groups of hamsters three hours 
before the administration of a single injection of BOP 
(20mg/kgBW, group 1) , simultaneously with BOP (group 
2) , or three hours after BOP (group 3) and sacrificed 
the animals 46 weeks after BOP injection. CCK-3 3 was 
administered in six subcutaneous injections 30 minutes 
apart to give a total dose of 20 IDU/kgBW per hamster. 
This dosing schedule had previously been shown to 
achieve maximal stimulation of pancreatic secretion 
(Helgeson et al, 1980). One additional group received 
CCK-33 daily for 15 weeks after the BOP injection 
(group 4). Control groups received either BOP or CCK 
alone (groups 5 and 6) . In the second experiment a 
similar treatment schedule was used but CCK-33 and BOP 
were given weekly for 20 weeks and the BOP dose was 
reduced (2.5mg/kgBW).
In the first experiment, the incidence of 
ductular proliferation was similar in each of the 
groups treated with BOP. Hamsters in group 1 (CCK 
then BOP) developed significantly fewer of these 
proliferative lesions than BOP controls, and those in 
groups 1 (CCK then BOP) and 2 (CCK with BOP) , 
significantly fewer than group 3 (BOP then CCK). The 
incidence of pancreatic a d e n o c a r c i n o m a  was 
significantly less in groups 1 (CCK then BOP) and 2
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(CCK with BOP) than the BOP only control group (group 
5) . Group 3 hamsters (BOP then CCK) had the highest 
incidence and multiplicity of malignant lesions 
comparable to the BOP only group. Pour concluded that 
the results of experiment 1 supported the concept that 
CCK administration did interfere with chemical 
carcinogenesis in the hamster model. His group 
suggested that CCK administration might increase the 
elimination of circulating and intracellular BOP 
resulting in tumour inhibition if the CCK was given 
before and with BOP, but not if given after BOP. As 
an alternative explanation, it was suggested that CCK 
might temporarily stimulate intracellular cytochrome 
p-450 with resulting N-demethylase, O-dealkylation of 
carcinogen as has been demonstrated in rats (Fang & 
Stroebel, 1981). In the second experiment, the 
incidence of all types of lesion was similar in all 
BOP treated groups. Pour was unable to satisfactorily 
explain this observation. A subsequent paper by 
Meijers and colleagues (1990) supported the findings 
of Pour et al's 1988 paper. They administered BOP 
(20mg/kgBW) at six, seven and eight weeks of age to 
male Syrian golden hamsters and subsequently injected 
the animals with gelatin vehicle, CCK-8 (2.5ug/kgBW), 
CR-1409 (a potent CCK-receptor antagonist) or CCK-8 
with CR-1409 in a regime similar to that used in this 
thesis. Although the dose of CCK-8 used was three 
times that used in this thesis, Meijer's group also
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failed to detect any effect of CCK-8 on the incidence 
of pre-neoplastic and neoplastic pancreatic lesions 
after 16 weeks of treatment.
It is interesting to note that Johnson et al 
(1983) administered CCK before or with BOP and 
reported inhibition of tumour development, whereas 
Howatson and Carter (1985) and Andren-Sandberg and 
colleagues (1984) administered the CCK or caerulein 
after the BOP and reported no such inhibition. In the 
current study CCK-8 was given both before and after 
BOP administration making interpretation of our 
results, in the light of Pour et al's 1988 paper, 
difficult. It remains possible that the CCK-8 dose 
administered before the BOP was injected was the only 
relevant dose of hormone given. Given that the 
control group in the current study did not develop any 
frankly invasive adenocarcinomata after 15 weeks of 
BOP administration it is difficult to assess whether 
CCK-8 inhibited development of malignant change, as 
Pour suggested it might.
Unlike the CCK-8 group, the secretin-treated 
animals in the current experiment did exhibit an 
increase in the d evelopment of p a n c r e a t i c  
adenocarcinoma compared to the control group. In 
another paper published in 1989, Pour & Kazakoff 
repeated the CCK experiment described above with 
secretin as the trophic stimulus. They expected 
greater inhibition of pancreatic carcinogenesis when
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secretin was administered before BOP than when CCK was 
so administered. Not surprisingly this was indeed 
what they reported. Hamsters injected firstly with 
secretin and then with BOP developed very few 
pancreatic carcinomata compared with the control group 
(p<0.0005). Secretin similarly inhibited the 
d evelopment of p a n creatic carcinomata when 
administered with BOP, albeit to a lesser degree, as 
might be expected from the earlier CCK experiment 
results.
The most interesting and unexpected finding in 
the current study was that SMS 201-995 seemed to 
promote pancreatic carcinogenesis when administered in 
low dosage. The explanation for this might be as 
discussed in the previous paragraph. There can be no 
doubt, however, that both the number of animals in 
whom malignant change occurred in the pancreas, and 
the extent of this malignant change was much greater 
in animals given low dose SMS.
If SMS 201-995 exerts an inhibitory effect on 
intracellular BOP metabolism in just the opposite way 
that Pour suggested that CCK and secretin might 
increase intracellular BOP metabolism, then perhaps 
this result should not be unexpected. There is no
published work on somatostatin and its analogues 
looking at this particular point.
Somatostatin analogues exhibit species specific 
effects on pancreatic tumours and varied efficacy
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within species. In 1984, Redding and Schally 
investigated the effects of three somatostatin 
analogues on transplanted acinar-cell pancreatic 
cancer DNCP-322 (CA-20948) in Wistar/Lewis rats and on 
transplanted hamster ductal pancreatic cancer in 
Syrian golden hamsters. They reported that in rats, 
one analogue ([L-5-Br-Trp8]-somatostatin) inhibited 
the growth of the transplanted tumour, while the other 
two analogues (cyclo Pro-Phe-D-Trp-Lys-Thr-Phe and 
somatostatin-28) had no effect. In the hamsters, only 
the somatostatin-28 had no effect. The behaviour of 
these transplanted tumours may differ from that of our 
own experimental pancreatic tumours in situ, and in 
addition, SMS 201-995 may simply not have the 
inhibitory effect of other analogues of somatostatin 
in the hamster.
The cyclical somatostatin octapeptide analogue 
RC-160 (D-Phe-Cvs-Tvr-D-Trp-Lvs-Val-Cvs-Trp-N^l when 
administered as a microcapsule designed to release 5ug 
analogue each day, inhibited the progression of 
established chemically induced hamster pancreatic 
cancer in hamsters (45 day survival in the treated 
group 70% vs 35% in the control group) (Paz-Bouza et 
al, 1987) . Continuous release of this analogue might 
account for tumour inhibition not seen in our study 
where the dose of analogue was both smaller and 
intermittent. More recent investigations using 
microcapsules which released lOug/day (Zalatnai &
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Schally, 1989a), 15ug/day (Szende, Zalatnai & Schally, 
1989) and 25ug/day (Zalatnai & Schally, 1989b) of RC- 
160 have confirmed the initial findings of Paz-Bouza's 
investigations. In Szende's paper, RC-160 treated 
tumours exhibited striking regressive changes 
characteristic of programmed cell death. In another 
paper from the same group, treatment with RC-160 was 
shown to result in down-regulation of cellular 
receptors for insulin-like growth factor and a 
decrease in binding capacity (Szende et al, 1990).
Upp and colleagues (1988) found that SMS 201-995 
inhibited the growth of two human pancreatic cancers 
transplanted into nude mice. The SMS 201-995 was 
administered in a dose of lOOug/kg body weight three 
times daily, a much higher dose than that used in our 
study. In addition, human tumours may be more 
susceptible to the effects of SMS 201-995 than hamster 
tumours. However, it is interesting to note that in a 
recent publication, none of 12 human pancreatic 
cancers examined demonstrated the presence of 
somatostatin receptors (Reubi et al, 1988). It is of 
course possible that SMS 201-995 exerted its effect 
indirectly through other hormones rather than directly 
on the pancreas.
Differences in response to various somatostatin 
analogues might be explained by the findings of Liebow 
and colleagues (1989). In a study of the human 
pancreatic cancer cell line Mia PaCa-2, this group
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demonstrated that inhibition of tumour growth was 
related to cellular tyrosine phosphatase activity 
affecting the epidermal growth factor receptor. The 
somatostatin analogue RC-160 caused the greatest 
stimulation of tyrosine phosphatase activity and the 
greatest inhibition of tumour cell growth. SMS 201- 
995 stimulated virtually no tyrosine phosphatase 
activity and did not inhibit tumour cell growth.
The increase in development of pancreatic 
a d e n o c a r c i n o m a  seen in the C C K - 8 / S M S - L D  and 
secretin/SMS-HD groups in this thesis is more 
difficult to explain than any of the other findings. 
It is possible that in the CCK-8/SMS-LD group the 
increase in tumour development was due to the effects 
of the SMS over CCK-8 and similarly, in the 
secretin/SMS-HD group to the effects of the secretin. 
This is difficult to accept given that SMS was 
administered in both groups, although the higher dose 
of SMS did not seem to exert any effect on 
carcinogenesis when administered alone.
To date there has been only one published paper 
on the use of SMS 201-995 as a possible treatment for 
pancreatic cancer in man (Klijn et al, 1990). 
Fourteen patients with metastatic pancreatic cancer 
were injected SC three times daily with 100-200ug of 
SMS 201-995. Only three patients exhibited stable 
disease while in the remainder, disease progression 
was reported. The median survival for the pancreatic
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cancer patients was only two months.
Somatostatin is a complex hormone and its many 
analogues possess different spectra of activity. The 
effects of SMS 201-995 alone and its interaction with 
other peptide hormones are obviously complex. 
Superficially, the current results indicate that in 
the hamster-nitrosamine model of pancreatic cancer, in 
certain situations and doses, SMS 201-995 can promote 
pancreatic carcinogenesis. This effect might be dose 
dependent and seems to be independent of the effects 
of other gastrointestinal peptide hormones. Caution 
must be exercised before extrapolating the results of 
this thesis to the human situation but at present more 
evidence for the potential benefits of analogues of 
somatostatin is necessary before their use in treating 
pancreatic cancer in man can be justified.
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CHAPTER 6
Analysis of the DNA content and cell cycle activity of 
BOP-treated hamster pancreas using flow cytometry and 
bromodeoxyuridine immunostaining.
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6.1 Introduction
The results of the experiments in the preceding 
two chapters of this thesis suggest that exogenously 
administered gastrointestinal hormones, or their 
analogues, can influence chemically induced pancreatic 
carcinogenesis when administered in doses which seem 
to have no detectable effect on the pancreas with 
respect to total DNA content and pancreatic wet 
weight. This suggests that, in order to influence 
carcinogenesis, hormone administration must occur when 
the pancreatic cells susceptible to the effects of BOP 
are at their most vulnerable, or alternatively, that 
BOP has more, or less, of an effect when pancreatic 
cells are under the influence of the hormones.
In 1988, Lawson and Nagel reported that BOP 
produced cellular DNA damage in the hamster pancreas; 
ductal cells were more susceptible to the effects of 
BOP than acinar cells largely as a result of a slower 
DNA-repair mechanism. Such BOP-induced damage was 
also demonstrated in rat pancreas, but in the rat the 
ability of cellular DNA to undergo rapid repair was 
much greater than that seen in the hamster, perhaps 
accounting, at least in part, for the seeming species- 
specificity of BOP with respect to pancreatic 
carcinogenicity.
The technique of flow cytometry has been 
increasingly investigated in recent years. It 
provides a rapid and objective method of analysing
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various cellular substances, such as DNA, using 
specific fluorochrome stains. The stained particles 
suspended in fluid are passed across a source of 
fluorescent light of appropriate wavelength one at a 
time. This light source is usually a laser. The 
stain is stimulated to fluoresce by the laser light 
and the amount of fluorescence emitted by each cell or 
particle is measured by a sensitive photoelectric 
cell. Computer storage of the fluorescence values for 
each particle allows subsequent display of the results 
in a histogram. The amount of fluorescence generated 
within each particle is proportional to the amount of 
DNA or other substance being measured (Koss & 
Greenbaum, 1986? Quirke & Dyson, 1986).
Tissue is prepared in such a way as to produce 
suspensions of single cell nuclei. Fresh tissue 
provides the best and most consistent results due to 
the fact that there is little background noise 
generated by cellular fragments. Despite this, 
meaningful results can be obtained from frozen or 
paraffin embedded tissue (Hedley et al, 1983; Oud et 
al, 1986). Normal human cells display a single
histogram peak corresponding to the amount of DNA in 
the normal number of 46 chromosomes (diploid). Many 
malignant cells have been shown by flow cytometry to 
exhibit abnormal amounts of DNA in relation to the 
normal diploid amount (aneuploidy) and this may relate 
to gene deletions and other genetic changes associated
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with tumour progression. In recent years, there has 
been considerable interest in the DNA content of cells 
in different forms of cancer. Tumours of many 
different types have been found to contain aneuploid 
clones (Friedlander, Hedley & Taylor, 1984). The 
significance of differences in tumour cell ploidy with 
respect to outcome in individual patients has been the 
subject of considerable debate. For example, in 
colorectal cancer, some authors have indicated that 
tumour cell ploidy was the single most important
f
determinant of outcome of many pathological and 
clinical variables studied (Kokal et al, 1986). 
Others have suggested that cell ploidy status has no 
prognostic significance, although patients with Duke's 
stage B aneuploid tumours tended to have a poorer 
prognosis than those with diploid tumours (Jones, 
Moore & Schofield, 1988). The situation with respect 
to cancer of the pancreas in humans is unclear, partly 
because of the consistently short time course of this 
disease from presentation to death.
Computer analysis of flow cytometry histograms 
can also be used to examine the cell cycle. After 
mitosis (M) , a new cell cycle begins. The largest 
number of cells in any tissue are in the resting phase 
(Gq) . Newly dividing cells then enter the phase 
during which the standard diploid complement of DNA is 
present (2N). Cells can remain in this phase for a 
variable length of time. Cells which pass through the
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G-l phase then enter the phase of DNA synthesis (S- 
phase), during which nuclear DNA content is doubled 
(4N). Cells then enter a relatively short (G2) phase 
during which RNA and protein synthesis occur. Mitosis 
then results in cell division and the production of 
two daughter cells (Sugarbaker et al, 1979). In a 
normal flow cytometry histogram (Figure 6.1), the tall 
narrow peak represents cells in the G0/G1 phases of 
the cell cycle, the second smaller peak represents 
cells in the G2 and M phases and the space between 
these two peaks represents cells in S-phase.
In the nitrosamine-hamster model of pancreatic 
carcinogenesis, BOP is thought to produce both cell 
death and sublethal cell injury. This is followed by 
a period of DNA synthesis reflecting DNA repair and 
cellular regeneration in cells which survived the 
lethal effects of BOP (Lawson & Nagel, 1988). Changes 
in cellular DNA content during the carcinogenic 
process induced in the hamster pancreas by BOP should 
be detectable using flow cytometry.
Bromodeoxyuridine (BRDU), a thymidine analogue, 
is taken up into cells during DNA synthesis. A 
monoclonal antibody has been developed which has led 
to the development of an immunoperoxidase technique 
which will label BRDU. This technique allows the 
identification of which cells have synthesized DNA, 
that is have incorporated BRDU into nuclear DNA, 
during a set time period and would identify which
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Figure 6.1: Flow cytometry histogram of nuclear DNA
in a normal hamster pancreas. The tall narrow peak 
represents DNA in cells in the Gq/G-^  phases of the 
cell cycle and accounts for 84.2% of nuclei. The 
small peak to the right of the Gq/G-^  peak represents 
DNA in cells in the G2/M phases of the cell cycle 
(8.1% of nuclei) and the space between these two 
peaks, cells in the S phase (7.6% of nuclei).
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cells are in or have gone through the S-phase of the 
cell cycle.
In the light of the results of the preceding 
chapters of this thesis, it was decided that a final 
aim should be included in the investigation. Using 
flow cytometry and BRDU immunostaining, an attempt was 
made to detect changes in cell cycle activity that 
occurred in hamster pancreas in response to 
administration of BOP, which might indicate cellular 
DNA damage and repair and cellular proliferation. 
Flow cytometry would identify whether any changes in 
cell cycle activity occurred in response to BOP and 
BRDU immunostaining would indicate in which cell types 
these changes occurred. In addition, an attempt would 
be made to detect aneuploid cell lines during the 
carcinogenic process and to determine whether 
aneuploidy could be ascribed to any particular stage 
of, or lesion seen during, the carcinogenic process.
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6.2 Materials and Methods
The animals used in this study were 8-10 week 
old male Syrian golden hamsters (WO GD Strain, Wrights 
of Essex), caged in groups of five in standard animal 
unit conditions with a 12 hours light/dark cycle and 
21% humidity, and fed standard small rodent diet with 
water ad libitum.
In the first part of the study, 40 hamsters were 
injected subcutaneously with the carcinogen BOP in a 
dose of 5mg/kgBW per week. Animals were sacrificed in 
groups after 5, 10, 15 and 20 weeks and after a full
post-mortem examination the pancreas was excised. 
After trimming of fat and extraneous connective tissue 
each pancreas was cut into twelve blocks. Five blocks 
were snap-frozen in liquid nitrogen and the remaining 
seven blocks fixed in PLPD (paraformaldehyde, lysine, 
sodium periodate and potassium dichromate) for 
subsequent staining with haematoxylin and eosin and 
histological examination. Two further animals were 
sacrificed prior to the injection of any substance to 
act as controls for the flow cytometer. Another 
untreated hamster pancreas was allowed to lie in air 
over a period of time; pancreatic tissue samples were 
taken at various time points and analysed to ensure 
that the results in the BOP treated animals did not 
simply reflect autolysis of hamster pancreas.
Each frozen tissue block was thawed and 
processed to produce single nuclear preparations
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(Vindelov, Christensen & Nissen, 1983). Nuclei were 
stained with propidium iodide and passed through an 
EPICS CS flow cytometer (Coulter, UK) . The EPICS 
Easy-2 programme was used for histogram analysis. 
Most of this analysis was carried out by Mr. Eric 
Miller. A frozen section was prepared from each block 
analysed in this way for staining with haematoxylin 
and eosin. Sections were examined for the presence of 
malignant and premalignant lesions. Growth fraction 
results were compared using a Mann Whitney U test for 
non-parametric data.
In the second part of the study a different 
group of hamsters was injected with either BOP 
(5mg/kgBW per week) or an equivalent volume of the BOP 
solvent (normal saline). Animals were sacrificed 
after five and ten weeks of treatment. Twenty hours 
prior to sacrifice hamsters were i njected  
intraperitoneally with BRDU (200mg/kg body weight? 
Sigma Chemical Company Ltd., Dorset, UK). At 
sacrifice, a full post-mortem examination was 
performed and the pancreas was excised and trimmed. 
Five blocks were snap-frozen in liquid nitrogen and 
the remaining seven blocks fixed in methacarn 
(methacarn fixation allows for better staining with 
BRDU than PLPD). After fixation, 2um step sections 
were cut from each block. Each section was stained 
using monoclonal anti-BRDU (Becton Dickenson, UK). An 
avidin-biotin-peroxidase (Dako Ltd., UK) method was
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used to detect anti-BRDU staining. Histological 
sections were examined and assessed for anti-BRDU 
staining. A qualitative assessment was made of the 
presence of BRDU-positive nuclei in ductular, acinar, 
inflammatory cells and 'pre-neoplastic' lesions.
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6.3 Results
During the first experiment one hamster was 
sacrificed under the terms of the animal licence due 
to weight loss in excess of 10% in one week. This 
animal is not included in any subsequent analysis. 
Five animals were sacrificed after five weeks of BOP 
treatment, 10 after 10 weeks, 15 after 15 weeks and 
nine after 20 weeks. Hamster pancreata exhibited the 
expected histological changes throughout the 20 week 
experimental period, described in Chapter 2 of this 
thesis.
The flow cytometry results are shown in Table 
6.1. In total, 210 tissue blocks from 42 animals 
(excluding the pancreas left to stand over time) were 
analysed using flow cytometry. Control pancreas 
exhibited a growth fraction (G2+M plus S-phase 
fractions) of 8.4 + 2.1% (mean + standard deviation). 
This increased to 17.5 ± 2% (p<0.02 compared to five 
week group) by 10 weeks and remained high in the 15 
and 2 0 weeks groups (20.0 + 4.6% and 21.2 + 3.1%? 
both p<0.01 compared to the five week group). The S- 
phase fraction increased over control values after 5 
weeks of BOP treatment whereas the G2 + M fraction did 
not show any obvious increase over the controls until 
after 10 weeks of BOP treatment. The half peak 
coefficient of variation was less than 3% for all flow 
cytometry histograms.
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Table 6.1: Flow cytometry analysis of BOP treated
hamster pancreas
Duration of
treatment S-phase G2 + M GF n
(weeks)
0 3.6 + 0.9 4.9 ± 0.2 8.4 + 1.1 2
5 8.9 + 1.9 4.1 ± 1.0 12.9 + 2.7 6
10 10.1 ± 1.9 7.4 + 1.4 17.5 ± 2.0 10
15 8.6 + 2.3 11.3 ± 3.8 20.0 ± 4.6 15
20 12.0 + 1.8 9.2 + 2.1 21.2 ± 3.1 9
(Excludes 7 aneuploids with DNA indexes <1.3)
(S-phase = S-phase fraction (%);
G2+M = G2+M fractions (%);
GF = growth fraction (%) (S-phase + G2+M); 
n = number of hamster pancreata)
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The pancreas left to stand in air and analysed 
at various time intervals in a 24 hour period did not 
show any changes in cell cycle activity with time.
In only seven of the 210 samples analysed were 
aneuploid peaks identified. These had DNA indices 
<1.3 and represented only approximately 10% of nuclei 
in each case which is at the limit of detection for 
the flow cytometer used. These peaks were seen from 5 
| weeks BOP treatment and there was no relationship to
I histological appearances as assessed by frozen section[
histology. Their significance is uncertain.
In the second phase of this study using BRDU
! immunostaining, 20 hamster pancreata were examined;[
| five in each group after five weeks of treatment and
| five after 10 weeks. As expected, sections with pre-
malignant lesions exhibited a marked inflammatory
i
response. Some inflammatory cells were BRDU labelled. 
In general there was only infrequent positivity in 
cystic complexes (Figure 6.2). More nuclei were BRDU 
| positive in areas of ductal hyperplasia (Figure 6.3)
| and ductal dysplasia (Figure 6.4).
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Figure 6.2: Bromodeoxyuridine immunostaining in a
cystic complex in hamster pancreas after 10 weeks of 
treatment with BOP. Labelled cells stain brown. 
(xl40 magnification) .
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Figure 6.3: Bromodeoxyuridine immunostaining in an
area of ductal hyperplasia adjacent to a small cystic 
complex, in hamster pancreas after 10 weeks of 
treatment with BOP. Labelled cells stain brown. 
(xl40 magnification).
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Figure 6.4: Bromodeoxyuridine immunostaining in an
area of ductal dysplasia in hamster pancreas after 10 
weeks of treatment with BOP. Labelled cells stain 
brown. (xl40 magnification).
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6.4 Discussion
The flow cytometry results in this study 
indicate that BOP produces changes which result in an 
increase in cell cycle activity in the hamster 
pancreas. Proliferation occurred in duct, acinar and 
inflammatory cells and was not necessarily related to 
'pre-neoplastic1 histological changes. Furthermore, 
maximal proliferation was established by 5 weeks, 
before any recognisable pre-neoplastic lesions were 
identifiable.
In 1979, Ames, interpreting the results of a 
number of investigations into the effects of 
carcinogens on bacteria, strongly suggested that 
carcinogens were mutagenic, i.e. that carcinogens 
resulted in increased cell division or proliferation 
which resulted ultimately in the development of 
malignant tumour. Unfortunately, it is now generally 
believed that this observation oversimplifies the 
situation in mammalian cells. Carcinogen-induced 
mutagenesis is considerably more difficult to achieve 
in mammalian cells and may be an important rate 
limiting step in malignant progression. The 
multistage theory of cancer causation suggests that 
malignant change requires the influence of an 
initiator or initiators, and a promotor or promotors, 
which stimulate proliferation of the altered cell(s) 
(Weinstein, 1991). In the hamster model, it seems 
reasonable to conclude, on the basis of the results of
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this thesis and many other publications that BOP is 
the initiator of the carcinogenic process. It also 
acts as a promotor to some extent although some of the 
hormones used in experiments in previous chapters of 
this thesis may be more important tumour promotors 
even under physiological conditions. The absence of 
any effect of these hormones on total pancreatic DNA 
content (Chapter 4) would suggest that any promotional 
effect is subtle and need not result in gross changes 
in pancreatic composition or increase in tissue mass.
The flow cytometry results in this chapter are 
interesting. BOP produces pancreatic cell death and 
this is followed by regeneration of surviving tissue 
resulting in a proliferating population of cells. 
Many of these cells are acinar or inflammatory and 
therefore are probably not related to tumorigenesis. 
However, given that proliferating cells are prone to 
undergo spontaneous mutation and that ductal cells may 
have less effective DNA repair mechanisms, it is 
possible that mutagenic injury has occurred leading to 
tumour initiation. The cytometer may be detecting the 
whole population of proliferating cells and cannot 
distinguish between simple regeneration/proliferation 
and potentially tumorigenic proliferation. Aneuploidy 
might have been uncommon because neoplastic changes 
were still at an early stage. Interestingly, recent 
flow cytometric analyses of human pancreatic cancers 
have indicated that the majority of such tumours
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analysed exhibit aneuploidy, and that the tumours with 
aneuploid nuclear DNA had the worst prognoses (Alanen 
et al, 1990; Wido et al, 1990? Weger et al, 1991).
In a r e c e n t  p u b l i c a t i o n  l o o k i n g  at 
diethylnitrosamine-induced hepatic carcinogensis in 
Sprague-Dawley rats, aneuploidy occurred in altered 
hepatic foci before any histological evidence of 
malignancy could be detected (Wang et al, 1990). This 
observation indicated that, in rat liver at least, 
aneuploidy may be an early phenomenon resulting from 
sublethal cell injury, DNA repair and subsequent 
proliferation of altered cells. The failure to detect 
significant aneuploid cell lines in the current study 
may be due to the inability of the flow cytometer to 
distinguish small foci of aneuploid cells in the 
overwhelming number of diploid cells. Certainly, 
Wang's results in rat liver were obtained by the 
technique of microspectrophotometric measurement which 
allowed DNA analysis of tiny areas of liver tissue 
which had undergone histologically detectable changes 
in appearance, generally accepted as being pre- 
malignant (altered hepatic foci).
It seems likely, therefore, that cell 
proliferation is an important factor in BOP-induced 
neoplasia. However, using conventional techniques we 
have not been able to d i s t i n g u i s h  between 
repair/regeneration particularly in acinar cells where 
there is not thought to be a risk of neoplasia in the
269
hamster, and neoplastic proliferation in ductal cells 
which represents the early stages of tumour initiation 
and promotion. To address this problem further will 
require the use of molecular techniques to study the 
control and regulation of specific genes thought to be 
involved in the development of neoplasia.
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CHAPTER 7
Conclusions
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The exact aetiology of pancreatic cancer in man 
remains obscure. Little progress has been made in 
elucidating the causes of this dismal disease in the 
last five years although further epidemiological 
evidence in support of some of the previously 
discussed risk factors has been forthcoming.
Some early studies, cited in Chapter 1 of this 
thesis, suggested that diet played an important part 
in increasing susceptibility to the development of 
pancreatic cancer. More recently, there have been a 
number of studies published which have added to the 
evidence in support of this assertion. In an 
epidemiological study of 247 patients with pancreatic 
cancer from Northern Italy, LaVecchia and colleagues
(1990) noted that there was a tendency to a decreased 
risk of pancreatic cancer with increasing consumption 
of fruit. Another group from the Netherlands noted 
that risk was diminished with total cooked vegetable 
consumption (especially cruciferous vegetables) and 
fresh vegetable consumption (Bueno de Mesquita et al, 
1991). Consumption of eggs and fish increased risk in 
this study. In a study of 249 patients with 
pancreatic cancer, Howe, Jain and Miller (1990) 
reported that pancreatic cancer risk was positively 
associated with total caloric intake, particularly in 
relation to carbohydrate consumption. Fibre intake 
from fruit, vegetables and cereals was inversely 
associated with risk in this study.
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Exactly how diet influences susceptibility to 
the development of pancreatic cancer remains unclear. 
A high dietary intake of fresh fruit and vegetables 
seems to reduce risk. Given that nitrosamines can
induce pancreatic cancer in experimental animal 
models, it seems reasonable to suggest that this 
protective effect might come about through a reduction 
in, or reversal of, gastric nitrosation reactions 
caused by high levels of vitamins C and E in fruit and 
vegetables. Whether dietary fibre intake can be 
implicated in a similar way is not clear.
Similarly, it remains open to speculation 
whether dietary factors implicated in increasing risk 
act via their effect on gastrointestinal hormone 
release. A recent publication has certainly suggested 
a role for gastrin and perhaps CCK in increasing 
susceptibility to pancreatic cancer (Borch et al, 
1988). A group of 3 61 patients with pernicious 
anaemia were followed up over a seven year period. 
Patients in the study group exhibited an increased 
incidence of both gastric and pancreatic cancer when 
compared to age and sex-specific incidence rates in 
the general population. Hypergastrinaemia resulting 
in both gastric and pancreatic hypertrophy was 
suggested as a possible explanation for these findings 
although the authors also speculate that increased 
nitrosation in the hypochlorhydric stomach might be an 
alternative, and perhaps more reasonable, explanation.
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Interestingly, in an addendum to the paper, the 
authors reported that serum CCK levels in 68 of their 
pernicious anaemia patients were significantly 
increased compared to a small group of control 
patients (although caution has been expressed 
regarding possible crossreactivity with gastrin in the 
assay; personal communication, I. Ihse).
Coffee consumption has been shown to confer no 
increase in risk of pancreatic cancer in three recent 
studies (Farrow & Davis, 1990; Ghadirian, Simard & 
Baillargeon, 1991; Jain et al, 1991)• Similarly, 
alcohol has recently been shown to confer no increase 
in risk (Bouchardy et al, 1990; Farrow & Davis, 
1990; Jain et al, 1991). Indeed Farrow's group 
suggested that daily white wine consumption was 
protective and Ghadirian et al (1991) suggested that 
those who consumed alcohol were generally at lower 
risk than non-drinking controls. Cuzick and Babiker 
(1989) noted in a study of 216 pancreatic cancer 
patients that cases drank significantly more beer than 
controls and that there was evidence of a positive 
trend in risk with total alcohol consumption.
Further investigations into genetic changes 
which occur in pancreatic cancer have been reported in 
the last five years. The initial findings of Hirai 
and colleagues (1985), demonstrating activated c- 
Kirsten-ras (c-K-ras) oncogene in a pancreatic cancer 
cell line, and Yamada et al (1986) reporting the
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finding of a point mutation at codon 12 in the same 
oncogene have been supplemented by other similar 
publications. In 1988, a group of investigators from 
New York and California reported that 21 of 22 human 
pancreatic cancers analysed exhibited a point mutation 
at codon 12 of the c-K-ras oncogene (Almoguera et al, 
1988) . In seven of the tumours analysed, the reported 
codon 12 mutation was noted in both the primary tumour 
and in metastases, suggesting that early c-K-ras 
mutational activation was an early event in the 
development of exocrine pancreatic cancer. Smit and 
colleagues (1988) from the Netherlands reported 
similar findings in 28 of 3 0 human pancreatic cancers 
analysed. They reported that the mutations were 
predominantly guanine-thymidine transversions, unlike 
colon cancer where similar mutations have been 
reported as predominantly guanine-adenine transitions. 
Aqueous extracts of cigarette tar have been shown to 
cause single strand breaks in DNA due to a reduction 
of oxygen to superoxide and hydroxyl radicals (Borish 
et al, 1987) . It is possible that such DNA damage 
could be the initial step in altering the pancreatic 
cellular genome to produce mutations in c-K-ras.
Cigarette smoking certainly remains the only 
convincing aetiological factor for the development of 
pancreatic cancer. A group from Toronto in Canada 
reported that cigarette smoking increased the relative 
risk of dying from the disease in a dose-dependent
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manner (Howe et al, 1991). Cessation of smoking 
resulted in the increased risk falling to that of a 
non-smoking population in 10 to 15 years. Cigarette 
smoke contains many different nitrosamines. It is 
interesting to note that until recently none of these 
nitrosamines could induce pancreatic cancer in animal 
models. In 1988, a group of investigators from New 
Y o r k  r e p o r t e d  t h a t  t h e  n i t r o s a m i n e  4- 
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a 
constituent of cigarette smoke, induced both benign 
and malignant neoplasms in rat pancreas (Rivenson et 
al, 1988). The malignant tumours were duct-like in 
morphology, including, in one animal, areas of 
epidermoid, keratin-generating tissue. The major 
metabolite of NNK, 4 - (methylnitrosamino)-1-(3- 
pyridyl)-1-butanol (NNAL) also produced pancreatic 
tumours in the rat when administered subcutaneously, 
and the authors suggested that this substance might be 
the proximate carcinogen affecting the pancreas.
The observation that a nitrosamine derived from 
cigarette smoke can induce pancreatic cancer in a 
rodent model underlines the importance of Parviz 
Pour's BOP-hamster model of pancreatic cancer. In 
this model, a nitrosamine administered in regular low 
dosage to the Syrian golden hamster, induces 
pancreatic cancer almost exclusively. Clinically, the 
chemically induced tumour has similar effects in the 
hamster to pancreatic cancer in man. Histologically,
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the induced tumour has a ductal or ductular morphology 
and resembles the tumour seen in man; it also 
possesses the ability to metastasize.
The first aim of this thesis was to successfully 
establish Pour's model of pancreatic carcinogenesis in 
our laboratory. This was achieved without undue 
difficulty. The histological appearances of the 
pancreata after different durations of BOP injection, 
were similar to those described by Pour and other 
workers in many previous publications. Concern over 
possible excessive morbidity in the hamsters due to 
repeated subcutaneous injections of BOP prompted a 
comparison of the effects of SC and IP BOP. The only 
morbidity experienced was in the IP group where a 
number of animals were sacrificed due to accidental 
injection of carcinogen into testes which had been 
retracted into the abdomen. The pattern of 
histological changes in the hamster pancreata in both 
groups was similar, although after 20 weeks of 
treatment, changes in the pancreata of IP injected 
hamsters were generally less extensive than those in 
the SC group, particularly with respect to the 
development of the premalignant lesions, ductular 
c a r c i n o m a - i n - si t u and m i c r o c a r c i n o m a , and 
adenocarcinoma itself. The reason for these 
discrepancies might lie in differences in the 
predominantly hepatic metabolism of BOP; SC injection 
would result in chemical appearing at the liver in the
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systemic circulation, whereas IP injection might 
result in a higher proportion of chemical appearing in 
the portal circulation with subsequent differences in 
cellular metabolism.
Previous publications have demonstrated that 
pharmacological doses of gastrointestinal hormones can 
influence pancreatic exocrine secretion both in man 
and in experimental animal models. The second aim of 
this thesis was to investigate the effects of 
intravenously infused physiological doses of secretin, 
CCK-8 and SMS 201-995 on pancreatic juice output and, 
where possible, composition, in the Syrian golden 
hamster. Intravenous infusions of increasing doses of 
secretin and CCK-8 increased pancreatic juice output 
and altered pancreatic juice composition with respect 
to protein and bicarbonate content. SMS 201-995 
suppressed pancreatic juice output: the small volumes
of pancreatic juice thus obtained made meaningful 
analysis of composition unfeasible.
Pancreatic juice output was suppressed during 
infusion of SMS 201-995 and remained suppressed during 
subsequent infusion of CCK-8. Increased pancreatic 
juice output stimulated by infusion of CCK-8 was 
suppressed by subsequent infusion of SMS 201-995. 
These results suggest that SMS 201-995 could overcome 
the stimulatory effects of CCK-8. The exact mechanism 
whereby SMS 201-995 achieves this result is not clear 
but may involve diminution in pancreatic blood flow
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(Conway, Djurlein & Prinz, 1988), reduction in 
pancreatic insulin secretion which is thought to play 
an important role in regulating pancreatic exocrine 
enzyme production and secretion (Muller et al, 1988), 
t h r o u g h  i n h i b i t i o n  of s e c r e t i o n  of o t h e r  
gastrointestinal hormones, by direct interference with 
cellular membrane bound CCK receptor sites or by 
stimulation of inhibitory intracellular messenger 
systems. The interaction between infused secretin and 
SMS 201-995 was similar to that seen with CCK-8 and 
SMS 201-995, although higher doses of SMS 201-995 were 
required to overcome the stimulatory effects of 
secretin. Secretin and somatostatin are thought to 
share the same intracellular messenger system, cyclic 
AMP, whereas CCK is thought to act via the 
diacylglycerol intracellular pathway. This might 
explain the slight differences in the results seen in 
this part of the study.
Subcutaneous administration of CCK-8, secretin, 
SMS 201-995 and combinations of SMS 2 01-995 with the 
other two hormones did not influence pancreatic wet 
weight or pancreatic DNA content after one or six 
weeks of treatment. In the light of previously 
published work, particularly with respect to secretin 
and cholecystokinin and analogues, this seemed 
initially to be a surprising finding. Unfortunately, 
considerable variations in the doses and preparations 
of hormones used in these papers makes direct
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comparison of results difficult. It is conceivable 
that the doses of hormones used were too small to have 
an effect on pancreatic trophism. Similarly, the 
intermittent dosing schedule used could have allowed 
pancreatic cells to recover from the effects of the 
hormone prior to sacrifice of the hamsters and 
analysis of the pancreas.
The final initial aim of this thesis was to 
determine the effects of subcutaneous injections of 
the hormones, in the doses used in the earlier 
experiments, on BOP carcinogenesis. CCK-8 failed to 
promote pancreatic carcinogenesis as had been expected 
from earlier published work with CCK and other CCK 
analogues. Subsequent publications have reported 
conflicting results with a number of CCK preparations? 
some have promoted carcinogenesis while others have 
not, and in some cases have in fact inhibited 
carcinogenesis. The timing of carcinogen injection in 
relation to administration of the hormone has been 
thought to be critical in explaining these conflicting 
results.
The most interesting finding of the experiment 
reported in Chapter 5 of this thesis was that at the 
lowest dose regime used, SMS 201-995 administration 
increased the number of animals affected by pancreatic 
adenocarcinoma and the premalignant lesions, ductular 
carcinoma-in-situ and microcarcinoma. In addition, 
the extent of the malignant change seemed to be more
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extensive in this group compared to all the other 
experimental groups. These results conflict, to a 
degree, with a number of papers which have reported 
that some somatostatin analogues can inhibit the 
growth of established pancreatic cancers (Paz-Bouza et 
al, 1987; Zalatnai & Schally, 1989a & 1989b; Szende, 
Zalatnai & Schally, 1990). These reports have used 
continuous release preparations of somatostatin 
analogues in pharmacological doses; as a consequence 
the results reported might be expected. Other groups 
have reported successful inhibition of the growth of 
transplanted human pancreatic cancers in nude mice 
using SMS 201-995 (Upp et al, 1988) . In this study 
thrice daily injections of very large doses of 
analogue were used. Although the experiment in this 
part of the thesis was designed to look not at cancer 
treatment but at the early stages of cancer 
initiation/promotion, the results should alert 
investigators to the possibility that intraperson 
variation in response to treatment of human pancreatic 
cancer might, in the unlucky few, result in tumour 
promotion rather than inhibition. Our knowledge of 
the actions of somatostatin and its analogues is still 
grossly inadequate to suggest that this substance 
should be used to treat human pancreatic cancer.
It was interesting to note that alterations in 
carcinogenesis could be induced by doses of hormones 
which did not affect total pancreatic DNA content or
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pancreatic wet weight. This prompted an additional 
experiment to look at the effects of BOP on pancreatic 
cell cycle activity using flow cytometry and BRDU 
immunostaining. BOP significantly increased cell 
cycle activity during the 20 week experiment. The 
percentage S-phase fraction increased after 5 weeks of 
BOP treatment whereas the percentage G2/M fraction did 
not increase until 10 weeks. Added together, the 
percentage growth fraction exhibited a steady increase 
over 20 weeks of BOP treatment.
The increase in cell cycle activity demonstrated 
by flow cy tom etr y indicated that cellular 
proliferation in the pancreas occurred in response to 
BOP administration. BRDU immunostaining indicated 
that this occurred predominantly in ductal and 
ductular cells. It remains unclear whether cellular 
p r o l i f e r a t i o n  occurred as a consequ enc e  of 
regeneration of cells which had survived the lethal 
effects of BOP or of replication of cells sublethally 
damaged by BOP which would become malignant lesions. 
Further investigation into the subcellular effects of 
carcinogens like BOP might help to explain why 
exogenously administered hormones can affect 
carcinogenesis without altering other aspects of 
cellular function.
$
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APPENDIX 1
DNA Assay - Preparation of Reagents
1. Phosphate Saline Buffer (PBS)
(a) Dissolve 35.814g of Na2HP04.12H20 (MW 358.14g) 
into 1 litre distilled water (Solution 1).
(b) Dissolve 15.601g of NaH2P04.H20 (MW 156.Olg) into 
1 litre distilled water (Solution 2).
(c) Take 810mls of Solution 1 and 190mls Solution 2 
and make up to 2 litres with distilled water 
(Solution 3).
This provides 2 litres of 0.05M NaP04 Buffer solution.
(d) Add 4 moles of NaCl to Solution 3 (Solution 4).
(e) Adjust pH of Solution 4 to 7.4 with 4N NaOH 
solution.
(f) Take 1 litre of Solution 4 and add 0.744g EDTA 
(Solution 5).
(g) Readjust pH of Solution 5 to 7.4.
Keep Solution 4 (Reagent Buffer) and Solution 5
(Sample Buffer); Solutions 1 and 2 can be retained
for later use.
2. Stock DNA Solution
(a) Dissolve purified calf thymus DNA in distilled 
water to final concentration of lmg/ml.
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(b) Make up DNA standards in the following concen­
trations :
500ng/ml lug/ml 1.5ug/ml 2ug/ml
2.5ug/ml 3ug/ml 3.5ug/ml 4ug/ml
3. Hoechst 33258 Reagent
(a) Dilute stock solution (200ug/ml) in distilled 
water to give final reagent concentration of lug/ 
ml .
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APPENDIX 2
Pancreatic wet weights in one-week treated animals. 
Results are expressed as mg/lOOg hamster body weight.
Groups Animals
Control 366 385 365 383 398 421 328 345
CCK-8 321 362 418 366 320 371 379 340
Secretin 385 408 377 404 394 391 343 339
SMS-LD 315 367 374 384 409 379 328 341
SMS-HD 380 333 370 369 352 386 357 394
CCK/SMS-LD 430 348 431 429 362 362 389 328
Sec/SMS-HD 347 363 432 391 316 344 375 365
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APPENDIX 3
Pancreatic wet weights in six-week treated animals. 
Results are expressed as mg/lOOcr hamster body weight.
Groups Animals
Control 299 346 323 359 356 350 316 326
CCK-8 335 364 301 367 334 376 360 346
Secretin 369 363 352 297 332 351 333 327
SMS-LD 290 303 331 280 375 310 339 333
SMS-HD 342 317 373 325 302 295 336 334
CCK/SMS-LD 403 400 348 331 342 389 445 352
Sec/SMS-HD 380 372 357 367 382 504 392 332
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APPENDIX 4
DNA assay results in one-week treated animals. DNA 
content values are shown for each pancreatic section 
analysed - three sections per animal pancreas, each 
sample paired. Results are expressed as ug DNA/lOQq 
pancreatic wet weight
Run 1 Run 2 Run 3 Run 4
Control 588 619 586 612 652 628 529 564
484 558 527 568 753 715 601 565
513 531 538 578 671 609 514 537
CCK-8 544 571 693 700 752 671 477 564
505 540 663 655 758 720 560 571
574 530 656 692 743 752 508 522
Secretin 441 452 541 566 630 626 601 594
530 514 560 581 525 501 550 554
468 468 733 737 541 557 604 626
SMS-LD 411 428 627 600 693 738 474 509
378 384 601 627 534 539 554 525
435 572 568 556 597 568 521 532
SMS-HD 497 516 517 543 722 704 497 517
536 524 502 511 571 559 500 575
476 496 574 629 748 705 579 596
CCK/SMS-LD 576 587 578 599 589 578 549 538
553 564 569 585 624 628 404 409
522 528 646 675 667 635 504 512
Sec/SMS-HD 520 526 616 626 588 592 437 452
543 543 653 667 586 558 559 575
437 482 665 640 570 642 615 598
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APPENDIX 4 (Continued)
Run 5 Run 6 Run 7 Run 8
Control 541 549 694 740 457 493 552 561
510 531 662 703 472 476 578 591
521 513 622 665 502 526 581 588
CCK-8 542 545 594 603 499 515 608 618
607 621 540 548 488 514 579 579
500 524 547 568 411 427 603 611
Secretin 486 514 585 608 401 416 586 602
- - 578 605 458 465 597 579
536 548 612 638 437 437 604 588
SMS-LD 507 520 732 762 490 513 580 659
502 514 685 693 477 492 612 638
515 551 651 684 418 432 682 654
SMS-HD 524 571 552 567 495 495 568 586
567 578 600 615 529 557 752 790
456 445 642 651 436 436 580 635
CCK/SMS-LD 550 570 686 721 549 569 564 568
505 522 639 648 453 468 672 681
468 456 612 637 428 456 562 579
Sec/SMS-HD 540 540 660 666 435 465 608 624
529 560 586 612 486 482 582 616
438 492 598 617 498 505 590 590
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APPENDIX 5
DNA assay results in six-week treated animals. DNA 
content values are shown for each pancreatic section 
analysed - three sections per animal pancreas, each 
sample paired. Results are expressed as ug DNA/lOQq
pancreatic wet weight.
Run 9 Run 10 Run 11 Run 12
Control 656 679 495 542 682 705 493 512
678 703 418 430 568 577 443 459
578 578 489 533 545 566 441 530
CCK-8 562 592 520 520 545 530 417 385
650 650 519 547 609 618 502 468
553 562 364 352 530 530 494 517
Secretin 589 631 525 559 606 602 493 507
655 647 650 606 560 579 460 465
578 601 518 545 630 630 489 482
SMS-LD 648 656 503 503 563 582 383 420
438 433 495 466 540 551 378 394
572 603 496 513 551 570 389 409
SMS-HD 493 488 535 520 608 583 495 472
605 595 442 451 534 561 444 447
637 650 398 402 580 597 440 432
CCK/SMS-LD 584 584 573 565 615 615 373 380
580 567 572 549 684 696 418 434
620 583 567 560 668 647 387 423
Sec/SMS-HD 524 419 582 591 601 620 420 444
584 584 534 534 576 580 396 435
610 624 522 533 602 624 441 445
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APPENDIX 5 (Continued)
Run 13 Run 14 Run 15 Run 16
Control 456 486 548 568 453 407 462 483
587 604 502 524 532 532 459 442
555 575 500 517 528 543 438 438
CCK-8 540 544 417 442 502 537 466 490
586 610 536 521 511 498 512 500
547 571 510 505 525 577 501 501
Secretin 504 518 659 672 522 522 499 518
488 492 566 589 596 567 512 486
524 524 607 636 580 560 476 509
SMS-LD 520 488 464 500 509 523 457 476
489 496 522 548 503 503 499 513
440 468 522 540 474 474 478 498
SMS-HD 535 543 427 415 565 578 474 452
582 623 492 504 539 539 422 439
624 620 466 497 498 514 448 469
CCK/SMS-LD 613 628 491 507 499 484 466 463
576 608 458 470 538 553 425 457
566 574 452 468 497 497 466 479
Sec/SMS-HD 509 522 370 340 548 528 507 516
466 501 455 478 502 524 509 522
460 484 560 574 537 544 492 476
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